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Osteoporosis and depression are prevalent among older postmenopausal women 65 years 
or older. Bisphosphonates (BPs) and selective serotonin reuptake inhibitors (SSRIs) or serotonin 
norepinephrine reuptake inhibitors (SNRIs) are commonly used medications to treat these 
conditions. Inhibitory effects of BPs on osteoclasts are responsible for the reduction in fracture 
risk. SSRIs, however, are associated with increased fracture risk through decreasing osteoblasts 
and increasing osteoclastic activity. These effects of SSRIs could attenuate the beneficial effects 
of BPs. This dissertation describes the concomitant use of BPs and SSRIs among postmeopausa 
 
 
 
 
women and reports findings from examining the association between concomitant use of BPs 
and SSRIs and fracture risk. 
Separate cross-sectional analyses were performed using data from the 2004-2008 Medical 
Expenditure Panel Survey (MEPS) and Medicare Part D prescriptions claims data (2008-2010) to 
examine usage patterns of BPs and SSRIs/SNRIs for women aged ≥45 years and ≥65 years, 
respectively. For our second objective, a nested-case control was conducted using Medicare 
claims data (2008-2010). Data from Medicare inpatient claims were linked to Medicare Part D 
data for all female BP users 65 years or older.  We used Cox proportional hazards model to 
assess the increased risk of osteoporotic-related fractures among propensity score matched (1:1 
ratio) cohorts of  concomitant users of BPs and SSRIs and BP alone users. 
Concomitant use of BPs and SSRIs was prevalent and increased with age for each 
timeframe examined. Findings showed that approximately 12% (using MEPS) and 28% (using 
Medicare data) of women on BPs were also on SSRIs. For the second objective, 4,214 propensity 
score matched pairs (average age=80.4 years) of subjects were analyzed. Findings showed that 
concomitant use of BPs and SSRIs was associated with statistically significant increased risk for 
any fracture (HR=1.29, 95% CI, 1.07-1.57), but statistically non-significant increased risk for hip 
(HR=1.16, 95% CI, 0.92-1.47) and vertebral fractures (HR=1.55, 95% CI, 0.97-2.48).   
Current findings indicate that concomitant use of BPs and SSRIs is not uncommon 
among postmenopausal women and suggest potential attenuation of antifracture efficacy of BPs 
by SSRIs. Further studies are needed to understand the clinical impact of concomitant use of 
these medications among older postmenopausal women. 
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Chapter 1 
 
1.0 INTRODUCTION 
1.1 Overview of the document 
This dissertation describes a pharmacoepidemiologic study to (1) describe the concomitant 
utilization pattern of selective serotonin reuptake inhibitors (SSRIs) and serotonin 
norepinephrine reuptake inhibitors (SNRIs) and bisphosphonates, examine (2) the increased risk 
of osteoporotic-related fractures associated with the concomitant use of SSRIs with 
bisphosphonate therapy, and (3) whether the risk of osteoporotic-related fractures is related to the 
role of serotonin in bone rather than the disease (depression). This chapter provides background 
on the basic understanding of osteoporosis and osteoporotic fractures and the associated risk 
factors, epidemiology, prevention and treatment of the disease, bisphosphonate therapy, and a 
brief statement on the safety concerns with simultaneous use of bisphosphonate therapy and 
SSRIs or SNRIs in postmenopausal women. Chapter 2 provides a more in depth overview of the 
literature of concomitant use of drugs and adverse drug events, concomitant use of drugs with 
bisphosphonates and risk of fractures, SSRIs or SNRIs and bone health, and 
pharmacoepidemiologic study design considerations. Chapter 3 provides details on a preliminary 
descriptive study to assess the utilization of these medications both separately and concomitantly 
using nationally-representative survey data in order to determine to what extent these 
medications are prescribed among women. Chapter 4 describes the methods used for this 
pharmacoepidemiologic study, whereas Chapter 5, Chapter 6, and Chapter 7 describe the results, 
and discussion and conclusions from the study, respectively. 
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1.2 Osteoporosis and osteoporotic-related fractures 
1.2.1 Basic understanding 
Bone is a highly specialized living supportive tissue with major functions of providing 
support for the body, protection of vital organs, providing an environment for marrow, and acts 
as a mineral reservoir for calcium homeostasis in the body. Bone is comprised of bone cells, an 
organic matrix of collagen and noncollagenous proteins (osteoid), and inorganic mineral matrix. 
Bone cells which include osteoblasts, osteocytes, and osteoclasts are concerned with the 
production, maintenance and modeling of osteoid (Figure 1.1).  
 
 
Figure 1.1. Bone cells 
Source: www.iofbonehealth.org 
 
Osteoblasts are bone-forming cells or they are the cells within bone that lay down the 
extracellular matrix and regulate its mineralization. Osteoclasts are bone degrading (resorption) 
cells at sites called Howship’s lacunae. Osteocytes, smaller in size than osteoblasts, are mature 
osteoblasts which eventually become calcified bone. Osteocytes are the most abundant cells in 
bone (or are the principal cell in adult bone) and are thought to be important in responding to 
changes in physical forces upon bone and to transducer messages to the osteoblastic cells on the 
bone surface, directing them to initiate resorption or formation responses.1,2  
Osteoporosis is a bone health disease characterized by the loss of bone mass (low bone 
mineral density) and strength that leads to an increased risk of fracture. Osteoporosis results from 
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the imbalance created in the process of bone remodeling, which is the major activity of bone 
cells in the adults skeleton.3 Bone remodeling is a process by which old bone is continuously 
replaced by new tissue through resorption and formation, balanced at an equilibrium, so that the 
bone adapts to mechanical load and strain.4 Diagnosis of osteoporosis is based on the World 
Health Organization (WHO) criteria for bone mineral density (BMD). Osteoporosis corresponds 
to BMD T-score of -2.5 or less compared to a normal, young adult population of the same gender 
(reference population) BMD T-score of -1.0 or higher. A T-score is useful to express BMD in a 
postmenopausal population and is expressed as standard deviation (SD) units.5 Factors associated 
with osteoporosis (or low BMD) and increased risk of fractures included in a new Fracture Risk 
Assessment Tool (FRAX®) for evaluating fracture risk are listed in Table 1.1. FRAX® was 
developed by the WHO to evaluate a patient’s 10-year probability of hip fracture and major 
osteoporotic fracture (i.e., clinical spine, forearm, hip, or shoulder fracture). Previously, 
clinicians could only estimate a 5-year fracture risk.6 
 
Table 1.1. Risk factors for osteoporotic fracture used in FRAX® 
 Age (50 to 90 years) 
 Sex 
 Body mass index 
 Low femoral neck BMD 
 Prior fragility fracture 
 Parental fragility fracture 
 Current tobacco smoking 
 Long-term use of glucocorticoids 
 Rheumatoid arthritis 
 Other causes of secondary osteoporosis (e.g., medications and medical conditions) 
 Alcohol intake of more than two drinks per day 
Adapted from the North American Menopause Society, 2010.6 
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Figure 1.2. The human skeletal system highlighting common osteoporotic fracture sites. 
 
In healthy postmenopausal women, BMD of both the entire skeleton and single 
anatomical sites have been shown to decrease progressively after the onset of menopause 
because of hormonal changes.7 Specifically, the rapid bone loss in postmenopausal women  
results from low estrogen production.8 Although postmenopausal osteoporosis affects the whole 
skeleton, vertebral fractures, hip fractures, and Colles’ (wrist/forearm) fractures are the most 
common osteoporotic fractures.9 Other osteoporotic fractures include pelvic, humeral, and other 
femoral fractures.10 A schematic diagram of the human skeletal system is shown in Figure 1.2 
highlighting the most common osteoporotic fracture sites. 
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1.2.2 Epidemiology 
Osteoporosis and its resulting problem of fractures among older adults are a major public 
health concern in the United States.11 The proportion of osteoporosis is significantly higher in 
postmenopausal women compared with men of the same age.12 The U.S. Preventive Services 
Task Force (USPSTF) recommends that women ≥65 years of age be screened routinely for 
osteoporosis, but there is no recommendation for or against routine osteoporosis screening in 
postmenopausal women who are younger than 60 years of age or in women 60 to 64 years of age 
who are not at increased risk for osteoporotic fractures.13 The prevalence of osteoporosis rises 
from 4% in women ages 50 to 59 years to 52% in women age 80 years and older.14 Thus, 
osteoporosis and osteoporotic fractures increases with age. This is further supported by the 
findings in a study of over 200,000 postmenopausal women. In this study, relative to women 
aged 50-54 years, the odds of having osteoporosis were found to be 5.9-fold higher in women 
aged 65-69 and 14.3-fold higher in women aged 75-79 years.15 This information suggests that 
older postmenopausal women are more prone to suffer from osteoporosis and thus are at 
increased risk of osteoporotic fractures in their lifetime.  
Roughly 4 in 10 white women age 50 years or older in the U.S. will experience a hip, 
vertebral, or wrist fracture sometime during the remainder of their lives and 13% of white men 
will suffer a similar fate. The estimated remaining lifetime risks after age 50 for hip, vertebral, 
and wrist/forearm fractures in women are 17.5%, 15.6%, and 16.0%, respectively.10 In the U.S., 
the rates of osteoporosis and/or osteoporotic fractures are higher among white women compared 
with Asian or African American women.16 It is estimated that 90% of all hip and vertebral 
fractures in white American women aged between 65 and 85 years old are attributed to 
osteoporosis.17  
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Of the most common osteoporotic fractures, hip and vertebral fractures are associated with 
pronounced burden on society and individuals in terms of clinical consequences and economic 
burden emphasizing the need for intervention in women at high risk.18 Specific burdens include 
chronic pain, disability, depression, loss of independence or functional ability and psychosocial 
difficulty, increased mortality, and increased healthcare costs.19 In 2005, osteoporosis-related 
fractures were responsible for an estimated $19 billion in costs in the U.S. By 2025, predictions 
show that these costs will rise to approximately $25.3 billion.20 It has been estimated, assuming 
there will be no changes over a long period of time, that hip fractures, the most prevalent in older 
adults, are projected to increase progressively to 2.6 million by 2025 and to 4.5 million by 2050 
worldwide.21 The current annual cost to the U.S. health care system for patients with hip 
fractures is more than $12.6 billion (an average of $37,000 per patient). Only 25% of hip fracture 
patients will make a full recovery; 40% will require nursing home care; 50% will need a cane or 
walker; and 24% of those over age 50 will die within 12 months, hence, the future post-fracture 
cost may even be greater.22 
As the U.S. population of older adults is projected to increase in the coming decades, a high 
prevalence of osteoporosis and/or osteoporotic-related fracture burden is expected. In fact, 
according to the U.S. Census Bureau, it is projected that by 2030, 20% of Americans will be 
aged 65 years and older and by 2050, the age group is projected to increase to 88.5 million from 
38.7 million in 2008. Similarly, the 85 years and older population is expected to increase to 19 
million by 2050 from 5.4 million in 2008.23 Moreover, among older adults, the current 
proportion of females in the U.S and other countries is greater than males and will still remain so 
in the future. The United Nations suggests that, “in many cases, the difference is so large that 
concerns of the older population should in fact be viewed primarily as the concerns of older 
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women”.  The difference in this ratio is generally driven by the fact that average life expectancy 
is greater for females than for males.24,25 
1.2.3 Prevention and treatment of disease 
1.2.3.1 Background 
Patients with osteoporosis and osteoporotic (or prevalent) fractures are offered 
opportunities for prevention (medication given to individuals with no prior fractures to prevent 
the onset of osteoporosis (i.e., further lowering of bone density and/or a first fracture) and 
treatment of disease (i.e., the person begins pharmacotherapy after having sustained fractures)  to 
reduce the risk of new fractures. These opportunities involve both nonpharmacological and 
pharmacological therapy interventions.26  
Nonpharmacological interventions involve measures such as falls prevention. Falls are 
defined as events which result in persons inadvertently coming to rest on the floor or ground or 
other lower level, excluding intentional change in position to rest in furniture, wall or other 
objects.27 Risk factors for falls among older adults include medications (e.g., antidepressants, 
hypnotics and anxiolytics, any central nervous system drug, analgesics, any cardiovascular drug, 
any endocrine system drug, any respiratory system drug), chronic diseases (coronary heart 
disease, any circulatory disease, diabetes, thyroid disease, chronic obstructive pulmonary 
disease, depression, eye disease, arthritis),28 and physical function in terms of one or more 
impairments of self-reported difficulty on five Instrumental Activities of Daily Living (IADLs, 
range 0-5) including walking two to three blocks, climbing up ten steps, preparing meals, doing 
heavy household chores, and shopping.29  
Falls are a common and serious public health concern among older adults 65 years and 
older. It is estimated that one in every three adults 65 years and older fall each year.30 Falls can 
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be especially injurious for this age group. About 20-30% of older people who fall suffer 
moderate to severe injuries (e.g., bruises, hip fractures, traumatic brain injuries, and upper limb 
injuries).31,32 Injurious falls can lead to hospitalizations, disability and loss of independence, 
functional decline, reduced quality of life, and even premature death.31-35  For example regarding 
hospitalization, a Statistical Brief presenting data from the Healthcare Cost and Utilization 
Project Nationwide Emergency Department Sample on emergency department (ED) visits among 
older adults in 2006 reported that of the more than 2.1 million visits to the ED for injurious falls, 
29.6% of visits resulted in hospital admission. The most common injuries related to falls were 
fractures, which accounted for 41% of injurious fall-related ED visits.33 Consistent with these 
findings, data from the National Center for Health Statistics showed that in 2007, there were 
264,000 fall-related hip fractures and the rate for women was almost three times the rate for 
men.36  
The preceding information further illuminates the fact that osteoporosis and osteoporotic 
fractures are a result of multifactorial factors (i.e., component causes for a sufficient cause).37 In 
other words, any single approach to optimal bone health is not thought to be adequate to prevent 
the disease from occurring. In addition to the appropriate pharmacologic therapy, clinicians are 
urged to educate patients about the use of nonpharmacologic interventions/measures (e.g., fall 
prevention, use of hip protectors) to assist patients at risk of osteoporotic fractures.38 A fall is 
neither necessary nor a sufficient cause of fracture.39 Osteoporotic fractures (e.g., spine fractures) 
which are pathologic can occur spontaneously,40 but a fall is considered the strongest single risk 
factor for fracture in an older adult.38 Thus, of the nonpharmacologic interventions for 
osteoporosis, fall prevention represents the foundation of prevention and management of disease, 
without which patients are unlikely to achieve the full benefit of pharmacologic therapy.41 The 
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Centers for Disease Control and Prevention recommends steps or interventions to reduce the risk 
of falling for older adults 65 years or older and these include using muscle strengthening 
exercise, being mindful of medications, keeping  vision sharp, and eliminating hazards at 
home.42  
With regards to pharmacologic therapy, the decision to intervene or selection of patients 
for treatment is based on the patient’s level of fracture risk profile and skeletal health assessment 
involving clinical judgment, not just on BMD assessment and the efficacy and side-effects of 
drugs likely to be prescribed.43,44 The National Osteoporosis Foundation recommends initiating 
therapy in postmenopausal women age 50 years and older presenting with a hip or vertebral 
(clinical or morphometric) fracture, BMD tests of T-score ≤-2.5 at the femoral neck or spine 
after appropriate evaluation to exclude secondary risk factors, T-score between -1.0 and -2.5 at 
the femoral neck or spine and a 10-year probability of a hip fracture ≥3% or a 10-year 
probability of a major osteoporosis-related ≥ 20% based on the U.S.-adapted WHO algorithm.45  
 
 
1.2.3.2 Pharmacologic therapy options 
Of the current U.S. Food and Drug Administration (FDA)-approved pharmacologic 
therapy options, bisphosphonates are widely prescribed46 and recommended by the North 
American Menopause Society as first-line pharmacologic treatments in the management of 
osteoporosis for postmenopausal women.6 The American College of Rheumatology recommends 
bisphosphonates as first-line therapy in medication-induced osteoporosis (e.g., in long-term users 
of glucocorticoids or oral corticocosteroids).47 Other pharmacologic options include the selective 
estrogen-receptor modulator (SERM; also known as estrogen agonist/antagonist) raloxifene 
(marketed as Evista® oral tablets), parathyroid hormone (PTH) or its analogues such as 
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teriparatide (recombinant human PTH 1-34) (marketed as Forteo®), estrogens, calcitonin, and 
denosumab (marketed as Prolia®).  
 
1.3 Bisphosphonates: FDA-approved 
  The current FDA-approved bisphosphonates in the management of osteoporosis for 
postmenopausal women in U.S. include alendronate (Fosamax®), ibandronate (Boniva®), 
risedronate (Actonel®), and zoledronic acid (Reclast®). Table 1.2 and Table 1.3 provide a list 
of these bisphosphonates with some additional information. It is unclear whether any of these 
drugs is more effective than any other. This is because there are no head-to-head clinical trials of 
bisphosphonates for the prevention of fractures.48 
 
Table 1.2. List and dosage of FDA-approved bisphosphonates in the U.S. 
Generic name Brand name Dosage, dosing interval, and formulation (s) Original FDA 
approval year 
Alendronate Fosamax® or 
Fosamax Plus D®  
Prevention (oral tablet of 5 mg daily or 35 mg 
weekly) and treatment (oral tablet of 10 mg 
daily or 70 mg weekly) 
1995 
Risedronate Actonel® Oral tablet doses of 5 mg daily, 35 mg 
weekly, 75 mg on 2 consecutive days once a 
month, or 150 mg monthly 
1998 
Ibandronate Boniva® 2.5 mg oral tablet daily, 150 mg tablet 
monthly (for prevention and treatment), or 
intravenous injection of 3 mg every 3-months 
(for treatment) 
2003 
Zoledronic acid Reclast® 5 mg intravenous injection yearly  for 
treatment 
2007 
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Table 1.3. List and description of FDA-approved bisphosphonates in the U.S. 
Drug product Indications Contraindications Geriatric use
Fosamax® 
(Alendronate 
sodium) 
Treatment and prevention of 
osteoporosis in 
postmenopausal women, 
glucocorticoid-induced 
osteoporosis, and Paget’s 
disease of bone 
 
- Abnormalities of the esophagus  
  (e.g., stricture or achalasia)-upper 
  gastrointestinal adverse reactions 
- Severe renal impairment 
 
Fosamax®-treated 
patients were at least 
65 years of age in 
postmenopausal 
osteoporosis studies 
Actonel® 
(Risedronate 
sodium) 
Prevention of postmenopausal 
osteoporosis, treatment and 
prevention of glucocorticoid-
induced osteoporosis, and 
Paget’s disease 
- Abnormalities of the esophagus  
  (e.g., stricture or achalasia)-upper 
  gastrointestinal adverse reactions 
- Hypocalcemia (mineral  
  metabolism) 
- Severe renal impairment 
Actonel®-treated 
patients were at least 
65 years of age in 
postmenopausal 
osteoporosis studies 
Boniva® 
(Ibandronate 
sodium) 
Treatment and prevention of 
postmenopausal osteoporosis 
 
- Upper gastrointestinal adverse 
  reactions 
- Severe renal impairment 
Boniva®-treated 
patients were at least 
65 years of age in 
postmenopausal 
osteoporosis studies 
Reclast® 
(Zoledronic acid 
Injection) 
Treatment of postmenopausal 
osteoporosis, and Paget’s 
disease of bone 
- Severe renal impairment 
- Hypocalcemia (mineral  
  metabolism) 
 
Reclast®-treated 
patients were at least 
65 years of age in 
postmenopausal 
osteoporosis studies 
 
 
1.3.1 Bisphosphonates: Efficacy 
Several studies have shown bisphosphonates to have beneficial clinical effects in reducing 
bone loss and the risk of fracture in older women.49-51 However, a recent report based on research 
conducted by the Southern California Evidence-based Practice Center under contract to the 
Agency for Healthcare Research and Quality found that comparative benefits in fracture risk 
reduction among the treatments for low bone density vary. The strength of evidence is high for 
reducing vertebral fractures, non-vertebral fractures, and hip fractures among postmenopausal 
women with osteoporosis. In contrast, the evidence for treatments of wrist fractures is low. A 
summary of strength of evidence and conclusions from various studies is presented in Table 
1.4.48 
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Table 1.4. Summary of comparative benefits of bisphosphonates in fracture reduction.48 
 
Strength of 
evidence 
Study design Conclusion 
High Randomized clinical trials 
(RCTs) 
Vertebral fractures: alendronate, risedronate, ibandronate, and 
zoledronic acid reduce the risk of vertebral fractures among 
postmenopausal women with osteoporosis 
High RCTs Non-vertebral fractures: alendronate, risedronate, and zoledronic 
acid reduce the risk of nonvertebral fractures among 
postmenopausal women with osteoporosis 
High RCTs Hip fractures: alendronate, risedronate, and zoledronic acid reduce 
the risk of hip fractures among postmenopausal women with 
osteoporosis. The effect of ibandronate is unclear, since hip fracture 
risk reduction was not a separately reported outcome in trials 
reporting nonvertebral fractures. 
Low  Wrist: alendronate reduces the risk of wrist fractures among 
postmenopausal women with osteoporosis. Risedronate in a pooled 
analysis of two trials was associated with a lower risk of wrist 
fractures, but did not quite reach the conventional level of 
statistical significance. 
Insufficient Head-to-head trials Data are insufficient from head-to-head trials of bisphosphonates to 
prove or disprove superiority for prevention of fractures for any 
agent 
 
Table 1.5. Adherence to bisphosphonate therapy and fracture rates in osteoporosis. 
 
 RR reduction in adjusted OR (%) 
Compliant cohort  
           Total fractures 21.1 
           Vertebral fractures 37.2 
           Hip fractures 37.3 
           Wrist fractures 9.2 
Persistent cohort  
           Total fractures 29.3 
           Vertebral fractures 40.0 
           Hip fractures 44.5 
           Wrist fractures 22.5 
                    Adapted from Siris, 200651 
It is important to note that compliance and persistence to these medications is an 
important factor in order to achieve the expected benefits. For example, a study to characterize 
the relationships between adherence (compliance and persistence) to bisphosphonate 
(alendronate or risedronate) therapy and risk of fracture types in 35,537 postmenopausal women 
using 2 claims databases from 45 employers and 100 health plans in the continental U.S., showed 
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that adherence to bisphosphonate therapy was associated with significantly fewer fractures at 24 
months (See Table 1.5).51  
Also beneficial clinical effects have been shown in medication-induced osteoporosis (i.e., 
long-term users of glucocorticoids and/or oral corticosteroids) 52,53 and in those supplemented 
with vitamin D and calcium.54 The American College of Rheumatology 2010 recommendations 
indicate pharmacologic treatment with bisphosphonates in postmenopausal women and men age 
≥50 years with glucocorticoid treatment with an anticipated duration of ≥3 months, or prevalent 
glucocorticoid therapy of a duration of at least 3 months.47 Glucocorticoid use is considered the 
most prevalent secondary risk factor for osteoporosis.52 
1.3.2 Bisphosphonates: Structure and pharmacology 
To appreciate the clinical benefits of bisphosphonates in osteoporosis and osteoporotic 
fractures, one needs to understand the molecular structure and mechanism of action at the 
molecular level. Bisphosphonates are characterized by their affinity for bone mineral because 
they bind to hydroxyapatite crystals,55 and inhibitory effects on osteoclasts.56 Bisphosphonates 
inhibit the aggregation of crystals and the crystal dissolution thereby inhibiting calcification. The 
attachment of bisphosphonates to crystalline hydroxyapatite is related to their structure. There 
are, however, differences among molecules in terms of configuration and the associated 
affinities. These molecules are ranked with respect to their affinities from lowest to highest as 
risedronate, ibandronate, alendronate, and zoledronic acid.58 It is important to note that the four 
molecules are classified as nitrogen-containing bisphosphonates that act specifically by 
inhibiting the enzyme farneslypyrophosphate synthase (FPP)57 within osteoclasts.  
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Figure 1.3. General structure of a bisphosphonate. 
The general structure of a bisphosphonate is shown in Figure 1.3. The R1 side chain is 
usually a hydroxyl, and R2 side-chain contains the nitrogen group that is responsible for potency. 
In relation to potency, the following schematic representation (Figure 1.4)58 summarizes the 
correlation between moieties and the potency, while Table 1.6 shows the structure-activity 
relationship of the FDA-approved bisphosphonates in the US and bisphosphonate concentration 
that gives 50% inhibition (IC50) for each compound.59 As can be seen from the table, the 
antiresorptive relative potencies for osteoclast inhibition (from lowest to highest) are: 
alendronate, ibandronate, risedronate, and zoledronic acid.  
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Figure 1.4. Bisphosphonate structure moieties and their role in potency for osteoclast inhibition. 
Table 1.6. US-approved bisphosphonates and their structures with IC50 values for the inhibition 
of FPP synthase.59 
 
Bisphosphonates R1 R2 initial IC50 (nM) final IC50 (nM) 
Alendronate -OH -(CH2)3NH2 2249±180 260.0±19.6 
Risedronate -OH -CH2-3-pyridine 452.9±16.6 5.7±0.54 
Ibandronate -OH -CH2CH2N(CH3)(pentyl) 1052±55.1 25.4±1.57 
Zoledronic acid -OH -CH2-imidazole 475.3±18.3 4.1±0.22 
 
Both bisphosphonates’ affinities for crystalline hydroxyapatite and inhibitory effects on 
osteoclasts are important pharmacological features. The high affinity for bone mineral allows 
bisphosphonates to achieve a high local concentration throughout the entire skeleton. Suppressed 
bone resorption after bisphosphonate initiation suggests bisphosphonate efficacy and potency in 
  The R2 side-chain varies widely  and is responsible for 
differences in potency 
The P-C-P group is  
essential for biological 
activity 
   The P-C-P acts as  “Bone Hook” and is essential 
for binding to hydroxyapatite 
R1 is usually a OH Group 
and this enhances binding  
to hydroxyapatite  
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promoting the apoptosis of osteoclasts actively engaged in degradation of mineral on the bone 
surface. Thus, bisphosphonates have become the primary therapy for managing skeletal 
conditions characterized by increased osteoclast-mediated bone resorption60 (i.e., osteoporosis 
and/or osteoporotic fractures). Overall, these studies clearly demonstrate that bisphosphonates 
(nitrogen-containing bisphosphonates) produce their beneficial clinical effect through the mode 
of osteoclast inhibition. The half-life of bisphosphonates ranges between 5 and 10 years.61 
 Whether the potential differences in molecular structure and clinical efficacy factors are 
related to safety issues of bisphosphonate use remains to be determined. For example alendronate 
(second highest in affinity but with lowest relative potency) has a stronger prophylactic effect 
against fractures than risedronate (lowest affinity but high potency) in rheumatoid arthritis 
patients on long-term corticosteroid therapy.53 In depth investigations of these differences and 
the safety of bisphosphonates with differences in molecular structures and potency are not the 
scope of this present study. However, the findings of this study suggest potential attenuating or 
negating effects of corticosteroid therapy (drug associated with increased risk of fracture) and the 
effects can be thought to be greater on risedronate than on alendronate therapy. Therefore, drugs 
that interfere with bone remodeling and associated with increased risk of fracture, and 
concomitant use of these drugs with bisphosphonates may alter the beneficial clinical effect of 
bisphosphonates and instead put the patients at increased risk of fracture. These are potential 
safety concerns that warrant further understanding and investigation. 
1.4 Problem statement 
Ideally, optimal efficacy of bisphosphonate therapy is expected to be achieved even in the 
presence of competing risk factors (e.g., medications) for osteoporosis and osteoporotic fractures 
(Table 1.1). There are two possible scenarios: 1) best case scenario: bisphosphonate therapy 
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supersedes the competing negative effects of risk factors for osteoporotic fractures and therefore 
treatment effects are beneficial, or 2) worst case scenario: the beneficial effects of 
bisphosphonate therapy are attenuated by the negative effects of risk factors for osteoporotic 
fractures and instead result in increased risk of new fracture. The second phenomenon is a 
serious safety issue and can be the case when bisphosphonate therapy is given concomitantly or 
simultaneously with medications that induce secondary osteoporosis such as SSRIs and SNRIs. 
Given that bone cell types possess a functional serotonin (5-HT) signal transduction mechanism 
(5-HT receptors and the serotonin transporters [5-HTT]) for both responding to and regulating 
the uptake of 5-HT suggest the involvement of 5-HT and 5-HTT in bone metabolism,62,63 the 
safety of these agents is of particular interest for individuals with osteoporosis and/or 
osteoporotic fractures.  
 
1.5 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake  
      Inhibitors: Use and Clinical Pharmacology 
 
     1.5.1 SSRIs 
The first SSRI to be used clinically was fluoxetine (Prozac®) which was approved by the 
FDA in 1987.64 Several other SSRIs have since become available including paroxetine (Paxil®), 
sertraline (Zoloft®), fluvoxamine (Luvox®), citalopram (Celexa®), and escitalopram (Lexapro®). 
Table 1.7 provides a list of these SSRIs with some additional information.  
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Table 1.7. List and description of FDA-approved SSRIs in the U.S. 
Drug product Indications Contraindications Geriatric use 
Lexapro® 
(Escitalopram) 
-Acute and 
maintenance 
treatment of Major 
Depressive Disorder 
(MDD) 
-Acute treatment of 
generalized anxiety 
disorder 
 
-****Serotonin Syndrome especially when 
co-administered with other serotonergic 
agents (including triptans, TCAs, fentanyl, 
lithium, tramadol, tryptophan, buspirone 
and St. John’s Wort) or using of MAOIs 
such as linezolid or intravenous methylene 
blue 
-Concomitant use of pimozide 
The number of elderly 
patients in controlled trials 
of Lexapro® in MDD was 
insufficient to adequately 
assess for possible 
differential efficacy and 
safety measures on the basis 
of age (approximately 6% of 
the 1144 patients were 60 
years of age or older) 
Celexa® 
(Citalopram) 
Treatment of 
depression 
-**** (see Lexapro®) 
-Concomitant use of pimozide 
-No overall differences in 
safety or effectiveness were 
observed between older 
subjects and younger 
subjects 
-Precautions-Hyponatremia 
Prozac® 
(Fluoxetine) 
-Maintenance 
treatment of MDD 
-Treatment of 
Obsessive 
Compulsive Disorder 
(OCD) 
-Acute treatment of 
panic disorder 
-**** (see Lexapro®) 
-Coadministration of pimozide, 
thioridazine due to QTc prolongation 
-Concomitant use of olanzapine 
No overall differences in 
safety were observed 
between geriatric and 
younger patients (approved 
for use) 
Luvox® 
(Fluvoxamine) 
Treatment of OCD -**** (see Lexapro®) 
-Coadministration of tizanidine, 
thioridazine, alosetron, pimozide 
No overall differences in 
safety were observed 
between geriatric and 
younger patients (approved 
for use) 
Paxil ® 
(Paroxetine) 
-MDD 
-OCD 
-Panic Disorder 
-Social Anxiety 
Disorder 
-Generalized Anxiety 
Disorder 
-Posttraumatic Stress 
Disorder 
-**** (see Lexapro®) 
-Concomitant use with thioridazine-
produces prolongation of the QTc interval-
associated with ventricular arrythmias 
-Concomitant use of pimozide 
Premarketing clinical trials 
with Paxil® (17% of patients 
treated with Paxil® were 65 
years of age or older). No 
overall differences in the 
adverse event profile and 
effectiveness between 
elderly and younger subjects 
Zoloft ® 
(Sertraline) 
-MDD 
-OCD 
-Panic Disorder 
-Posttraumatic Stress 
Disorder 
-Social anxiety 
disorder 
-**** (see Lexapro®) 
-Concomitant use of pimozide 
-with ANTABUSE® (disulfiram) due to 
the alcohol content of the concentrate 
 
-No overall differences in 
pattern of adverse reactions 
and efficacy were observed 
in the U.S. geriatric clinical 
trial subjects relative to 
younger subjects 
 
For over a decade now, SSRIs have been the most popular psychotropic medications in 
treating depression65 with a better safety and tolerability profile than older agents of 
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antidepressants (e.g., tricyclic antidepressants [TCAs], monoamine oxidase inhibitors 
[MAOIs]).66  SSRIs are considered first-line drug treatment in older patients,67 especially in 
relieving depression in women.68 In addition, SSRIs are useful in a variety of other medical 
conditions which include possible management of chronic painful rheumatologic conditions such 
as fibromyalgia,69 diabetic peripheral neuropathic pain,70 anxiety and panic disorders,71 and 
treatment of vasomotor symptoms such as hot flashes.72-74 Hot flashes have been reported to be 
persistent into the late postmenopausal years.75  
The clinical benefit of SSRIs is believed to derive from increasing the synaptic levels of 5-
HT by antagonizing the 5-HTT to block neuronal 5-HT reuptake from the extracellular space and 
thereby prolonging 5-HT receptor activation.76 Despite the better safety profile and tolerability of 
SSRI use, they are not completely devoid of adverse effects. Examples of adverse effects 
include, but are not limited, to bleeding, serotonin syndrome, hyponatremia, sleep disturbances, 
nausea, diarrhea, and bone loss (or osteoporosis)- a risk factor for osteoporotic-related 
fractures.77,78 
 
1.5.2 SNRIs 
Serotonin norepinephrine reuptake inhibitors have been associated with bone loss (or 
bone resorption) thus potentially increasing the risk of fracture in older adults.71,79 SNRIs are 
dual action antidepressants that inhibit both 5-HT and norepinephrine (NE) transporters. The 
FDA-approved SNRIs include venlafaxine (Effexor®), duloxetine (Cymbalta®), desvenlafaxine 
(Pristiq®), which is an active metabolite of venlafaxine, and levomilnacipran (Fetzima®).64 
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1.6 Significance  
Increased risk of osteoporotic fractures associated with use of SSRIs, and potentially 
SNRIs, introduces additional clinical consequences of concern about bone health in 
postmenopausal women. Concomitant SSRIs or SNRIs with bisphosphonate (BP) utilization may 
continue to rise in postmenopausal women because of the projected future increase in the 
population of older adults. Therefore, results from this study could add to the gap in the current 
body of literature and be useful for physicians treating osteoporosis and/or osteoporotic fractures 
by highlighting possible safety concerns that may be important to consider when optimizing 
patient care. Currently, there are no specific guidelines for the management of bone loss 
observed with antidepressants, yet considerable evidence suggests SSRIs and SNRIs have an 
effect on bone health. Results from this study may provide useful information to be integrated 
into the monitoring of the routine care for osteoporosis and/or osteoporotic-related fractures in 
the same way that other drug-related risk factors for osteoporosis (e.g., glucocorticoids)47 are 
monitored. Also these results might be relevant to policymakers concerned with meeting the 
needs of aging Americans, especially the health of older women.  
1.7 Objectives of the study 
There are three specific aims for this study: 
 
1. To describe the concomitant utilization pattern of SSRIs and SNRIs with BPs. 
2. To assess the risk of osteoporotic-related fractures associated with the concomitant use of BPs 
and SSRIs. 
3. To assess the increased risk of osteoporotic-related fractures associated with the concomitant 
use of BPs and SNRIs and whether the risk of osteoporotic-related fractures is related to the 
role of 5-HT in bone rather than the disease (depression). 
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1.8 Hypotheses  
The following null hypotheses are being tested in this study: 
H0(1) Concomitant use of SSRIs with BPs will have no effect on the risk of fractures compared to 
use of BPs alone (i.e., HR=1) 
H0(2): Concomitant use of SNRIs with BPs will have no effect on the risk of fractures compared 
to use of BPs alone (i.e., HR=1) 
  Like many observational studies, confounding is a common threat in this study. Confounding 
will be controlled at the design stage using propensity score matching. Propensity score is 
defined as the probability of receiving treatment rather than the control for a patient conditional 
on observed baseline covariates.80 Details of motivation to use propensity score method in the 
design of a pharmacoepidemiologic study are provided in Section 2.8 of Chapter 2. 
 
1.9 Summary 
Osteoporosis and osteoporotic-related fractures are serious public health burdens in 
postmenopausal women. The burden is expected to rise due to the projected future increase in the 
population of older adults. Pharmacologic therapy using BPs in prevention and treatment is 
currently a popular option. However, SSRIs and, potentially SNRIs, are associated with 
increased risk of fracture and might potentially attenuate the beneficial effects of bisphosphonate 
therapy. These serious safety concerns have not been investigated yet. 
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Chapter 2 
 
2.0 LITERATURE REVIEW 
2.0.1 Overview 
This chapter will provide 1) a brief understanding of the motivation to concomitant drug use and 
adverse drug events as a consequence, 2) a detailed literature review of concomitant use of 
specific drugs with BPs and potential adverse drug events such as increased risk of fracture, 3) 
description of concomitant use of SSRIs with bisphosphonates and increased risk of fracture and 
suggested supporting evidence, 4) the description to determine the role of depression versus 5-
HT in bone health, and 5) pharmacoepidemiologic study design considerations.  
2.1 Concomitant Use of Osteoporosis-Inducing Medications with Bisphosphonates and 
      Increased Risk of Fracture 
 
2.1.1 Introduction 
The number of older Americans suffering with multiple chronic health conditions 
(multimorbidity)1 is large and growing over time. Estimates have shown that 68.4% of Medicare 
beneficiaries have two or more chronic conditions and 36.4% have four or more chronic 
conditions. Moreover, these multiple chronic conditions (MCCs) increase with age and are more 
prevalent among women than men across all age groups.2 For example, in 2010, in a study of 
Medicare fee for service beneficiaries, over 70% of women had two or more chronic conditions 
compared with 65% of men.3 The 15 common chronic conditions (and their proportions) that are 
available in the 2010 CMS Chronic Condition Warehouse research files include 
hypertension/high blood pressure (58%), high cholesterol (45%), ischemic heart disease (31%), 
arthritis (29%), diabetes (28%), heart failure (16%), chronic kidney disease (15%), depression 
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(14%), chronic obstructive pulmonary disease  (12%), Alzheimer’s disease (11%), atrial 
fibrillation (8%), cancer (8%), osteoporosis (7%), asthma (5%), and stroke (4%).3 This list 
corresponds with a list of chronic conditions used to define MCCs by the Department of Health 
and Human Services Strategic Framework on Multiple Conditions.4 
With regard to the trend of MCCs, findings from the 1998, 2004, and 2008 waves of the 
Health and Retirement Study (a nationally representative survey of older adults over 50 years in 
the U.S.) showed that the proportion reporting one or more chronic diseases increased from 
86.9% in 1998, to 91.2% in 2004, and 92.2% in 2008.5 Similarly, recent estimates using data 
from the National Health Interview Survey found that the percentage of adults aged 45 years and 
over with two or more of nine self-reported chronic conditions  increased from the 1999/2000 
collection period to the 2009/2010. During that 10-year period, the percentage of adults aged 45-
64 years who had been diagnosed with two or more chronic conditions rose from 16% to 21%, 
and rose from 37% to 45% among adults aged 65 years or older.6 The increasing prevalence of 
MCCs has significant impact for the aging population. People with MCCs are particularly 
vulnerable to suboptimal quality care, have more physician contacts, fill more prescription drugs, 
and are more likely to be hospitalized each year than those with only one chronic condition.7,8 
Therefore, care management of MCCs requires heightened coordination of complex medical and 
longitudinal psychosocial care, and management of prescribed drugs.6   
Medication management of MCCs is a challenging task. As the number of chronic 
conditions increases, the number of medications prescribed also increases. According to the 
National Center for Health Statistics, the percentage of persons who used two or more 
prescription drugs (concomitant use) increased from 25% in 1999-2000 to 31% in 2007-2008.9 
Women use more prescriptions than men, and this increases with age suggesting that women are 
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at a greater likelihood of experiencing an adverse drug event (ADE).10,11 It is important to note, 
however, that the association of ADEs and age is a complex issue that can, in part, be explained 
by pharmacokinetic and pharmacodynamic changes, patient-specific physiologic and functional 
characteristics that occur with aging, and pharmacoeconomics rather than simple chronologic 
age.12,13 
Medication management of postmenopausal osteoporosis is the particular focus of this 
review. Postmenopausal osteoporosis is a result of reduced production of estrogen after 
menopause and increases the risk of fracture.14  The National Osteoporosis Foundation reports 
that about 80% of the estimated 10 million Americans with osteoporosis are women. In addition, 
approximately one in two women age 50 years and older will break a bone because of 
osteoporosis.15 Bisphosphonates are widely prescribed16 and recommended by the North 
American Menopause Society as first-line pharmacologic treatment in the management of 
osteoporosis for postmenopausal women.17 Bisphosphonates are characterized by their affinity 
for bone mineral through binding to hydroxyapatite crystals18 and inhibitory effects on 
osteoclasts.19 
 Examples of chronic conditions that can exist in osteoporotic postmenopausal women older 
than 50 years of age include diabetes, depression, chronic inflammatory joint disease, chronic 
inflammatory bowel disease, and breast cancer. These chronic conditions may increase the 
severity of osteoporosis and often affect the management of osteoporosis by increasing the risk 
of fracture.20 Other factors include medications such as glucocorticoids (GCs) for the treatment 
of chronic inflammatory joint disease. Management of both osteoporosis and chronic 
inflammatory joint disease is an example of management for MCCs that requires concomitant 
use of medications and could also affect the management of osteoporosis. This is of concern 
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because concomitant uses of medications have the potential for clinically important interactions 
that may result in ADEs leading to patient harm.  
In a study using the 2000-2002 National Ambulatory Medical Care Survey to examine 25 
clinically important drug-drug interactions, Aparasu et al. found that patients over 44 years of 
age, especially older adults, Medicare beneficiaries, and those prescribed multiple medications, 
were at risk of receiving concomitant medications with the potential for a clinically important 
drug-drug interaction when compared to patients less than 25 years of age. Moreover, the study 
showed that the annualized visit rates involving interacting medications were high among 
persons over 64 years vs. less than 64 years, females vs. males, and whites vs. others. 
Interestingly, of the examined potentially interacting medications, none of the combinations 
included osteoporosis treatment agents such as bisphosphonates.21 The U.S. Department of 
Human Services framework to address the population with MCCs highlights that recognizing 
drug-drug interactions and potential ADEs from complex medication regimens is one of the 
strategies for medication management.22  
Drug-drug interactions occur when one therapeutic agent alters the absorption, distribution, 
metabolism, and/or excretion of another drug (pharmacokinetic interactions) or the biological 
effect of another agent (pharmacodynamic interactions). In the case of pharmacodynamic 
interactions, the two drugs act at the same or interrelated receptor sites and may behave in an 
additive, synergistic, or antagonistic fashion.23 Pharmacokinetic interactions often occur via the 
cytochrome P-450 (CYP450) enzymes, which is the most common pathway for drug-drug 
interactions.24 Transporter-based interactions (analogous to drug interactions mediated by P450 
enzymes) have also been documented in recent years. Transporters can play a role in drug 
absorption, distribution, metabolism (in concert with metabolizing enzymes), and excretion.25  
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With regard to osteoporosis treatment agents, Table 2.1 outlines drug-drug interactions 
involving BPs and the potential outcomes sourced from the FDA prescribing and labeling 
information; however, there is evidence in the literature of additional possible interactions that 
are not documented in the product label. For example, within the past 10 years, studies have 
suggested that medications associated with increased risk of fracture (see Table 2.2), such as 
proton pump inhibitors (PPIs), might attenuate the beneficial effects of BPs when used 
concomitantly. Drug-drug interactions between BPs and medications, which result in negative 
effect on bone strength leading to increased risk of fracture, have been hypothesized to be a 
pharmacodynamic interaction.26 In support of this hypothesis, an explanation follows.  
 
Table 2.1. Bisphosphonate-drug interactions and ADEs from the FDA prescribing and labeling 
information. 
Bisphosphonate drug Co-administered drug (s) Outcome 
Fosamax® (alendronate sodium), 
Boniva® (ibandronate sodium), 
Actonel® (risedronate sodium) 
Calcium 
supplements/Antacids 
Interference with absorption 
of drugs 
Fosamax® (alendronate sodium), 
Boniva® (ibandronate sodium), 
Actonel® (risedronate sodium) 
Aspirin/ Nonsteroidal anti-
inflammatory drugs 
(NSAIDS) 
May worsen gastrointestinal 
irritation 
Boniva® (ibandronate sodium), 
Actonel® (risedronate sodium) 
H2 blockers and PPIs May affect oral 
bioavailability, but 
interactions are not considered 
to be clinically relevant 
Reclast® (zoledronic acid) Nephrotoxic drugs Renal failure 
Reclast® (zoledronic acid) Aminoglycosides May have additive effect to 
lower serum calcium for 
prolonged periods 
Reclast® (zoledronic acid) Loop diuretics May increase risk of 
hypocalcemia 
 
 
Pharmacologic actions of bisphosphonates are osteoclast-mediated. Bisphosphonates inhibit 
bone resorption by preventing osteoclast recruitment, differentiation and activity, and inducing 
osteoclast apoptosis.19 Therefore, suppression of osteoclast bone resorption is the 
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pharmacodynamic effect of bisphosphonates. On the other hand, medications associated with 
osteoporosis and increased risk of fracture such as GCs and PPIs affect bone by inhibiting 
osteoblast differentiation and activity, bone formation, and/or increasing bone resorption.27,28 In 
this case, concomitant GC/PPI and bisphosphonate use may increase the risk of 
osteoporosis/bone loss through the antagonizing or attenuating  effects of GC/PPI on any 
beneficial effects of bisphosphonates. The pharmacodynamic interaction of these combinations 
would result in attenuation of bisphosphonate effects, hence increasing the risk of fracture for the 
patient.  
Table 2.2. Medications associated with increased risk of fracture in older people. 
Medication class Generic drug examples 
Oral GCs Hydrocortisone, prednisone, dexamethasone 
Aromatase inhibitors Letrozole, anastrozole 
SSRIs  Citalopram, fluoxetine, paroxetine 
PPIs (acid suppressive drug). Esomeprazole, omeprazole, lansoprazole 
Thiazolidinediones Rosiglitazone, pioglitazone 
Thyroid hormones Levothyroxine 
Anticoagulants Heparin, warfarin 
Anticonvulsants Phenobarbital, oxcarbazepine, valproic acid 
Benzodiazepines Lorazepam, triazolam 
Atypical antipsychotics Olanzapine, quetiapine, risperidone 
Opioid analgesics Hydrocodone, oxycodone, morphine 
Loop diuretics Furosemide, bumetanide 
Methotrexate Methotrexate 
 
Although Table 2.2 includes a number of medications associated with osteoporosis 
and/or increased risk of fracture in older people, this review focuses only on five selected 
medication classes (GCs, PPIs, SSRIs, aromatase inhibitors, and thiazolidinediones) and one 
medication (levothyroxine). The rationale for the selection is because there is supportive 
evidence in the literature suggesting that the biological mechanisms of these drug effects can 
influence bone metabolism and increase the risk of fracture (i.e., have negative effects on normal 
bone remodeling process). Medications that were not reviewed are those with poorly understood 
 
 
34 
 
pharmacological actions on bone (e.g., anticonvulsants)29 and/or that the pharmacodynamic 
effect of increased risk of fracture may be explained primarily through increased risk of falls 
(e.g., anticonvulsants30 and benzodiazepines31). Similar to these drug examples, it is worth 
mentioning that the association between SSRIs and increased risk of fractures can be fall-related, 
for example through sedating effects of SSRIs.32 However, SSRIs have been included for review 
because there is sufficient evidence that the biological mechanisms of these drug effects can 
influence drug metabolism. We review the literature and outline the results of the clinical 
outcomes of concomitant use of these agents with BPs and increased risk of fracture through 
potential attenuation of BPs. Furthermore, we summarize the pharmacology of these agents and 
potential harm on the bone and suggest future areas of research.  
2.1.2 Literature search strategy 
We performed a Medline search for articles published from January 2003 to January 2013. The 
following medical subject headings (MeSH) terms were used: bisphosphonates (formerly termed 
diphosphonates) OR bone density conservation agents OR glucocorticoids OR acid-suppressive 
drugs/proton pump inhibitors OR levothyroxine OR thiazolidinediones OR aromatase inhibitors 
OR selective serotonin uptake inhibitors AND bone fractures. CINAHL and PsychINFO 
databases were also searched for any additional relevant publications. The abstracts of all 
potential articles were reviewed for relevancy. Other references were obtained from citations 
from retrieved articles. Studies were included if they specifically reported results of concomitant 
use of any of these medications with bisphosphonates and risk of fractures, focused on women, 
and were published in the English language. Articles that focused generally on use of one of the 
listed medications and fractures without particular emphasis on use with bisphosphonates and 
potential antifracture efficacy or attenuation of bisphosphonates were excluded. There were no 
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studies of concurrent use in the literature to review thiazolidinediones, aromatase inhibitors, and 
SSRIs and therefore studies suitable for conducting this review only focused on acid-suppressive 
drugs, GCs, and levothyrozine. Following is a review of these medications in more detail. 
 
2.1.2.1 Proton pump inhibitors 
Acid-suppressive drugs, such as PPIs, may be associated with increased risk of fractures. 
In a pooled analysis of PPI use, Kwok et al. showed significant risk for spine fractures (4 studies, 
OR:1.50; 95% CI, 1.32-1.72) and hip fractures (10 studies, OR:1.23; 95% CI, 1.11-1.36). Where 
duration of follow up was reported, this ranged from a median of 6.5 weeks to a mean of 7.8 
years. Longer duration of exposure (typically >3 years, pooled result of 6 studies) was associated 
with higher increased risk of fracture (OR:1.40; 95% CI, 1.14-1.72) when compared with the 
increased risk of fracture (OR:1.23; 95% CI, 1.19-1.27) at shorter duration of exposure (<12 
months, pooled result of 5 studies).33 PPIs are the most effective pharmacological option for 
managing gastrointestinal disorders such as gastroesophageal reflux disease (GERD).34 BP drugs 
have been shown to cause upper gastrointestinal adverse events such as GERD,35 thus resulting 
in the concomitant use of BPs and PPIs. Concomitant use of PPIs with BPs may increase the risk 
of fracture by reducing the antifracture efficacy of bisphosphonates. With regard to this 
hypothesis, three studies were identified. 
De Vries et al. conducted a retrospective cohort study using the UK General Practice 
Research Database in patients who started either acid-suppressive medication (PPIs or H2 
receptor blockers) or BP therapy (alendronate, risedronate, ibandronate, or etidronate) between 
1988 and 2007. The primary objective was to assess the association between concomitant use of 
BPs and acid suppressants and attenuated fracture risk in patients aged 40 years and older. 
Concomitant use of acid suppressants was defined as a prescription within 6 months before start 
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of 3 month-long BP episodes. The periods of follow-up (defined from the first BP or acid-
suppressive medication prescription) was divided into periods of current (the period from the 
prescribing date up to 91 days after the estimated end of the prescription) and past exposure for 
BPs and acid suppressive medication. In the BP cohort, the findings indicated a significant 
association between current concomitant use of H2 receptor blockers and BPs and risk of 
vertebral fracture (ARR: 1.56; 95% CI, 1.24-1.96); concomitant use of PPIs and BPs and 
increased risk of any fracture (ARR:1.08; 95% CI, 1.01-1.16) and hip fracture (ARR:1.24; 95% 
CI, 1.08-1.42), when compared with current users of BP alone (i.e., patients who never used acid 
suppressants or who stopped taking acid suppressants for at least 6 months before the start of the 
BPs).  Further investigations on these data showed that the risk of fracture was observed to be 
dose-dependent with fracture risk increasing as daily dose increased. The authors concluded that 
these findings suggest that BP use does not counteract the increased risk of fracture seen with 
acid-suppressive medication use.36 
In a cohort study using Danish national health care data from 38,088 people from 1996 to 
2005, Abrahamsen et al. found that concomitant PPI use with alendronate was associated with a 
dose-dependent attenuation of risk reduction against hip fracture in patients aged 70 years and 
older. Based on theoretically complete (100%) refill compliance, the risk reduction in PPI users 
was not significant (19%; HR: 0.81; 95% CI, 0.64-1.01), but there was a 39% risk reduction 
(HR: 0.61; 95% CI, 0.52-0.71) in patients who were not PPI users. The attenuation of the risk 
reduction depended on the cumulative PPI dose. A cumulative PPI dose of 1 to 359 defined daily 
doses (DDDs) had no impact on the treatment response at the hip, but the authors demonstrated 
no risk reduction with alendronate in patients exposed to more than 360 DDDs of a PPI.  No 
such effects were observed with concomitant histamine H2 receptor blockers.37 A previous case-
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control study also showed that PPIs (calculated as cumulative DDDs) were found to be 
associated with an increase in fracture risk while H2 receptor blockers were not, but the reasons 
were unclear.38 Both H2 receptor blockers and PPIs are potent antisecretory agents39 and this 
would seem to suggest that acid suppression is not the mechanism for the effects on bone. Yang 
et al. have proposed that the increased risk associated with PPIs may be linked to a decreased in 
calcium absorption.28  
In contrast to the preceding studies, Roux et al. found that concomitant PPI use did not 
demonstrate canceling effects of anti-fracture efficacy of BPs.  This study was a recent post hoc 
analysis of a subset of patients who had participated in three prospective, randomized, placebo-
controlled clinical trials (Vertebral Efficacy with Risedronate Trial-MultiNational, Vertebral 
Efficacy with Risedronate Trial-North America, and the risedronate Hip Intervention Program) 
with durations of up to 3 years. In this post hoc analysis, it was found that concomitant PPI use 
with risedronate was not associated with incident vertebral fractures, when compared to PPI non-
users. The vertebral fracture rate was similar among PPI users (16.1%) and PPI non-users 
(16.9%). Overall findings from this study showed that risedronate reduced fracture risk of new 
vertebral fractures in PPI users (RR:0.43; 95% CI,0.23-0.81) and PPI non-users (RR:0.62; 95% 
CI, 0.52-0.73).40 
The evidence on concomitant use of PPIs and bisphosphonates and antifracture efficacy 
of bisphosphonates is conflicting. Two cohort studies indicated a significant antifracture efficacy 
of bisphosphonates with concomitant PPIs and bisphosphonates use, but the randomized clinical 
trial (RCT) did not indicate significant association. Although the cohort studies were of good 
quality (e.g., sample size, generalizability of the databases, and follow-up periods long enough to 
capture the outcomes being evaluated) and controlled for measurable confounders, the studies 
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are subject to selection bias making it difficult to determine if the attenuation of BPs are because 
of PPIs or some source of bias. On the other hand, the RCT by Roux et al. may reflect a true 
causal-relationship of non-significant attenuation of BPs due to PPIs because they eliminate 
selection bias.41 From an methodological standpoint, RCTs are superior to observational studies, 
such as cohort studies, and are thus considered a gold standard for determining causal 
relationships.42 This is because in observational studies participants are not randomized to a 
treatment or control group, but differences in outcomes (between participants with varying 
characteristics) are observed after treatment decisions. In contrast, in RCTs, participants are 
randomly assigned to a treatment or control group, thus participants under study are expected to 
have the same characteristics. Findings from the RCT above would be considered “stronger” 
than findings from the two cohort studies. However, two important concerns about this particular 
RCT are noted. First, the trials included relatively healthy postmenopausal women with 
osteoporosis or radiographically identified vertebral fractures and had no recent use of drugs 
known to affect bone (e.g., BPs), and had no major illness. Applying these exclusion and 
inclusion criteria limits the generalizability of the findings from RCT populations as they are not 
representative of broader populations included in observational studies. Second, the Roux et al. 
study was a post hoc analysis of a subset of patients who had participated in prospective RCTs. 
The initial hypothesis in these RCTs was not PPI effects on bisphosphonates. In such case one 
could argue that all of the methodological benefits of an RCT do not necessarily apply. Both of 
these reasons could explain why the RCT and the two cohort studies did not arrive at the same 
conclusions. Given this conflicting evidence and the methodological challenges, it is premature 
to conclude one way or the other based on these few studies. Additional well-designed studies 
are needed to help determine valid conclusions. 
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 2.1.2.2 Glucocorticoids 
Glucocorticoids (GC) (also called corticosteroids) used in the management of many 
inflammatory conditions are considered the most prevalent secondary risk factor for 
osteoporosis.43 Van Staa et al. in a prospective study using data from two large, prospective, 
randomized, controlled trials, showed that postmenopausal oral GC users have considerably 
higher fracture risk compared to nonusers (adjusted RR:5.67; 95% CI, 2.57-12.54) at similar 
baseline levels of bone mineral density (BMD).44 Chronic treatment with GC in postmenopausal 
women can independently result in significant reduction in BMD.45  
In a population-based, case-control study using a hospital discharge registry in Denmark, 
Vestergaard et al. found an association between cumulative GC use (more than an average dose 
of approximately 71 mcg prednisolone per day)  and increased risk of hip fracture compared with 
never users.46  Using the same database in a large community-based sample in Denmark, 
Vestergaard et al. later conducted a case-control study to examine the risk of fractures in subjects 
exposed to systemic and topical GCs and found an increased risk of fracture among oral GC 
users at dosages higher than 2.5 mg prednisolone equivalents per day (adjusted OR:1.15; 95% 
CI, 1.09-1.22 for dosages of 2.5-7.49 mg/day, and adjusted OR:1.59; 95% CI, 1.49-1.70 for 
dosages of ≥7.5 mg/day).47 Manuel et al. conducted a cross-sectional study of 513 men and 
women in Spain and found that the use of oral GCs over a 3-month period at doses higher than 
7.5 mg/day of prednisone or equivalent was associated with risk of non-vertebral fractures (a 
prevalence of 28.3%).48 In a case-control study using patients within the Dutch PHARMO-RLS 
database, De Vries et al. found that current use of oral GCs was associated with an increased risk 
of hip/femur fracture (adjusted OR:1.43; 95% CI, 1.22-1.67) in patients 50 years and older, 
especially at higher daily dosages.49  
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It is evident that oral GCs used for a longer duration are associated with increased risk of 
fracture and the risk is dose dependent. Bisphosphonates are recommended as first-line therapy 
in these patients.50 This is in agreement with the current guidelines and recommendations 
developed by the American College of Rheumatology. In addition, the American College of 
Rheumatology recommends calcium and vitamin D supplementation counseling for all patients 
beginning GC therapy.51 Bisphosphonates have been shown to be beneficial in medication-
induced osteoporosis such as in long term users of oral GCs43,52 and in those supplemented with 
vitamin D and calcium.53 Maintenance of sufficient calcium and vitamin D is needed for optimal 
benefits of bisphosphonates.54  
Concomitant use of GCs with BPs has been reported. A recent descriptive study using the 
1999-2008 U.S. National Health and Nutrition Examination Survey found that the prevalence of 
GC use in the U.S. general population 20 years and older is 1.2% (95% CI, 1.1-1.4), 
corresponding to 2,513,259 persons, but the prevalence rate increases with age. Women (53.3%, 
95% CI, 47.2-59.4) represented a larger proportion of oral GC users than men. Oral GC users 
reported concomitant use of BPs (8.6%), hormone replacement therapy (5.9%), calcium (22.7%), 
vitamin D (18.5%), and other medications (37.9%). Women reported greater concomitant use of 
all antiosteoporosis pharmaceutical interventions.55 Despite the current recommendations for BPs 
use in GC-induced osteoporosis and the prevalent concomitant use, the potential for GCs to 
attenuate the effects of BPs and any resulting increased risk of fracture remains unclear in the 
literature.  
A review of case series and case reports conducted by a taskforce of the American 
Society for Bone Mineral Research to assess reports of atypical femoral fractures in patients 
receiving long-term BPs suggests that concomitant use of medications such as GCs might be an 
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important risk factor for these atypical femoral fractures. The taskforce recommended that 
assessment of concomitant use of GCs is one of the key areas for the evidence when evaluating 
the long-term use of BPs and atypical femoral fractures.56,57 Similarly, Giusti et al. conducted a 
systematic literature review of postmenopausal women treated with BPs who sustained 
subtrochanteric/diaphyseal fractures and found that concomitant use of GC therapy might be an 
important risk factor.58 Evidence from case series and reports may constitute only a small 
percentage of the total number of cases that exist. Larger studies have yet to be conducted to 
examine this potential attenuating effect of GC on BPs and increased risk of fracture.  
Considering that oral GCs are widely accepted risk factors for fracture, it is not our 
intention to suggest that large studies on oral GCs and their contribution to the increased risk of 
fracture are lacking in the current literature; however, through our review we found that none of 
the large studies we identified and reviewed that demonstrate strength of association between 
oral GCs and fractures investigated an interaction with bisphosphonates. In other words, 
concomitant use of oral GCs and bisphosphonates was not investigated as an independent risk 
factor. Instead, bisphosphonate use was either not assessed at baseline44,47-49 or was only adjusted 
for as a potential confounder.46 
2.1.2.3 Levothyroxine  
The prevalence of thyroid diseases (i.e., hyperthyroidism and hypothyroidism) increase 
with age and is more common among older women than men. Women are five times more likely 
than men to have thyroid problems.(www.thyroid.org) A recent review of studies from Europe, 
Japan, and the U.S. shows that the prevalence ranges between 0.6 and 12 per 1000 in women and 
between 1.3 and 4.0 per 1000 in men.59  Levothyroxine (LT4) replacement therapy is the 
treatment of choice for hypothyroidism in postmenopausal women. The goal of LT4 treatment is 
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to normalize serum thyroid stimulating hormone (TSH) values.60 Both hyperthyroidism, defined 
as suppressed TSH, and suppressive T4 treatment are associated with a reduction in BMD and an 
increased risk of fracture in postmenopausal women and in men aged 50 years and older.61 It is 
worth noting that the effects of thyroid hormone on bone are related to the dose. Excess thyroid 
hormone increases the risk of fracture, therefore it is recommended that the lowest possible dose 
of thyroid hormone be used to correct the medical problem being addressed.62 The patient fact 
sheet provided by the American College of Rheumatology also recognizes excess thyroid 
hormone replacement in those taking medications for low thyroid or hypothyroidism as an 
important risk factor for osteoporosis. One of the steps suggested to prevent, treat, or manage 
osteoporosis and/or increased risk of fracture is to use bisphosphonates.63 The important 
question, however, is whether anti-fracture efficacy of BPs can be counteracted when 
levothyroxine is given concomitantly with BPs. Two relevant articles were available in the 
current literature for review. 
 Panico et al. conducted a prospective cohort study involving seventy four 
postmenopausal women aged 52-65 years with low BMD (T-score ≤ -2.5) and thyroid carcinoma 
using long-term LT4 therapy (3-9 years) versus non-users. Effectiveness of alendronate on BMD 
in this study was observed to be worsened as the duration of LT4 treatment increased when 
measured at 12 and 24 months.64 Specifically, changes in BMD were significantly less in 
alendronate-treated osteoporotic women who had been on TSH-suppression therapy for 9 years 
than those receiving therapy for 3 years or those who had not been taking LT4 (i.e., controls). 
Patients treated for 3 years showed an increase of BMD at the lumbar level by 7.88%, those 
treated for 6 years by 4.63%, and those treated for 9 years by 0.86% from their baseline BMD 
measurements. Similarly, the increase of BMD at the femoral level was 4.62% in those treated 
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for 3 years, 3.01% in those treated for 6 years, and 0.95% in those treated for 9 years.64 In the 
control group (women who had not been taking LT4 and were treated with BPs) BMD increased 
8.2%. These findings suggest that LT4 may have attenuated the beneficial effects of alendronate 
and potentially other BPs when the two agents are co-administered. 
Turner et al. conducted a nested case-control study consisting of 213,511 adults aged 70 
and over prescribed LT4 between April 2002 and March 2007 and followed them for fractures 
until March 2008. Descriptive results showed that a total of 22,236 (10.4%) people sustained at 
least one fracture and of these cases 20,514 (92.3%) were current users of LT4 at the index date 
(the date of admission to hospital for the first fracture). Of particular interest, the authors 
reported that cases were more likely than controls to have a diagnosis of osteoporosis (27% vs. 
22%) and to use BP (28% vs. 23%). Despite this, the association between concomitant LT4 and 
BP use and increased risk of fracture was not examined.  Bisphosphonate use was adjusted for as 
a potential confounder. Nevertheless, when the association between LT4 and increased risk of 
fracture was examined, current use (if the duration of their prescription encompassed the index 
date) of LT4 when compared with remote use (if the prescription ended more than 180 days 
before the index date) was associated with a higher risk of fracture in women (adjusted OR:1.98; 
CI, 1.80-2.19) than men (adjusted OR:1.42; CI, 1.15-1.76). Among current users, high 
cumulative doses of LT4 (>0.093 mg/day) were associated with an increased risk of fractures 
(adjusted OR:3.45; CI, 3.27-3.65) compared with low doses (<0.044 mg/day).65 
 
  2.2 Selected medications and pharmacology on bone 
The mechanisms of action of medications associated with increased risk of fracture are 
via their impact on osteoblasts and osteoclasts. These effects have an overall influence on the 
 
 
44 
 
balance of the bone remodeling process. As pointed out in this review, there is some clinically 
significant evidence in the literature suggesting possible attenuating effects of PPIs, oral GCs, or 
LT4 on BPs. This interaction might also be clinically significant between SSRIs, aromatase 
inhibitors, or thiazolidinediones and BPs. Currently there is a lack of evidence in the literature on 
these latter medications with regard to these potential interactions. To provide insight into the 
potentially similar pharmacodynamic interaction of attenuation of BPs and increased risk of 
fractures when these medications are co-administered with BPs, we briefly outline the proposed 
mechanisms of action on bone for PPIs, GCs, LT4, SSRIs, aromatase inhibitors, and 
thiazolidinediones in Table 2.3.  
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Table 2.3. Medications likely to be prescribed concomitantly with bisphosphonates that can influence 
bone metabolism and increase the risk of fracture. 
Medication type Proposed mechanism Reference 
PPIs Gastric acid suppression can result in hypergastrinemia and 
may cause malabsorption of calcium and vitamin B12.  
Decreased calcium absorption leads to decreased plasma Ca2+ 
concentration leading to elevated levels of parathyroid 
hormone, followed by increased bone resorption, decreased 
volumetric BMD, and consequently decreased bone strength. 
Vitamin B12 is involved in osteoblast activity and bone 
formation. Deficiency of vitamin B12 can result in a sequence 
of events which includes decreased osteoblastic activity, 
decreased bone formation, and decreased volumetric BMD 
that finally results in decreased bone strength. Another 
potential pathway to decreased bone strength is that 
deficiency of Vitamin B12 can induce homocysteinemia by 
interfering with collagen cross-linking. Decreased bone 
strength leads to increased risk of fracture. 
Yang Y-X, et al. 
2010.28 
GCs The GC effect is mediated via the GR. GR is present in 
osteoblasts and is required for inhibition of bone formation 
and, consequently, bone loss. Suppression of osteoblast 
differentiation and inhibition of bone formation may be 
central to the association between GC and increased risk of 
fractures. 
Rauch, et al., 
2010.27 
LT4 Physiological variation in normal thyroid status is related to 
BMD, with hyperthyroid status resulting in decreased BMD 
(increased bone resorption), and leading to increased risk of 
fractures. 
Murphy et al. 
2010.66 
SSRIs Osteocytes and osteoblasts possess a functional 5-HT signal 
transduction mechanism (5-HT receptors and the 5-HTT) for 
both responding to and regulating the uptake of serotonin. 5-
HT uses one predominant receptor, Htr1b, to affect osteoblast 
biology. Brain-derived high levels of 5-HT binds to 5-HT 
receptors on osteoblasts which in turn negatively controls 
osteoblast proliferation via molecular clock Cyclin (Cyc D1) 
gene cascade leading to decreased bone formation. The 
binding of 5-HT also positively regulates bone resorption via 
activation of a protein kinase A/ATF4-dependent pathway, 
leading to increased synthesis of RANKL, an activator of 
osteoclast differentiation and function. 
Bliziotes et al. 
2001, Takeda et al. 
2002, Karsenty 
2006.67-69 
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Table 2.3. …..CONTINUED 
Medication type Proposed mechanism Reference
Aromatase 
inhibitors (AIs) 
AIs act by blocking the peripheral conversion of estrogen 
from androgen precursors and thus lowering tissue and 
circulating estrogen levels. Estrogen deficiency leads to the 
development of osteoporosis and increased risk of fracture. 
Estrogen receptors and aromatase are both expressed in 
bone. Normally, estrogen has suppressive, antiresorptive 
effects on osteoclasts during remodeling by stimulating the 
expression of antiresorptive factors such as osteoprotegerin. 
This results in the attenuation of RANK and RANKL 
signaling, leading to inhibition of osteoclastogenesis and 
decreased bone resorption. Therefore, the presence of AIs 
leads to estrogen deficiency, which in turn leads to increased 
synthesis of RANKL. 
Gaillard et al. 
2011.70 
Thiazolidinediones 
(TZDs) 
Users of TZDs are at increased risk of low BMD and 
fractures which result from bone marrow AG. Bone marrow 
AG is stimulated from the switch of mesenchymal stem cells 
into the fat lineage via activation of PPAR-γ and this leads 
indirectly to suppression of osteogenesis. TZD-mediated 
activation of PPAR-γ accelerates osteoblast differentiation 
and is ultimately followed by increased osteoblast apoptosis. 
This concept builds the molecular basis for clinically 
observed bone marrow AG, diminished bone formation, and 
increased fracture rate in TZD-treated patients. 
Bruedigam et al. 
2010.71 
Abbreviations: GR, glucocorticoid receptor; 5-HT, serotonin; 5-HTT, serotonin transporters; ATF-
4, activation transcription factor protein 4; RANKL, receptor activator of nuclear factor  kappa B 
ligand; RANK, nuclear factor  kappa B receptor;  AG, adipogenesis;  PPAR-γ, peroxisome proliferator-
activated receptor γ.  
 
2.3 Conclusions and recommendations   
Available literature suggests that concomitant PPIs, GCs, or LT4 with BPs could lead to 
increased risk of fracture through the attenuation of beneficial effects of BPs. This attenuation 
could be because of the negative/antagonistic pharmacodynamic interaction. Although we did 
not find sufficient evidence in the literature to suggest that SSRIs, AIs, or TZDs might attenuate 
the effects of BPs when given concomitantly, we hypothesize the possibility of this phenomenon. 
Potentially, there may be a common underlying mechanism for attenuation effects.  What these 
drugs have in common is that they result in bone loss and increased risk of fracture via inhibition 
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of osteoblastic activity and bone formation and/or increased bone resorption caused by increased 
osteoclast differentiation and function. This similarity of negative effects on bone might suggest 
analogous evidence (and may have a biologic rationale) to demonstrate a potentially clinically 
important association between concomitant use of SSRIs, AIs, or TZDs with BPs and attenuation 
of antifracture effects of BPs.  
The Bradford Hill criterion of analogy72 can be useful in evaluating causal associations in 
pharmacoepidemiology.73 The criteria may be applied in this situation because all the listed 
medications in Table 2.3 have similar pharmacological actions on bone and are associated with 
increased risk of bone loss and fracture in patients. Therefore, given the analogy to 
pharmacological actions of drugs such as PPIs, it is plausible to suppose that the phenomenon of 
attenuation of BPs might exist among concomitant users of medications associated with 
increased risk of fracture with BPs for the treatment of postmenopausal osteoporosis. This is an 
important drug safety issue concerning prescribing and use of BPs that has not been addressed in 
clinical guidelines commonly used by clinicians.  
Recommendations developed in the current Clinician’s Guide to Prevention and 
Treatment of Osteoporosis on the drug safety issues of BPs include side effects of BPs (e.g., 
atrial fibrillation), contraindications in certain patients, osteonecrosis of the jaw, and atypical 
femoral fractures associated with long-term use of bisphosphonates.74 Furthermore, currently 
there are no ongoing or documented safety review reports of concomitant use of PPIs, GCs, 
TZDs, AIs, SSRIs, or LT4 with BPs and potential increased risk of fracture by the FDA. With 
this gap in the current clinical guidelines, and lack of ongoing drug safety reviews by the FDA 
regarding the concomitant use of BPs with any of the aforementioned drugs, it calls for more 
research to investigate this hypothesis by conducting pharmacoepidemiologic studies to 
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investigate which pharmacodynamic interactions might be clinically important and have the 
potential for harm on the bone, and if necessary, prompt further prospective pharmacodynamic 
studies of these drug combinations. These future research efforts add to prescribers’ knowledge 
of potential safety issues during the process of medication management of MCCs, especially, 
comorbid osteoporosis. This current study focuses on concomitant use of SSRIs or SNRIs with 
BPs and increased risk of fracture. This phenomenon has not been reported yet.  
2.4 SSRIs Use and Icreased Risk of Fractures in Postmeopausal Women 
 
2.4.1 Literature review results 
A number of prospective studies and studies based on administrative databases have 
demonstrated the association between SSRIs use and increased risk of fracture, especially among 
postmenopausal women. The results are discussed as follows. 
In a large United Kingdom (UK) case-control and case series study using data from the UK 
General Practice Research Database involving 16,341 cases, 79% women of mean age 79 years 
old with a recorded diagnosis of hip fracture or fractured neck of femur, analysis of the data 
showed a strong association of prior SSRI exposure and hip fracture (OR=1.42; 95% CI 1.28-
1.58). However, the authors noted that the results were probably overestimated because of 
selection and indication bias. The case-series design ascertained the true adverse impact of 
antidepressants on hip fracture risk through removing the influence of factors that varied 
between individuals, such as frailty and severity of depression.75 
Bolton et al. performed a case-control study involving 15,792 cases (70.3% females) of 
persons aged 50 years and older using a population based administrative health data in Canada 
aimed at determining the effects of individual psychotropic medications (SSRIs, other 
monoamine antidepressants, lithium, typical antipsychotics, atypical antipsychotics, or 
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benzodiazepines) and increased risk of osteoporotic fractures. The findings showed that of the 
current psychotropic medications used, SSRIs had the strongest positive association with 
fractures (OR=1.45; 95% CI 1.32-1.59; p<0.01) in a multivariable model and showed a 
significant trend of increasing fracture with increasing dose.76 These two studies based on 
administrative database are in agreement with other prospective studies. 
Ensrud and colleagues77 conducted a prospective Study of Osteoporotic Fractures from 
August 4, 1992 to July 31, 1994 involving 9,704 women 65 years and older who were CNS 
active medication users. Among the antidepressant users, 103 (21%) were SSRIs users 
(fluoxetine, paroxetine, and sertraline). Findings from the study showed women using SSRIs had 
moderate increased risk of hip fracture (multivariable HR= 1.54; 95% CI, 0.62-3.82) compared 
with central nervous system (CNS) medication nonusers. However, the results were not 
statistically significant38 possibly because of the small sample size.  
Diem et al.78 in a prospective Study of Osteoporotic Fractures involving 9,704 women aged 
65 years and older (of whom 198 [7.3%] were SSRI users), found that women taking SSRIs 
experienced a higher age-adjusted rate of bone loss at the total hip than nonusers (-0.77% vs -
0.49% per year; p=0.005) and the results were not significantly altered in a multivariable model.  
Overall, the authors concluded that at any of the sites (hip, femoral neck, or trochanter), the 
adjusted rate of bone loss among SSRI users was at least 1.6-fold higher than that among 
nonusers of antidepressants.78  
Similar results by Williams et al. in a retrospective cohort study have been reported. The 
study aimed at investigating the effect of SSRIs use on BMD among older women with a lifetime 
history of depressive disorder. The results showed that BMD among SSRIs users was 5.6% 
lower at the femoral neck (p=0.03), 6.2% lower at the trochanter (p=0.04), and 4.4% lower at the 
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mid-forearm (p=0.03) sites compared with nonusers.79 Loss of BMD has been associated with 
increased risk of hip and spine fracture incidence in postmenopausal women.80  
Richards et al.81 found that postmenopausal women on SSRIs exhibited bone loss and had a 
two-fold increase in the risk of fragility fracture. The study involved a prospective cohort of 
5008 community-dwelling adults 50 years and older aimed at investigating the effect of daily 
SSRI use on the incidence of clinical fragility fracture. Daily SSRI use was associated with 
increased risk of fragility fracture (adjusted hazard ratio [HR], 2.1; 95% CI 1.3-3.4). A dose 
effect of SSRIs on clinical fragility fracture was also noted (HR, 1.5; 95% CI 1.1-2.1). The 
clinically relevant sites were 40% forearm, 21% ankle and foot, 13% hip, 13% rib, 9% femur, 
and 4% back. Furthermore, daily SSRI users demonstrated decreased fracture-free survival 
compared with nonusers.81  
Spangler et al. in a prospective cohort study of 93,676 postmenopausal women, found that 
compared with women using other types of antidepressants, women using SSRIs had increased 
adjusted risk of any fracture (HR=1.30; 95% CI 1.20-1.41), clinical spine (HR=1.25;95% CI 
0.96-1.63), wrist (HR=1.29; 95% CI 1.07-1.56), and fractures at other sites (HR=1.32;95% CI 
1.21-1.45). Statistical significance was not achieved at the hip (HR=1.33; 95% CI 0.95-1.86). 
Also, it can be seen that the confidence intervals for clinical spine included 1.0, but the authors 
did not mention whether this was an issue for their findings. This was probably because 
antidepressants were associated with increased risk of clinical spine fracture (HR=1.36; 95% CI 
1.14-1.63) and the study was primarily looking at antidepressant use or depressive symptoms as 
primary exposures.82  
Diem et al.83 in a recent study based on a 10-year follow-up medication-use data involving 
the same population of 9,704 women aged 65 years and older recruited in the prospective Study 
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of Osteoporotic Fractures, showed that of these women 2,809 experienced an incident nonspine 
fracture over the follow-up period, including 936 with a hip fracture and 582 with a wrist 
fracture. Women taking SSRIs experienced a higher age-adjusted risk of nonspine fracture 
compared with nonusers (HR=1.36, 95% CI 1.11-1.67) and was not substantially altered after 
adjusting for other covariates (HR=1.38, 95% CI 1.10-1.72) in a multivariable model. The risk of 
wrist fracture was HR=1.54 (95% CI 1.01-2.36) for SSRIs users compared with nonusers. The 
risk of hip fracture was close to 1.0 (HR=1.01, 95% CI 0.71-1.44) for SSRIs users compared 
with nonusers secondary to potential confounding factors.83 
The results provided above are from single studies. In order to provide reliable and a more 
generalizable summary of the results, meta-analysis becomes useful for reviewing and 
combining research results. Meta-analyses keeps researchers from relying on the results of a 
single study in attempting to understand a phenomenon. Thus, meta-analysis helps us to see the 
similarities and differences among the methodologies and the results of multiple studies.84 It is in 
this effort that studies aimed at understanding the phenomenon of SSRIs and fracture risk have 
demonstrated more reliable evidence though meta-analysis. Summary of the results of the three 
most recent meta-analyses are presented as follows.  
The Wu et al. results showed that overall, SSRIs use was associated with a significantly 
increased risk of fracture (RR=1.72;95% CI, 1.51-1.95, p<0.001).85 Eom et al. in a meta-analysis 
based on 12-observational studies showed that the overall risk of fracture was higher among 
people using SSRIs (adjusted OR=1.69, 95% CI 1.51-1.90).86 Rabenda et al., based on a total of 
34 studies, found that use of SSRIs showed systematically a higher increase in the risk of 
fractures of all types, non-vertebral, and hip fractures than studies investigating TCA use.87 
Clearly, evidence from the meta-analyses adds more weight to the literature from single studies 
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discussed in this section. To the best of our knowledge, based on this evidence, we can conclude 
that indeed SSRIs may be associated with increased risk of fracture. 
2.5 Serotonin System and Bone Health and Potential Attenuating Effects of SSRIs 
on Bisphosphonates 
 
2.5.1 Serotonin and bone health 
The link between SSRIs and bone health is based on the adverse effects of 5-HT on the 
bone remodeling process. The bone is comprised of bone cells, an organic matrix of collagen and 
noncollagenous proteins (osteoid), and inorganic mineral matrix. Of particular interest in this 
study is that bone cells (i.e., osteocytes, osteoblasts, and osteoclasts) possess a functional 5-HT 
signal transduction mechanism (5-HT receptors and the 5-HTT) for both responding to and 
regulating the uptake of 5-HT.67,88  
Preclinical in vitro and in vivo studies support the potential for direct skeletal effects of 
SSRIs through 5-HTT inhibition.89 In an earlier study by Warden and colleagues, the authors 
showed that inhibition of 5-HTT has significant detrimental effects on bone mineral accrual in 
the mouse skeleton. This study aimed to investigate the impact of 5-HTT inhibition on bone 
mineral accrual in the growing mouse skeleton. The study was achieved by assessing: 1) mice 
with a null mutation in the gene encoding for the 5-HTT, and 2) normal growing mice treated 
with a SSRI. The findings showed that the null mutation of the gene encoding for 5-HTT 
resulted in a consistent skeletal phenotype of reduced mass, altered architecture, and inferior 
mechanical properties. Moreover, inhibition of 5-HTT using SSRI resulted in reduced bone 
mineral accrual during growth.90  
Similar findings on the effects of SSRI on mouse skeleton were later reported in another 
study by Warden and colleagues. The study involved adult female mice. Findings showed that 
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daily introduction of fluoxetine hydrochloride 5 and 20 mg/kg/d, equivalent with the standard 
(20 mg/d) and maximum (40-80 mg/d) recommended fluoxetine doses used to treat depression in 
humans, for four weeks reduced gains in lower extremity and vertebral BMD and negatively 
altered trabecular architecture within both the distal femur and L5 vertebra, independent of 
estrogen deficiency.  The authors further suggested that these findings might support clinical data 
demonstrating SSRI use to be associated with decreased bone loss after menopause.91 Further 
studies have demonstrated that the negative skeletal effects associated with pharmacological 5-
HTT inhibition are independent of drug effects on animal physical activity levels and not 
supposedly altered skeletal loading.92 Although there are still inconsistencies between some 
reported animal studies, most animal studies have reported convincing data to demonstrate 
skeletal effects of SSRIs.93 
Since 5-HTT is a transporter, 5-HT needs to be present locally within the skeleton for the 
5-HTT to influence bone cell activity.89 5-HT acts through binding on the 5-HT receptors. There 
are 14 genetically, pharmacologically, and functionally distinct 5-HT receptors belonging to 
seven families termed 5-HT1 through 5-HT7. 5-HT receptors belong to the G-protein coupled 
receptor (GPCR) family, with the exception of the 5-HT3 receptor, which is a ligand-gated ion 
channel.94 A number of these receptors have been located in bone cells. Three serotonin 
receptors: 5-Htr1b, 5-Htr2a, and 5-Htr2b, are expressed in osteoblasts.88 
In a study by Westbroek et al., the presence of 5-Htrb receptors was reported in fetal 
chicken bone tissue and isolated bone cells (i.e., osteocytes, osteoblasts, and periosteal 
fibroblasts [a population containing osteoblast precursor cells]).95 It has been demonstrated that 
5-HT via 5-Htrb receptors is a peripheral modulator of osteoblast recruitment in bone formation 
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in aging mice.96 These studies suggest that 5-HT and 5-HTT may be involved in bone 
metabolism and the potential consequences on bone health.  
5-HT uses one predominant receptor Htr1b, to affect osteoblast biology. In gut-derived 5-
HT on osteoblasts, binding of 5-HT to 5-Htr1b, which is linked to the Gαi protein, inhibits 
adenylyl cyclase which in turn inhibits second-messenger cAMP production and protein kinase 
A (PKA)-mediated cAMP response element-binding (CREB) phosphorylation. Most of the 
actions of cyclic AMP are carried out by protein kinase A, which phosphorylates specific sites on 
downstream effector processes. This process leads to decreased expression of Cyclin (Cyc D1) 
genes and decreased osteoblast proliferation. As a result, bone formation is slowed down.68 In 
other words, higher 5-HT levels secondary to inhibition of 5-HTT by SSRI, contributes to the 
decrease in bone formation.  
In brain-derived 5-HT on osteoblast, serotonergic neurons of the dorsal raphe signal to 
ventromedial hypothalamic nuclei neurons via the Htr2c receptor to inhibit the synthesis of 
epinephrine and thereby decrease sympathetic tone. This decrease is relayed in osteoblasts by 
decreased signaling via the β2 adrenergic receptor (Adrβ2), which negatively controls osteoblast 
proliferation via molecular clock gene (Cyc D1) cascade and positively regulates bone resorption 
via activation of a PKA/ATF4-dependent pathway (ATF-4: a transcription factor protein), 
leading to increased synthesis of receptor activator of nuclear factor kappa B ligand (Rankl), an 
activator of osteoclast differentiation and function.69 In other words, 5-HT activation can also 
directly produce RANKL in addition to the RANKL produced during normal bone remodeling 
process. In normal bone remodeling in healthy physiologic systems, bone stromal cells, 
including cells of the osteoblast lineage, provide a limited amount of RANKL, which leads to 
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osteoclast differentiation, survival, and activation and subsequent bone resorption. Resorption is 
balanced by osteoblast-dependent new bone formation.97 
Treatment of homozygous oim/oim mice (the oim/oim mouse is an established model of 
moderate to severe osteoporosis) with either a bisphosphonate (alendronate) or Rankl inhibitor 
(Rank-Fc) causes similar decreases in fracture incidence.98 This data suggests a link between 
SSRIs-Rankl-bisphosphonates. Similarly, Sutherland et al. in an in vitro study using rabbit 
osteoclasts treated with 100 µM clodronate or alendronate for up to 48 hours in the absence or 
presence of 100ng/mL RANKL found that RANKL significantly attenuated (or antagonized) the 
ability of both clodronate (CLO) and alendronate (ALN) to induce osteoclast apoptosis and 
inhibit bone resorption (Figure 2.1). The number of apoptotic rabbit osteoclasts was significantly 
lower in cultures treated for 48 hrs with ALN or CLO in the presence of RANKL than in cultures 
treated with the bisphosphonates alone. The authors conclude that RANKL protects osteoclasts 
from the apoptosis-inducing and anti-resorptive effects of bisphosphonates in vitro. 99  
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Figure 2.1. The percentage of non-apoptotic and apoptotic osteoclasts. Data are expressed as the mean ± 
SEM (n = 3 replicates).  ***P = 0.001 compared with ALN or CLO alone (analysis of variance). 
#Treatment with ALN or CLO alone caused a significant decrease in osteoclast number compared with 
control (CTL) cultures (P = 0.01) and a significant increase in osteoclast apoptosis compared with control 
cultures (P = 0.001).99 (Disclaimer: This is an open access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited) 
 
2.5.2 Potential attenuating effects of SSRIs on bisphosphonates 
Based on Bradford Hill causal criteria of plausibility (refers to the biological plausibility 
of the hypothesis) and the evidence from laboratory experiments on animals,72 SSRIs and 
skeletal effect association can be considered to be causal. However, Rothman and coworker100 
warns that, “evidence from human experiments, however, is seldom available for most 
epidemiologic research questions, and animal evidence relates to different species and usually to 
levels of exposure very different from those humans experience.” Despite this limitation, he adds 
that, “logically, however, experimental evidence is not a criterion but a test of the causal 
hypothesis, a test that is simply unavailable in most circumstances.”35 This underscores our 
hypothesis and provides a plausible reasoning to conduct this current study. Steps in which 
SSRIs might negate the beneficial effects of bisphosphonate therapies are given in Figure 2.2. 
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Figure 2.2. Schematic representation of the proposed model tested in this study. 
2.6 Role of Depression versus Serotonin System on Bone Health 
 
2.6.1 Depression and increased risk of fracture 
Although the preceding discussion demonstrates that SSRIs, commonly used for the 
treatment of depression, increases the risk of fracture through the 5-HT transporter inhibition, it 
is still unclear whether the ADE of increased risk of fracture is associated with burden of the 
disease (depression) or the serotonin transporter system.  
Depression is thought to be an independent risk factor for osteoporosis or decreased BMD, 
with depressed women, particularly those who are postmenopausal, showing a higher risk than 
men.101 Diem and colleagues have shown that depressive symptoms are associated with higher 
bone loss, leading to low BMD, in older women with Geriatric Depression Scale score (GDS) of 
at least 6 independent of antidepressants.79 Silverman et al. found that postmenopausal women 
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with prevalent vertebral fracture reported more symptoms as assessed by the GDS than women 
without prevalent vertebral fracture (1.54 vs 1.26; p=0.001).102 Tolea et al. found that high 
depressive symptoms were associated with increased risk of osteoporosis (OR=1.39, 95% CI, 
1.02-1.91)  and new fractures (OR=1.39, 95% CI, 1.01-1.95) among Mexican American women 
aged 65 years and older.103  
In contrast to these findings, Spangler and colleagues in a cohort study of 93,676 
postmenopausal women found no statistical significant association between depressive 
symptoms and mean change in 3-year BMD at the hip or spine. Similarly, no significant 
association was found between the use of antidepressants and 3-year changes in hip, spine, or 
whole body BMD. Moreover, depressive symptoms were not associated with increased risk for 
hip, spine, or wrist fracture, but were only associated with minimal increased risk for any 
fracture.83 Therefore, not only is the association between depression and osteoporosis and/or 
fractures uncertain, but also the causal relationship has not been fully elucidated.68 This presents 
challenges in need of further investigations.   
To investigate this dilemma, we compare the association of concomitant SNRIs with 
bisphosphonates users and concomitant SSRIs with bisphosphonates users and increased risk of 
fracture. Selective serotonin reuptake inhibitors and, possibly SNRIs, are associated with 
osteoporosis and increased risk of fracture.104 Currently there are no specific studies on the 
association between SNRIs and fracture.105 However, studies on antidepressants other than 
SSRIs and fracture might implicate SNRIs. Vestergaard et al. found that venlafaxine (an example 
of a SNRI) was associated with statistically significant increased risk of forearm fracture at a 
dose of >0.5 DDD/day (OR=1.54 95% CI 1.12-2.12) and spine fracture at a dose of ≤0.25 
DDD/day (OR=1.97; 95% CI 1.18-3.29). There were no statistically significant results for hip or 
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any fracture or at other drug doses.106 (One DDD is the dose thata person on average uses of the 
drug in 1 day. The amount of DDD was calculated from the number of prescriptions, the number 
of tablets prescribed, and the dose of the pills in the actual 
prescription).[www.whocc.no/atcddd/] Vardel et al. found that non-SSRI/non-TCA 
antidepressants drugs (including venlafaxine) were associated with osteoporotic fracture 
(OR=1.40; 95% CI 1.06-1.85).107 Why the comparison? This is because of the binding 
characteristics and selective nature of SNRIs on 5-HT receptors. 
2.6.2 Selective nature of SNRIs and bone health 
Serotonin norepinephrine reuptake inhibitors are dual action antidepressants that inhibit 
both serotonin (5-HT) and norepinephrine (NE) transporters. The FDA-approved SNRIs include 
venlafaxine (Effexor®), duloxetine (Cymbalta®), and desvenlafaxine (Pristiq®) which is an active 
metabolite of venlafaxine, and levomilnacipran (Fetzima®).108 The ability of these drugs to block 
5-HT and NE transporters in vitro and in vivo has been reported.  
Duloxetine potently inhibits binding to the human 5-HT (Ki=0.8 nM) and NE transporters 
(Ki=7.5 nM). Venlafaxine, however, inhibiting binding to the human 5-HT was 106 times less 
potent (Ki=82 nM) than duloxetine and also inhibits binding to NE transporters (Ki=2480 nM). 
Thus venlafaxine binds to NE transporter with 331 times lower affinity than duloxetine. Results 
from in vitro studies showed that duloxetine inhibited 5-HT (Ki=4.6 nM) and NE (Ki=16), 
whereas venlafaxine inhibited 5-HT and NE with 17- and 34-fold lower potency. Furthermore, 
duloxetine blocked ex vivo 5-HT and NE transporter binding with ED50 values of 0.03 and 0.7 
mg/kg subcutaneous (s.c). Venlafaxine was 67 and 77-fold less potent than duloxetine at 
inhibiting 5-HT and NE ex vivo transporter binding. These findings indicate that higher doses of 
venlafaxine were needed to block the NE transporter.109  
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Desvenlafaxine has higher affinity for the human 5-HT transporter (Ki=40.2 nM) 
compared with NE transporter (Ki=3385 nM). In addition, assays indicate that desvenlafaxine is 
approximately 10-fold more potent at inhibiting 5-HT uptake (IC50=47.3) than NE uptake 
(IC50=531.3).110 Despite the findings from different assays, the findings suggest that the relative 
potencies for 5-HT transporter inhibition relative to NE transporter inhibition is in the order (low 
to high): venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran.   
Of particular interest is that venlafaxine acts as a SSRI at lower doses (75 mg/day, FDA 
labeling recommended starting dose), and a SNRI at higher doses (150-225 mg/day).111 This 
mode of action might also be observed with desvenlafaxine and duloxetine in relation to the 
relative potencies. Higher doses of venlafaxine for the treatment of a severe depressive episode 
are well tolerated.112 The recommended therapeutic dosage for desvenlafaxine is 50 mg/day for 
MDD patients and higher doses (50-400 mg/day) are well tolerated.113 On the other hand, the 
recommended and with demonstrated efficacy dose for duloxetine in the treatment of MDD is 60 
mg/day and higher doses can be tolerated up to 120 mg/day.114  
The important question is whether the selectivity of SNRIs on 5-HT vs. NE transporters 
is clinically relevant as drug doses are increased with respect to the effects of SNRIs115 and 
increased risk of osteoporotic fracture. A dose-dependent effect of SSRI use on fracture cases 
has been observed. Vestergaard et al. has shown that users of SSRIs reported an increased risk of 
any fracture (OR from 1.1 at doses <0.15 daily defined dose (DDD)/day to 1.4 at doses ≥0.75 
DDD).106 This dose-effect (in the opposite direction than what might be expected) may or may 
not be observed with SNRIs use. We hypothesize that if the risk of fracture is the same between 
SSRIs vs. SNRIs, then the increased risk of fracture may be related to the role of depression. In 
contrast, if the risk of fracture differs, and is greater among SSRIs users compared to SNRIs 
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users, then there is a higher likelihood of 5-HT playing a role but, not depression, in increased 
risk of fracture. Findings from this investigation can add new knowledge to understand the role 
of depression as an important risk factor for fracture as opposed to 5-HTT. 
2.7 Summary 
Bisphosphonates are effective in the prevention and treatment of osteoporosis and/or 
osteoporotic fractures in postmenopausal women. However, safety concerns of potential 
attenuation of BPs with concomitant use of medications with skeletal effects (e.g., SSRIs) and 
increased risk of fracture have been raised. Literature review has demonstrated the association of 
SSRI use with increased risk of fracture among postmenopausal women. However, these studies 
did not report fracture outcome comparisons between concomitant SSRIs with bisphosphonate 
users and nonusers (BP alone users). Most studies investigating the effect of SSRIs on bone in 
postmenopausal women exclude users of BP medications or BP use was not examined as a 
specific risk factor/ exposure of interest. Instead, it was just adjusted for,75-83 thus missing the 
opportunity to investigate this potential event of possible attenuation of BPs by SSRIs and 
eventual increased risk of fracture.  
Since BPs are considered a mainstay of pharmacologic therapy for the prevention and 
treatment of osteoporosis and/or osteoporotic-related fractures, it is highly likely that 
postmenopausal women prescribed BPs would be using SSRIs as well, if needed. A descriptive 
study using a large U.S. claims database (from 1999 to 2004) of women aged ≥50 years has 
shown that concomitant medications are used by women receiving daily or weekly BP therapy 
and this increased with age. The study did not include monthly or yearly BP therapies. 
Furthermore, of the medications that were concomitantly used with BPs, SSRIs or SNRIs were 
not described, highlighting a gap in the literature.116 Descriptive concomitant use of 
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SSRIs/SNRIs with bisphosphonates is explored and results are provided in Chapter 3 and 
Chapter 5. In order to assess the association between concomitant use (section VI) and the role of 
5-HT in bone (section VII), a pharmacoepidemiologic study was conducted and results and 
discussion are presented in Chapter 6 and Chapter 7, respectively. 
2.8 Study design considerations 
2.8.1 Background 
This study focuses on the effects of concomitant SSRIs/SNRIs with bisphosphonates in large 
numbers of patients, which is the definition of pharmacoepidemiology, a discipline that applies 
epidemiological principles and methods. Pharmacoepidemiological studies are often conducted 
after approval for drug marketing has been granted. These studies are classified as observational 
in nature.117 Observational research involves the direct observation of individuals (rather than 
manipulated [e.g., through randomization]) in their natural setting.118 For example, studies using 
Medicare claims data are observational because the investigator is observing the subjects’ health 
care utilization without any contact or involvement with the subjects.118  Unlike clinical trials 
where individuals are randomized to receive an intervention or not, in observational studies, 
receiving an intervention or not is determined by individual preferences, practice patterns, or 
policy decisions.119  
The most commonly used study design types for observational pharmacoepidemiologic 
studies include cohort studies, case-control studies, crossover studies,120 and nested case-control 
studies121. In order to attribute a particular effect to the use of a drug, one of the key components 
to consider is the study design. Studies designed to minimize confounding bias (e.g., 
experimental designs), provide the most convincing evidence for a causal relationship between 
exposure and outcome of interest.117 Confounding bias is of particular concern in observational 
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epidemiologic studies of drug effects.122 In observational designs, the researcher must identify 
and measure potentially confounding variables, or the internal validity of the study will be 
undermined. As a consequence of lacking internal validity, conclusions about relationships are 
incorrect, and any generalization, regardless of the level of external validity, is meaningless.123 
Therefore, it is important to identify and handle confounding in observational studies. 
2.8.2 Identification of confounders 
Confounding is defined as the mixing effects between an exposure (X), an outcome (Y), 
and a third extraneous variable known as a confounder. As such, confounders are factors 
(exposures, interventions, treatments, etc.) that explain or produce all or part of the difference 
between the measure of association and the measure of effect that would be obtained with a 
counterfactual ideal.100 The ideal comparison group in a cohort study consists of exactly the 
same individuals in the exposed group had they not been exposed. The ideal comparison would 
help to answer the question of what would have happened to those who did receive treatment, if 
they had not received treatment. Practically, this ideal comparison is unobservable and only an 
estimate of them can be created. Thus, the ideal comparison is referred to as counterfactual 
ideal.100 
There are three criteria that must be met in order for a variable to be considered a 
confounder: 1) that the variable must be associated with the exposure in the population that 
produces the cases, 2) the variable must be an independent cause or predictor of the disease, and 
3) the variable cannot be an intermediate step in the causal pathway between the exposure and 
disease. Figure 2.3 depicts the relationship between the confounder, the exposure, and the 
disease and Figure 2.4 depicts a variable that is a step in the causal pathway between exposure 
and a disease.124  
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Figure 2.3. Schematic representation of the association between the confounder with both the 
exposure and disease. 
 
 
Figure 2.4. Schematic representation of the variable that is a step in the causal pathway between 
the exposure and the disease. 
 
With regards to osteoporotic fractures, Table 2.4 shows potential risk factors associated 
with osteoporosis (or low BMD) and increased risk of fractures included in a new Fracture Risk 
Assessment Tool (FRAX®) for evaluating fracture risk. FRAX® was developed by the WHO to 
evaluate a patient’s 10-year probability of hip fracture and major osteoporotic fracture (i.e., 
clinical spine, forearm, hip, or shoulder fracture).17 Assuming one of the risk factors is 
considered an exposure (X), then the remainder  of the risk factors are considered as the third 
extraneous variables known as confounders. 
 
 
 
 
 
 
Exposure Variable Disease 
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Table 2.4. Risk factors for osteoporotic fracture used in FRAX®. 
 Age (50 to 90 years) 
 Sex 
 Body mass index 
 Low femoral neck BMD 
 Prior fragility fracture 
 Parental fragility fracture 
 Current tobacco smoking 
 Long-term use of glucocorticoids 
 Rheumatoid arthritis 
 Other causes of secondary osteoporosis (e.g., medications and medical conditions) 
 Alcohol intake of more than two units daily 
Adapted from The North American Menopause Society, 2010.17 
 
2.8.3 Handling confounding 
2.8.3.1 Background 
The central target of most health sciences research studies is the elucidation of cause-
effect relationships among variables of interest and outcomes.125 In epidemiology, variables of 
interest are commonly referred as exposure or treatment. When a statistical association is 
reported in an epidemiology study, it is stated with the hope of using the association measures to 
give insight into a causal-effect relationship.126 Confounding is termed a “causal concept”125 and 
thus can be an impediment to elucidation about true causal effects. In other words, recognizing 
confounding, one ought to understand what is meant by causal effect.  A causal-effect can be 
defined as the effect due to a certain treatment or exposure.126 
 For illustration, suppose Ya=1 is the outcome variable that would have been observed 
under exposure value a=1, and Ya=0 the outcome variable that would have been observed under 
the exposure value a=0. The exposure has a causal effect in the population if Pr[Ya=1=1] ≠ 
Pr[Ya=0=1], where the probability Pr[Ya=1] is the proportion of subjects that would have 
developed the outcome Y had all the subjects in the population of interest received exposure 
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value a. Note that the risk Pr[Ya=1] is computed using all subjects of the population had they 
received the counterfactual exposure a (that is, it is an unconditional or marginal probability).127 
On the other hand, exposure or treatment and outcome are associated if Pr[Y=1|A=1] ≠ 
Pr[Y=1|A=0]. Where the probability Pr[Y=1|A=a] is the proportion of subjects that developed 
the outcome Y among those subjects in the population of interest that happened to receive 
exposure value a (that is, it is a conditional probability). In other words, the distribution of Y 
conditional on variable A is defined as examining the distribution of Y within levels of variable 
A. The symbol “|” denotes conditional relations. Therefore, the definition of association involves 
two disjoint subsets of the population determined by subjects’ actual exposure value, whereas 
causation involves the same subset (for example, the entire population) under two potential 
exposure values. Hence the cliché “association is not causation.” In ideal randomized 
experiments (assuming no loss to follow-up, full compliance with assigned treatment, and blind 
assignment), association is causation.127  
In non-randomized (e.g., observational) studies association is not necessarily causation 
because of the potential lack of exchangeability of exposed and unexposed subjects. 
Exchangeability means that the risk under the potential exposure value a among the exposed, 
equals the risk under the potential exposure value a among the unexposed.127 Therefore, 
pharmacoepidemiologic research aimed at assessing cause-effect relationships would prefer 
randomized experiments as the gold standard method of design. Unfortunately, randomized 
experiments are not always feasible because of cost, ethical, or practical reasons.128,129 Therefore, 
even though exchangeability is not guaranteed, conducting observational studies is the only 
option available to pharmacoepidemiologists to identify associations or relationships and 
determine causal-effect relationships using observational data and statistical analyses. 
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Correlation, regression, risk ratio, and odds ratio are examples of associational concepts whereas 
confounding and randomization are examples of causal concepts. Bias or confounding exists 
when an association measure differs from the corresponding effect measure that would prevail 
under ideal experimental conditions and this is the case with non-randomized (observational 
studies).125 This highlights the challenges pharmacoepidemiologists face when they draw 
conclusions about effects of drugs in large populations. How do we explain this challenge?  
The fundamental problem of addressing a causal-effect research question is how to 
reconstruct outcomes that are not observed (counterfactuals or potential outcomes) because they 
are not what happened. The outcome can be observed only (or more precisely, at most) under 
one, and not under both conditions. Hence, reconstructing the counterfactuals is crucial to 
estimate unbiased causal-effects. The treatment that an individual actually does not receive is 
called counterfactual treatment.130 How can we address this problem? One approach would be to 
reconstruct counterfactuals using propensity score method (PSM). 
2.8.3.2 Propensity score method 
PSM allows researchers to reconstruct counterfactuals using observational data, a 
situation similar to random assignment, albeit only with respect to observed variables.131 
Propensity score method does this by reducing the bias due to the measured confounders.132 The 
strategy does not control for hidden biases.131 Using PSM it is possible to duplicate one crucial 
feature of randomized experiment of designing an observational study without access to the 
outcome data. In experiments design, the way data will be collected is decided before observing 
the outcome data which is a tremendous stimulus for “honesty” in experiments and can be in 
well-designed observational studies as well.133 
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Propensity score method was introduced by Rosenbaum and Rubin and was defined as 
the probability of treatment assignment conditional on observed baseline covariates: 
ei=Pr(Zi=1|Xi), where Z=1 for treated and Z=0 for control. The propensity score (ei) exists in both 
randomized experiments and in observational studies. Like all probabilities, a propensity score 
ranges from 0 to 1. In randomized experiments, the propensity score is known and is defined by 
the study, whereas in an observational study, it must be estimated from the data on indicator for 
received treatment (treated and controls) and observed covariates. The propensity is most often 
estimated using a logistic regression model.134  
Given random assignment to treatment or control in randomized experiments (e.g., 
tossing a coin), each person has a 50% chance of being in treatment. Thus, each person has a true 
propensity score of 0.5. In non-randomized quasi experimental studies where the investigators 
have no control over the treatment assignment, the probabilities of receiving treatment (ei) are a 
function of individual characteristics and are likely to vary from 0.50. For example, consider 
treatment assignments Z=1 and Z=0, then ei above 0.50 would mean the person was more likely 
to select into treatment than control, and score below 0.50 would mean the opposite.135 
In observational studies, propensity scores are used primarily to reduce bias and increase 
precision. There are four different PSMs researchers can use for removing the effects of 
confounding when estimating the effects of treatment on outcomes which involve balancing of 
nonequivalent groups. These include propensity score matching, stratification on the propensity 
score, covariance adjustment, or inverse probability of treatment weighting using the propensity 
score.136 In this research project, the focus was on propensity score matching. Propensity score 
matching is the commonly used in the medical literature.137 Furthermore, previous research has 
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demonstrated that matching on propensity score can result in a greater reduction in treatment 
selection bias than stratification on propensity score.138  
2.8.3.3 Propensity score matching 
The propensity score (PS) is a potential matching variable because it does not depend on 
response information that will be collected after matching.134,139 Propensity score matching refers 
to pairing of treatment and control subjects, to form matched sets, with similar values (or 
distribution) of PS so that treated subjects are similar to the control subjects with respect to 
background variables (or covariates) measured on all subjects, just like in a randomized 
experiment. Thus, two matched subjects (one in treated and one in control group), with the same 
propensity score, are imagined to be ‘randomly’ assigned to each group in the sense of being 
equally likely to be treated or control. It is important to note that PS achieves balance in observed 
covariates whereas randomization in experimental studies achieves balance in all covariates 
(observed and unobserved).134,136,139 
The implication of the balancing property of the propensity score in all observed 
covariates is that, when matching on PS, any differences in outcomes between treated and 
control subjects cannot be due to observed covariates. In other words, matching on PS tends to 
produce unbiased estimates of the treatment effects when treatment is strongly ignorable. 
Treatment assignment is considered strongly ignorable if the treatment assignment, Z, and the 
response, Y, are known to be conditionally independent given the covariates, X. Moreover, these 
design efforts, which result in more balanced distributions of covariates across treatment groups, 
make subsequent model-based adjustments (e.g., covariance adjustments, instrumental variables) 
more reliable.133,134  
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There are advantages for designing this pharmacoepidemiologic study using the PS 
matching strategy. First, a matched data set allows for simple, transparent analysis. Second, a 
matched analysis based on a well-formulated propensity score has the advantage of deleting from 
analysis those subjects with measurable contra-indications (or absolute indications) for treatment 
who have no available treated (or untreated) comparison subject. Confounding by indication is 
often the main challenge to validity in pharmacoepidemiology and the PS focuses directly on the 
indications for use and non-use of the drug under study.140 For example, Zoledronic acid 
(Reclast®) is contraindicated in patients with severe renal impairment (i.e., creatinine clearance 
less than 35 ml/min) or in patients with evidence of acute renal impairment. A complete list of 
indications, contraindications, and geriatric use information for BPs is shown in Table 1.7 in 
Chapter 1. Third, matched or stratified analyses do not make strong assumptions of linearity in 
the relationship of propensity with the outcome which is the assumption made when PS is 
included in a multivariate model together with actual treatment.140 The estimated treatment 
effects can be biased if this assumption does not hold.134 
The most common approach to PS matching is 1:1 matching and this research project 
used 1:1 matching strategy, where each treatment subject is matched to its 1 nearest neighbor. 
Matching at ratios of 1:n can increase statistical efficiency in case-control141 and cohort 
studies.142 However, it should be noted that 1:n matching increases bias because it is likely that 
less similar cases are matched with increasing number of matches.142 Upon matching, balance of 
the covariates is assessed and then the treatment effect is estimated directly comparing outcomes 
between treatment and control groups in the matched sample.  
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2.8.3.4 Sensitivity test 
The sensitivity test is the final step used to investigate whether causal effect estimated 
from PSM is susceptible to the influence of unobserved covariates. There are three approaches 
for conducting a sensitivity test: 1) changing the specification in the equation, 2) using the 
instrumental variable, and 3) use of Rosenbaum Bounding approach.126 
 
2.9  Summary 
Concomitant uses of medications are associated with ADEs. Literature shows that 
concomitant use of medications known to induce osteoporosis (e.g., GCs, PPIs, or LT4) with BPs 
have  potential attenuating effects of BPs resulting in increased risk of fracture. SSRIs are 
associated with increased risk of fracture and might also have potential attenuating effects. Also, 
the role of depression versus 5-HT on bone is unclear. Both of these latter hypotheses will be 
investigated in this study. To ensure internal validity of estimated effects, confounding bias of 
observed covariates will be handled using the PSM. 
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Chapter 3 
3.0 Preliminary study 
3.1 Abstract 
Title: Utilization patterns of bisphosphonates and selective serotonin reuptake inhibitors from 
2004 to 2008 among women 
Introduction: Comorbid osteoporosis and/or fractures and depression is prevalent in older 
postmenopausal women in the United States. Both conditions might require pharmacologic 
therapy. The most popularly used are antidepressants of the SSRIs or SNRIs and BPs. SSRIs and 
SNRIs have been associated with increased risk of osteoporosis and/or osteoporotic fractures. 
SSRI, SNRIs, and BPs utilization has become more common over time among women. The 
potential for attenuation of the effect of BPs by SSRIs/SNRIs and increased risk of fracture has 
not been investigated yet. Before the investigations, it was important to explore the extent to 
which these medications are prescribed concomitantly. 
Specific aims: 1) to examine the proportion of BP users who are also on SSRIs/SNRIs and 
patterns of use over time, and 2) to explore the relationship between concomitant use and patient 
age among women aged 45 years and older. 
Methods: A cross-sectional analysis was performed using data from the 2004-2008 Medical 
Expenditure Panel Survey (MEPS) to examine usage patterns of BPs and SSRIs/SNRIs for 
women aged ≥45 years. Analyses were based on yearly consolidated data and prescribed 
medicines files. Weighted descriptive statistics were used to evaluate patterns of medications use 
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and proportions were reported. Age was categorized into four groups: 45-54, 55-64, 65-74, and 
75-85 years old. 
Results: Of the survey respondents, proportions of women 45-64 years old were higher 
compared to those women 65-85 years old. Also, for each year about 80% of the respondents 
were white women. In the timeframe examined, 8.9% of women in 2004, 9.9% in 2005, 10.3% 
in 2006, 9.8% in 2007, and 10.0% in 2008 received bisphosphonates. In the same period, 13% of 
women in 2004, 12.7% in 2005, 12.8% in 2006, 12.2% in 2007, and 11.9% in 2008 received 
SSRIs. In addition, 2.7% of women in 2004, 3.3% in 2005, 3.0% in 2006, 3.9% in 2007, and 
4.6% in 2008 received SNRIs. Concomitant use (BPs+SSRIs) was observed in 11.7% of women 
in 2004, 12.1% in 2005, 13.3% in 2006, 14.1% in 2007, and 13.5% in 2008. Overall, the trend of 
concomitant use of BPs+SSRIs increased across the five-year period (slope=0.56; p-value=0.04). 
In the same timeframe examined, no statistically significant trend in concomitant use of 
BPs+SNRIs was observed (slope=0.33; p-value>0.05). Furthermore, no structured odds ratios 
were observed for the association of age and concomitant use of BPs+SSRIs.  
Conclusion:  Concomitant use of BPs and SSRIs in adult women ≥45 years is not uncommon 
and might be higher in older postmenopausal women. The observed concomitant use presents 
drug safety challenges surrounding the bone health of postmenopausal women. Studies are 
needed to investigate the potential interactive effects of SSRIs on BP therapy. 
 
3.2 Introduction 
Osteoporosis and depression are known to coexist and it is still unclear the association 
between these two chronic conditions.1 Also, these two conditions can exist together as 
comorbidities of other diseases such in patients with chronic obstructive pulmonary disease.2 
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Comorbid osteoporosis and depression is prevalent in patients 65 years and older.3 The 
prevalence is higher in women (postmenopausal) than men.1 The interaction between 
osteoporosis and depression is complex and as such single interventions are unlikely to be 
effective in improving outcomes in patients with these coexisting conditions.4 Management of 
both conditions often requires pharmacologic therapy interventions and these include 
antiresorptives for osteoporosis and antidepressants for depression.  
Of the current FDA-approved antiresorptives, BPs are recommended as first-line 
pharmacologic therapy in the management of osteoporosis and/or fractures, especially in older 
postmenopausal women.5 Bisphosphonates have become the primary therapy for managing 
skeletal conditions characterized by increased osteoclast-mediated bone resorption6 such as 
osteoporosis (or low bone mineral density). Bisphosphonates have been shown to reduce fracture 
risk by 40-50% in patients with low BMD.7 The pharmacological features of BPs include a high 
affinity for crystalline hydroxyapatite in the bone and inhibitory effects on osteoclasts. The high 
affinity for bone mineral allows BPs to achieve a high local concentration throughout the entire 
skeleton.6  
The use of antiresorptive treatment (e.g., BPs) appears to be fairly common, with one 
study reporting that 43% of premenopausal women (mean age 37± 8) have used BPs.8 Perreault 
et al. in a study to determine use of antiresoptives (bone-specific drugs [BP, calcitonin, raloxifen] 
and hormone replacement therapy) among older women who had an osteoporotic fracture or 
were at risk of osteoporic fracture found that the use of these agents was reported to have 
increased over time—from 1.9 per 100 person-years in 1995 to 31 per 100 person-years in 2000 
among those with prior osteoporotic-related fracture and 0.5 per 100 person-years in 1995 to 11 
in 2000 for controls.9  Gold et al. in a study using a large U.S. patient claims database accessed 
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through Wolters Kluwer Health found that female BP recipients increased from 78,909 in 1999 
to 250,286 in 2004.10 Also, other studies showed a significant reduction in hormone replacement 
therapy (HRT) utilization and a corresponding increase in newer anti-osteoporosis medications 
or nonhormonal therapy (e.g, BPs) after release of the Women’s Health Initiative study11 in 2002 
that reported an association between HRT and increased risk of cardiovascular health disease and 
breast cancer among postmenopausal women.12,13,14 Alternative medications to HRT for 
postmenopausal symptoms include clonidine,  SSRIs, SERMs, and BPs.15 
On the other hand, with a better safety and tolerability profile than older classes of 
antidepressants, SSRIs and SNRIs have become the most popular medications in treating 
depression and are considered first-line drug treatment in older patients.16,17 An analysis of the 
Medical Expenditure Panel Survey (MEPS) has reported that SSRI and SNRI use has become 
more common (54.8% of antidepressant use in 1996 and 66.89% of antidepressant use in 2005) 
over time. Use of newer agents which include SNRIs has also been shown to be common over 
time (23.6% of antidepressant use in 1996 and 37.9% of antidepressant use in 2005). Of the 
individuals in the MEPS analysis, general antidepressant use (rates per 100 persons treated) was 
highest among those aged 50 years or older in women (7.62% in 1996 and 13.42% in 2005) than 
men (3.96% in 1996 and 6.68% in 2005).18 In agreement, a recent Medicare Current Beneficiary 
Survey by Akincigil et al. showed that use of SSRIs and SNRIs increased over a period of 10 
years (between 2002-2005 compared to 1992-1995) and was higher in females.19 
The studies discussed above demonstrate an increasing trend of utilization of BPs and 
SSRIs /SNRIs. Whether this trend can also be observed for concomitant SSRIs or SNRIs with 
BPs remains an open question. Because of comorbid osteoporosis and depression,1 BPs and 
SSRIs or SNRIs could be prescribed together. In the study by Caughey et al., the authors 
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determined the prevalence of potentially inappropriate medicines and treatment conflicts, for 
older people dispensed an antidepressant. In this study, patients with comorbid osteoporosis 
(already at-risk population for fractures), almost half were dispensed a SSRI and were at even 
higher risk for decreased bone density over time and increased risk of fracture.3 Treatment for 
osteoporosis was not addressed. To the best of our knowledge, no studies have been reported 
describing the utilization pattern of concomitant SSRIs or SNRIs with BPs. Therefore, the 
primary objective of this study was to examine the proportion and use over time of BP users who 
are also on SSRIs or SNRIs and to explore the relationship between concomitant use and patient 
age among women aged 45 years and older.  
 
3.3 Methods 
             3.3.1 Data sources and patient population 
Data from the 2004-2008 MEPS was used to examine usage patterns of BPs and 
SSRI/SNRI antidepressants for women aged 45 years or older. MEPS, a survey cosponsored by 
the Agency for Health Care Research and Quality (AHRQ) and the National Center for Health 
Statistics (NCHS), is a relatively large, longitudinal study of health care use among the U.S. 
civilian, non-institutionalized population (e.g., not in prisons or nursing homes). The survey is 
conducted as a national probability survey using a complex stratified multistage area probability 
design.20 The National Health Interview Survey (NHIS), another large ongoing Federal health 
survey conducted by the National Center for Health Statistics of the Centers for Disease Control 
and Prevention, U.S. Department of Health and Human Services, serves as the sampling frame 
for MEPS.  
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The MEPS household component collects information on demographic and socio-
economic characteristics, health care use, expenditures, respondent’s health status, sources of 
payment, and health insurance coverage for all the members of the household. The survey is 
designed such that certain groups, including racial minorities (Blacks, Hispanic, and Asian 
individuals), and low-income households, are oversampled from the NHIS. Data from the MEPS 
household participants are collected over a two and half year period. Each new MEPS annual 
sample is referred to as a panel. The MEPS conducts the survey annually and employs an 
overlapping panel design to collect data whereby each year a new panel of households is selected 
from among those households that participated in the previous year’s NHIS.  This design 
provides data which can be combined and used for cross-sectional or longitudinal analysis.20,21 
3.3.2 Identification of exposure 
Concomitant use was defined as receipt of at least one prescription of a bisphosphonate 
and a SSRI or SNRI antidepressant during a calendar year. The assigned Multum Lexicon Drug 
Database values (Cerner Multum Inc., Denver, CO, USA; http://multum.com/Lexicon.htm) were 
used to identify drug products in the MEPS survey. The Multum Therapeutic category values are 
217 (BPs), 208 (SSRI antidepressants), and 308 (SNRI antidepressants).  
3.3.3 Statistical analysis 
Analyses were based on yearly consolidated data, and prescribed medicines files. The 
demographic characteristics (including age, race, health insurance coverage, socio-economic 
status, marital status, and education) and prescribed medicines information of the qualified 
participants was obtained from the Full Year Consolidated Data, and the Prescribed Medicines 
Files respectively of the 2004-2008 MEPS household components. Weighed descriptive statistics 
were used to evaluate patterns of medication use and proportions were reported. Respondents 
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who self-identified as “White” were categorized as “White” and also “Black” respondents were 
classified as “Black”. However, respondents who self-identified as either “American 
Indian/Alaskan Native” or “Asian” or “Native Hawaiian/Pacific Islander” or “Multiple races” 
were re-classified as “Other”. 
Based on age, and race, first, the proportions of women aged ≥45 years old who filled at 
least one SSRI or SNRI antidepressants, and BPs, both separate were calculated. Second, the 
analysis was limited to only women who were on BPs. The proportions of BP users who are also 
on SSRI or SNRI antidepressants were calculated for each calendar year and these proportions 
were further analyzed by age-groups: 45-54, 55-64, 65-74, and 75-85 years old. Age was defined 
as age at the end of each calendar year.  All estimates were calculated using the survey 
procedures (PROCSURVEYFREQ) of the software SAS 9.3 version (SAS Institute, Cary, NC) 
including variables for generating weighted national estimates and for use of the Taylor series 
linearization method for variance estimation for complex survey designs. These variables are: 
person-level weight (PERWT0xF); stratum (VARSTR); and cluster/psu (VARPSU).22,23 
For trend analysis, the frequencies of overall utilization and utilization by age of SSRIs or 
SNRIs with BPs were calculated for each year. Then, any change in these frequencies across the 
5-year period were described and analyzed for statistical significance. A linear regression was 
performed using the proportions of BP+SSRI/SNRI use from 2004 to 2008 to test for significant 
linear trend across the 5 survey years for concomitant users. 
Logistic regression was used to examine the relationship between increasing age and 
utilization of BPs+SSRIs/SNRIs and whether the relationship was linear. The categorized age 
groups (categorical variable) were thought of as ordered. Thus a Cochran-Armitage trend test 
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was performed to test whether there was a linear relationship. Odds ratios were reported for the 
age group categories in the model. For all analyses statistical significance was set at p<0.05.  
 
3.4 Results 
3.4.1 Summary descriptive statistics 
In the time frame examined in this study, there were a total of 34,403 observations in 2004, 
33,961 observations in 2005, 34,145 observations in 2006, 30,964 observations in 2007, and 
33,066 observations in 2008. The demographic information of women ≥45 years are presented in 
Table 3.1 for MEPS 2004-2008. In addition, the population patterns of these participants are 
presented in Figure 3.1 which parallels the actual annual estimates from the U.S. Census Bureau 
in Figure 3.2.24 The proportion of women ≥45 years during a calendar year increased gradually 
and steadily, from 19.5 percent in 2004 to 20.4 percent in 2008 (Table 3.1 and Figure 3.1). Of 
these participants, White women accounted for the largest proportions followed by African 
American women and the rest were of other racial backgrounds. 
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Table 3.1. Demographic information of U.S. women aged 45 years and older for MEPS 2004-
2008. 
 
Year 2004 2005 2006 2007 2008 
Total N (5846) N (5834) N (6113) N (5550) N (5574) 
Characteristic % % % % % 
Age      
     45-54 2058 (34.0) 2088 (34.2) 2168 (34.4) 1941 (33.3) 2005 (33.4) 
     55-64 1624 (28.8) 1646 (29.2) 1737 (29.2) 1665 (30.4) 1690 (30.5) 
     65-74 1098 (18.5) 1030 (17.5) 1103 (17.4) 1001 (17.9) 1003 (18.0) 
     75-85 1066 (18.6) 1070 (19.2) 1105 (19.0) 943 (18.4) 876 (18.1) 
Race      
  White 4626 (83.7) 4528 (83.5) 4704 (83.5) 4240 (83.4) 3960 (83.1) 
  Black 874 (10.7) 952 (10.6) 1037 (10.6) 919 (10.7) 1124 (11.1) 
  Other  365 (5.6) 368 (5.9) 384 (5.9) 407 (5.9) 517 (5.8) 
 Marital status      
   Married 2986 (54.5)  2988(55.1) 3184 (55.9) 3020 (55.7) 2994 (55.3) 
   Divorced/Separated 1160 (18.1) 1172 (18.1) 1229 (18.2) 1110 (19.4) 1103 (19.0)) 
   Widowed 1310 (21.5) 1265 (20.8) 1256 (19.6) 1033 (18.5) 1021 (19.0) 
   Never Married 389 (5.8) 409 (6.0) 444 (6.2) 387 (6.2) 456 (6.7) 
Family income      
   Low income or below 2211 (29.4) 2245 (29.1) 2348 (28.3) 1975 (28.6) 1970 (29.6) 
   Middle income 1633 (29.0) 1586 (28.5) 1673 (28.6) 1574 (27.7) 1653 (27.7) 
   High income 2002 (41.6) 2003 (42.5) 2092 (43.1) 2001 (43.8) 1951 (42.7) 
Insurance type      
   Private 3617 (70.8) 3553 (70.4) 3690 (70.2) 3418 (68.6) 3370 (65.9) 
   Public 1633 (22.0) 1639 (22.0) 1719 (21.4) 1498 (22.9) 1523 (25.0) 
   Uninsured 596 (7.2) 642 (7.6) 704 (8.4) 634 (8.6) 681 (9.2) 
Education      
   <High school 1542 (17.3) 1479 (16.8) 1548 (17.1) 1292 (16.3) 1293 (15.5) 
   High school 2869 (53.2) 2878 (53.2) 2941 (51.2) 2689 (50.9) 2680 (52.2) 
   >4 years college+ 1435 (29.4) 1477 (30.0) 1624 (31.6) 1569 (32.8) 1601 (32.3) 
   
 
Figure 3.1. Plot of population patterns of US women aged 45 years and older, MEPS 2004-2008. 
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Figure 3.2. Annual estimates of the U.S. resident population of women aged 45-85 years: July 1, 
2004 to July 2008.24  
 
Table 3.2 shows the proportions of those women 45 years or older reporting use of BPs, 
SSRIs, SNRIs by year. According to the MEPS-HC for 2004-2008, 8.9 percent of women in 
2004, 9.9 percent in 2005, 10.3 percent in 2006, 9.8 percent in 2007, and 10.0 percent in 2008 
were using BPs. In the same period, 13.0 percent of women in 2004, 12.7 percent in 2005, 12.8 
percent in 2006, 12.2 percent in 2007, and 11.9 percent in 2008 were using SSRI antidepressants. 
2.7 percent of women in 2004, 3.3 percent in 2005, 3.0 percent in 2006, 3.9 percent in 2007, and 
4.6 percent in 2008 were using SNRI antidepressants. 
 
Table 3.2. Utilization patterns of bisphosphonates and SSRIs in U.S. women aged 45 years and 
older for 2004-2008. 
 
Year 2004 2005 2006 2007 2008 
Total N (5846) N (5834) N (6113) N (5550) N (5574) 
Medication use % % % % % 
Bisphosphonates (BPs) 8.9 9.9 10.3 9.8 10.0 
SSRIs 13.0 12.7 12.8 12.2 11.9 
SNRIs 2.7 3.3 3.0 3.9 4.6 
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3.4.2 Overall concomitant use of BPs and SSRIs or SNRIs 
Among those women who were using BPs, concomitant SSRIs with BPs use was 
observed in 11.7 percent of women in 2004, 12.1 percent in 2005, 13.3 percent in 2006, 14.1 
percent in 2007, and 13.5 percent in 2008 (Table 3.3). Graphic representations of these findings 
are shown in Figure 3.3. A steady increase in BPs+SSRIs concomitant use was observed 
between 2004 and 2007 and then decreased slightly in 2008 (Table 3.3 and Figure 3.3).  
Whereas, for BPs+SNRIs utilization, an increase in concomitant use was observed from 2004 to 
2005, followed by a downward utilization trend in 2006 and then a steady upward trend in 2007 
and 2008 (Table 3.4 and Figure 3.3). Overall, between 2004 and 2008, the utilization rate of 
BPs+SSRIs increased (from 117 to 135 concomitant use per 1000 persons) and this increase had 
a significant linear trend (slope=0.56;p=.04). When weighted, this increase represented an 
increase of 0.66 million BPs+SSRIs users in 2004 to 0.86 million in 2008. On the other hand, a 
non significant increase in utilization rate (from 25 in 2004 to 43 concomitant use per 1000 
persons in 2008) was observed for concomitant BPs+SNRIs (slope=0.33; p>0.05). 
Table 3.3. Utilization patterns of concomitant use of bisphosphonates and SSRIs by age in U.S. 
women aged 45 years and older for MEPS 2004-2008. 
 
Year 2004 2005 2006 2007 2008 
Total N=497  N=519 N=556 N=496 N=466 
BPs+SSRIs use      
45-54 years, n (%) 6 (12.6) 10 (16.5) 8 (16.2) 5 (10.8) 11 (26.9) 
55-64 years, n (%) 20 (18.4) 24 (19.4) 20 (9.8) 23 (13.3) 9 (7.3) 
65-74 years, n (%) 12 (7.5) 11 (6.6) 25 (16.2) 19 (13.0) 15 (12.3) 
75-85 years, n (%) 14 (8.8) 17 (9.5) 27 (13.4) 26 (16.6) 27 (15.9) 
All, n (%) 52 (11.7) 62 (12.1) 80 (13.3) 73 (14.1) 62 (13.5) 
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Figure 3.3.  A plot of utilization patterns for concomitant use of BPs+SSRIs, and BPs+SNRIs in 
U.S. women aged ≥45 years, MEPS 2004 to 2008. 
 
Table 3.4. Utilization patterns of concomitant use of bisphosphonates and SNRIs by age in U.S. 
women aged 45 years and older for MEPS 2004-2008. 
 
Year 2004 2005 2006 2007 2008 
Total N=497 N=519 N=556 N=496 N=466 
BPs+SNRIs use      
45-54 years, n (%) 1 (5.5) 4 (12.1) 1 (2.3) 1 (3.0) 4 (11.5) 
55-64 years, n (%) 3 (3.0) 4 (4.0) 4 (3.3) 10 (5.9) 6 (5.1) 
65-74 years, n (%) 2 (1.6) 6 (4.0) 3 (1.5) 0 (0) 5 (4.8) 
75-85 years, n (%) 3 (1.9) 1 (1.1) 3 (1.7) 6 (3.8) 2 (2.1) 
All, n (%) 9 (2.5) 15 (3.8) 11 (2.2) 17 (3.5) 17 (4.3) 
 
3.4.3 Concomitant use of BPs and SSRIs/SNRIs by age and year 
When concomitant use of SSRIs with BPs use was examined by age group in each 
calendar year (Table 3.5 and Figure 3.4), we observed a significant linear trend (slope=2.1; 
p=0.01) of concomitant use among women aged between 75-85 years which increased steadily 
between 2004 and 2008. Although a similar upward trend was observed among women aged 65-
74 years, the linear trend was nonsignificant (slope=1.6; p>0.05). In the group aged 65-74 years, 
utilization decreased between 2004 and 2005, increased sharply in 2006, and then decreased in 
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2007 and 2008. Of the qualified participants in this study, interesting findings were observed 
among women aged 55-64 years. Among women of this age group, unstable (“zigzag”) 
downward, but nonsignificant, trend (slope=-2.8; p=0.06) was observed from 2004 to 2008. A 
look at year to year utilization pattern shows an increase from 2004 to 2005 then decreased 
sharply in 2006, increased sharply in 2007 and then decreased in 2008. Finally, a non significant 
overall upward utilization trend (slope=2.3; p>0.05) was observed among women aged 45-54 
years old. In this age group, the utilization trend increased upward from 2004 to 2005 then 
remained almost unchanged in 2006, decreased in 2007, and then increased sharply in 2008. 
 
Figure 3.4. Plot of utilization patterns of concomitant BPs+SSRIs use by age of U.S. women age 
≥45 years and older, MEPS 2004-2008. 
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Table 3.5. Trend analysis for concomitant SSRIs use with BPs. 
 
Year 2004 2005 2006 2007 2008 Slope; p-value 
Total N=467 N=519 N=556 N=496 N=466  
BPs + SSRIs 
use 
      
45-54 (%) 12.6 
(7.04-18.24) 
16.5 
(15.81-17.11) 
16.2 
(14.10-18.22) 
10.8 26.9 
(0.16-53.59) 
2.3; p>0.05 
55-64 (%) 18.4 
(16.01-20.87) 
19.4 
 (14.53-24.26) 
9.8 
(7.21-12.30) 
13.3 
(10.31-16.26) 
7.3 
(3.46-11.04) 
-2.8; p>0.05 
65-74 (%) 7.5 
(2.57-12.41) 
6.6 
(4.12-9.10) 
16.2 
(12.85-19.52) 
13.0 
(10.66-15.32) 
12.3 
(8.67-16.02) 
1.6; p>0.05 
75-85 (%) 8.8 
(7.53-10.00) 
9.5 
(6.33-12.59) 
13.4 
(8.69-18.06) 
16.6 
(12.47-20.81) 
15.9 
(12.03-19.78) 
2.1; p=0.01 
All, n (%) 11.7 
(8.67-14.74) 
12.1 
(9.56-14.73) 
13.3 
(10.57-16.01) 
14.1 
(11.57-16.72) 
13.5 
(10.37-16.56) 
0.56; p=0.04 
Note: The denominator for age categories is the total number of women in that particular age 
group and for that particular year, whereas the denominator for “All” is the “Total” number of 
women in that year. 
 
When concomitant use of BPs+SNRIs was examined by age group in each calendar year 
(Table 3.6 and Figure 3.5), we observed a positive, but nonsignificant linear trend across all age 
groups of concomitant use between 2004 and 2008 (slope range=+0.24 to +0.61; p >0.05). 
 
Figure 3.5. Plot of utilization patterns of concomitant BPs+SNRIs use by age of U.S. women 
age ≥45 years, MEPS 2004-2008. 
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Table 3.6. Trend analysis for concomitant SNRIs use with BPs. 
 
Year  2004  2005  2006  2007  2008  Slope; p-
value  
Total  N=467  N=519  N=556  N=496  N=466   
BPs+SNRIs 
use  
      
45-54 (%)  5.5 
(5.21-5.78)  
12.1 
(11.67-12.63)  
2.3 
(1.98-2.55)  
3.0  11.5 
(5.79-17.24)  
0.29p>0.05  
55-64 (%)  3.0 
(1.37-4.56)  
4.0 
(1.05-6.90)  
3.3 
(1.58-4.99)  
5.9 
(4.44-7.41)  
5.1 
(1.14-9.13)  
0.61;p>0.05 
65-74 (%)  1.6 
(0-4.23)  
4.0 
(1.85-6.20)  
1.5 
(0.20-2.85)  
0  4.8 
(2.67-6.93)  
0.24;p>0.05 
75-85 (%)  1.9 
(1.72-2.06)  
1.1 
(0-3.24)  
1.7 
(0-3.68)  
3.8 
(1.24-6.42)  
2.1 
(1.96-2.23)  
0.31;p>0.05 
All, n (%)  2.5 
(0.76-4.26)  
3.8 
(1.87-5.76)  
2.2 
(1.05-3.29)  
3.5 
(2.38-4.71)  
4.3 
(1.55-7.05)  
0.33;p>0.05 
Note: See Table 3.5  
3.4.4 Relationship between concomitant use of BPs+SSRIs and age  
The findings from examining whether age is associated with utilization pattern of 
concomitant use of BPs+SSRIs (Table 3.7) shows no structured pattern of odds ratios, overall. 
However, we noticed the highest odds of concomitant use with increasing age in the year 2007 
(odds ratios ranging from 1.24 to 1.66). Also, we observed that the pattern of odds ratios were 
similar in the years 2005 and 2008 which might suggest a need for further investigations.  
A time-trend analysis of the age effect shows a statistically non significant decreasing 
probability trend for BPs+SSRIs concomitant use in 2004 (p>0.05) and a statistically significant 
decreasing trend in 2005 (p<0.05), a statistically non significant increasing trends in 2006 to 
2008 (p>0.05). See Table 3.8. 
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Table 3.7. BPs+SSRIs concomitant utilization odds ratio (and 95% confidence interval) for age, 
by year; MEPS 2004-2008. 
 
Year 2004 2005 2006 2007 2008 
Total N=467  N=519  N=556  N=496  N=466  
BPs+SSRIs 
use 
     
      Age      
45-54  1.00 1.00 1.00 1.00 1.00 
55-64  1.56 (0.76, 3.20) 1.22 (0.59, 2.54) 0.56 (0.26, 1.24) 1.27 (0.46, 3.55) 0.21 (0.07, 0.62) 
65-74  0.56 (0.22, 1.43) 0.36 (0.14, 0.90) 1.00 (0.48, 2.11) 1.24 (0.46, 3.35) 0.38 (0.16, 0.94) 
75-85  0.66 (0.32, 1.39) 0.53 (0.24, 1.16) 0.80 (0.35, 1.85) 1.66 (0.63, 4.36) 0.52 (0.25, 1.08) 
 
Table 3.8. Cochran-Armitage Trend test of concomitant use of BPs+SSRIs for age, by year; MEPS 
2004-2008. 
 
Year  2004  2005  2006  2007  2008  
Statistic (Z)  1.438  2.547  -0.229  -0.699  -0.319  
0ne-sided p-value  0.075  0.005  0.410  0.242  0.375  
Trend (‘1’)  decrease  decrease increase  increase  increase  
 
3.5 Discussion 
This study described national estimates across five-year period of concomitant SSRIs/SNRIs 
with BPs and the trend over time. We also screened the effects of age on utilization patterns in 
order to provide information that might be useful in supporting the need for further detailed 
investigations. Both overall utilization patterns of concomitant use as well as utilization for four 
age categories were presented. 
3.5.1 Overall utilization and trends of concomitant use 
We found that overall concomitant SSRIs with BPs use is prevalent and increased 
slightly across the five-year period among the study population. Although we observed 
concomitant SNRIs with BPs use, based on the National Center for Health Statistics minimum 
standard for reliability of estimates,25 overall patterns of use across the five-year period were 
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considered too small for any meaningful interpretations and therefore concomitant SNRIs with 
BPs use findings are not discussed further. The low cell sizes can be attributed to the fact that 
SSRIs are widely used than SNRIs. Although SSRIs and SNRIs are both most popular 
antidepressants with comparable efficacy,26 all SSRIs (citalopram, fluoxetine, fluvoxamine, 
paroxetine, and sertraline) but only one SNRI (venlafaxine) are the most commonly used 
medications for depression. This was according to the 2000 American Psychiatric Association 
practice guideline for the treatment of patients with major depressive disorder. These 
medications are likely to be optimal in terms of the patient’s acceptance of side effects, safety, 
and quantity and quality of clinical data.27 Also, the 2001 expert consensus panel recommended 
venlafaxine as an alternative to SSRIs as a first-line treatment for depression in older adults.28  
With regards to the overall increasing trend of concomitant SSRI with BP use, it is 
unclear why the simultaneous use of these agents increased across the five-year period and what 
might explain the effects of age on patterns of use. Since this present study did not intend to 
determine the predictive factors influencing the patterns of use, we explored the literature in an 
effort to suggest explanations for our findings. Three suggested explanations are provided and 
these include, 1) increasing population of women in the US and demographic factors, 2) 
increasing diagnosis of osteoporosis or fractures and/or depression, 3) side effects associated 
with HRT use and the influence on alternative therapies, and 4) newer indications for both BPs 
and SSRIs in women. 
Population increase is an important factor to consider when assessing changes in trend of 
drug utilization, and in the present study concomitant SSRIs with BPs use. In our study we 
observed that overall the female population increased in numbers from 2004 (36%) to 2008 
(40%) (see Figure 3.2).24 Utilization can increase if the chances that more females begin taking 
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medications increases. This can be supported by the fact that females are more likely to visit 
their healthcare providers than males and this has an overall influence on medication 
utilization.29 Furthermore, of the women surveyed, we observed a large number of white women 
compared to other races across the five year period. The old National Osteoporosis Foundation 
Guide, last updated in 2005, applied only to postmenopausal white women30 and this might have 
influenced both the patient preference and physician prescribing habits in shared decision-
making.  
Another perspective related to population increase might be the increase in the incidence 
of osteoporosis or fractures and/or depression. This is an important factor that could result in an 
overall increased demand for prescription drugs. The incidence of osteoporosis and risk of 
fractures in postmenopausal women continues to increase over time. It is estimated that 10 
million individuals in the United States have osteoporosis, eight million are women and two 
million are men.31 According to estimated figures, osteoporosis was responsible for more than 2 
million osteoporotic fractures in 2005.  Due to specialized tests for diagnosis there has been a 
five-fold increase in office visits for osteoporosis (from 1.3 to 6.3 million) based on data from 
1996 to 2006. This data suggests that improved diagnosis can lead to therapeutic follow-up to 
treat or prevent osteoporosis and/or risk of fractures through administering antiresorptives (e.g., 
bisphosphonates) and this will have an overall impact of increasing utilization of such 
medications. Low BMD in combination with low-trauma fracture or fracture risk factors 
(smoking and weight) remains the strongest predictor or drivers of BPs use in postmenopausal 
women.32,33 
 The WHO suggests that major depression is the leading cause of burden of disease in the 
Americas accounting for 7.5% of total disability-adjusted life years (DALYs) and is expected to 
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be leading worldwide by year 2030 accounting for 6.2% of total DALYs. Moreover, the WHO 
report indicates that depression is the leading cause of disease burden in young women (15-44 
years).34 As with younger women, among older persons, the burden of depression is higher in 
older women than older men, but is less common during the postmenopausal years.35,36 For 
example in the study by Barry et al. it was found that among those who were non-depressed, 
women were more likely to transition to a depressed state, with an adjusted odds ratio of 2.02 
(95% CI;1.39-2.94).36 It is important to note that depression in older adults is not directly 
associated with advancing age37, but rather is considered a disorder co-morbid with other 
illnesses associated with aging.38 
According to the Agency for Healthcare Research and Quality (AHRQ), about 60% of 
depressed outpatients have at least one other chronic medical condition as well. The challenge of 
treating depression is a big issue in older adults. AHRQ research comparing older adult patients 
with and without depression in a primary care clinic found that the depressed patients had almost 
1.5 more ambulatory care visits per year, over 12 percent more visits to the emergency 
department, and 5% more hospitalizations.39 Despite the complexity of treatment of patients with 
comorbidity, patients with cormobid disorders continue to receive treatment to improve the 
quality of care.40 With the high prevalence of depression in postmenopausal women attributed to 
improved diagnosis through increased contacts with the healthcare system, antidepressant 
prescriptions are likely to be driven up as result in order to meet the desired goal of improving 
the quality of care for patients with depression. This is in agreement with previous literature 
which found that guideline concordance (guideline of the 1999 Canadian Network for Mood and 
Anxiety Treatments) increased prescribing physician visits in the year following diagnosis. In 
this study 2,742 patients (mean age 42 years; 64% female patients) met the study criteria. Of the 
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beneficiaries to whom psychoactive medication was dispensed, 2,047 (75%) received an 
antidepressant as the initial starting drug and 1958 (71%) received a recommended first-line 
antidepressant. In a multivariable model, recommended first-line medication (z=6.17, df 11, 
p=0.001), starting dose (z=5.70, df 11, p=0.001), and duration (z=9.49, p=0.001) were associated 
with more visits to prescribing physicians.41 
Another factor that might have influenced use of bisphosphonates and/or SSRIs/SNRIs is 
the study by the Women’s Health Initiative (WHI) about the adverse effects of estrogen in 
women. In 2002, data from a WHI study was published highlighting the side effects (breast 
cancer and cardiovascular disease) of estrogen plus progestin in healthy postmenopausal 
women.42 In response to these concerns, use of alternative therapies increased.  This is evident 
from the reported increase in nonhormonal options as alternatives to estrogen, given with and 
without progestin (or HRT), for postmenopausal symptoms such as osteoporosis and hot flushes 
that respond only to prescription medications following WHI study. The North American 
Menopause Society released a position statement in 2003 recommending options for women with 
concerns or contraindications relating to estrogens. The nonhormonal options included 
antidepressants such as venlafaxine (SNRI), paroxetine, and fluoxetine (both of which are 
SSRIs). This statement in now retired.43 Huot et al. showed a decrease in HRT and increase in 
bisphosphonate prescriptions from 2004 to 2006 in women aged 50 years and older.44 Vegter et 
al. showed that those who stopped HRT received more nonhormonal therapies for menopausal 
symptoms from 2002 to 2006 compared to those who continued hormonal therapy; incidence 
risk ratio (IRR) of bisphosphonates was significant (IRR=2.54, 95% CI 1.16-5.55) and overall 
IRR of antidepressants was not statistically significant (IRR=1.34, 95% CI 0.97-1.86). 
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Antidepressant use was increased for both tricyclic antidepressants and SSRIs, but not for other 
types of antidepressants (including SNRIs).45 
Another way through which side effects of HRT use may influence alternative therapy 
choices could be to increase healthcare costs. The long-term safety concerns of breast cancer 
associated with HRT use increases management costs for HRT users because women are more 
likely to get excess rates of resource utilization for uterine- and breast-related diagnostic and 
treatment procedures, thus, increasing the healthcare cost pressures.46 Considering that the 
current US Preventive Service Task Force guidelines recommend alternatives such as 
bisphosphonates for osteoporosis therapy,47 these recommendations plus the induced additional 
healthcare-related cost pressures might have reinforced the need to consider therapeutic 
alternatives to HRT. 
Consensus guidance recommendations support new indications for BPs or SSRIs and the 
new indications may contribute to expanded utilization of either or both drugs. Additional 
indications for bisphosphonate use include reducing skeletal complications of many 
malignancies, including multiple myeloma, breast and prostate cancer, and other solid tumors, 
and palliation of cancer-associated bone pain.48 Data from the Surveillance, Epidemiology, and 
End Results from 2004-2008 showed that the trend of cancer incidence for females of all races 
remained stable with an annual percentage change of 0.4%. (www.seer.cancer.gov) In addition, 
data from the Centers for Disease Control (2004-2008) indicate that the site with the highest 
incidence rate (about 120 per 100,000 population) was of the female breast followed by the lung. 
The highest death rate among females was from lung cancer (www.apps.nccd.cdc.gov). Other 
indications for SSRIs include, generalized anxiety disorder, social anxiety, panic disorder, 
posttraumatic stress disorder, obsessive compulsive disorder, and eating disorder.(www.fda.gov)  
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Given that some of the commonly associated health conditions in the postmenopausal 
years include osteoporosis, depression, diabetes, and cancer (www.menopause.org), it is 
plausible to suggest that coexistence of osteoporosis and depression or osteoporosis and other 
indications for SSRIs or depression and other indications for BPs, or other indications for both 
BPs and SSRIs are prevalent. Coexistence of any of these diseases can influence overall 
expanded utilization of simultaneous SSRIs with BPs use.  
3.5.2 Utilization patterns and trend of concomitant use with age 
The main reason to further classify patients into age groups is that age-related 
characteristics (e.g., clinical) are heterogeneous.49 As a result, age-related differences might 
influence health services and medications utilization. The differences are especially significant 
among women within the older age groups 65 years and older.50 In this present study, the 
tabulated results by year for each age category showed increasing utilization of concomitant 
SSRIs with bisphosphonates use among respondents 65 years and older across the five-year 
period and the pattern might be time-dependent.  This was further explained by looking at the 
age-specific odds ratios. Although the odds ratios showed no structured pattern, the observed 
highest odds ratios of older respondents with simultaneous use of BPs+SSRIs in 2007 is 
probably because 90% of older adults 65 years and older had regular source of health care 
regardless of other factors and the use of physician services was found to be high among this 
population.51 The higher contact with healthcare providers could have had an overall influence in 
medications use. In addition, major policy changes of year 2006 following the implementation of 
The Medicare Modernization Act Prescription Drug Benefit (Part D)52 made it possible for older 
adults 65 years or older to voluntarily subscribe to drug coverage which in turn resulted in 
modest increase in average drug utilization.53 Another primary contributor to upward drug trend 
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in this age group is the decline in unit costs of medications due to entry of lower-cost options 
(generic drugs).54 Zoloft® (sertraline) was one of the generic drugs introduced in mid-2006.55 
In 2005 and 2008 the similar low odds ratios observed suggested important factors that 
might have impacted utilization of medications. In 2005 Gunnell et al. reported that SSRIs use 
was associated with increased risk of suicidality in older adults.56 It is probably in response to 
these concerns that SSRIs prescribing and hence utilization growth declined. In addition to the 
implementation of Medicare Part D prescription drug coverage in 2006 which resulted in 
increased drug utilization among older adults 65 years and older, the first generic 
bisphosphonate, Fosamax® (alendronate), that is approved to treat osteoporosis was introduced 
in 2008.57 As would be expected, the introduction of generic bisphosphonate into the 
pharmaceutical market would decrease the unit costs of the most popular bisphosphonate drug. 
Both the guaranteed prescription drug coverage and decreased unit costs were expected to further 
drive the utilization of medications upwards and possible increased likelihood of simultaneous 
SSRIs with BPs users. Instead, a decline in utilization was observed and there are two suggested 
contributing factors: 1) the safety and effectiveness concerns related to medications for 
postmenopausal osteoporosis published in 2007, and 2) the economic downturn-related factors in 
2008.  
Of the medications that have been proven to be effective in decreasing the risk of 
osteoporotic-related fractures in postmenopausal women, bisphosphonates are the most popular. 
Suboptimal compliance and persistence with bisphosphonate treatment was associated with 
increased fracture risk. However, the benefits of oral bisphosphonates use over extended period 
of time were unclear suggesting that decisions on optimal clinical effectiveness achieved during 
indefinite use of bisphosphonates could not be supported.58 In a randomized, double-blind trial 
 
 
106 
 
conducted at 10 U.S. clinical centers that participated in the Fracture Intervention Trial of 
postmenopausal women using alendronate, findings showed that discontinuation of alendronate 
for up 5 years does not appear to significantly increase fracture risk but therapy beyond 5 years 
was recommended for women at high risk of clinical vertebral fractures.59 Considering that the 
journal has a high impact factor, looking at the time of publication of this article (December 
2006) the findings might have created confusion among physicians and patients as well during 
the year 2007.  
At about the same time of publication of the article by Black et al.59 a review by Briot et 
al. which assessed optimal treatment duration of use of bisphosphonates determined that there 
was no proof that these drugs prevented fractures after the first 4 to 5 years of treatment and so, 
long-term use of these drugs was recommended for 4-5 years.60 Additional articles with 
consistent conclusions have since been reported. During the year 2007, these findings were 
widely publicized which also may have spilled over to 2008. As a result, it is plausible to 
suppose that the negative impact on physician prescribing habits and patient preference was 
unavoidable and, thus, had an overall influence in the decline in utilization of bisphosphonates.  
As was mentioned earlier, the second suggested contributing factor to changes in 
utilization of concomitant SSRIs with BPs was the impact of the economic crisis in 2008. The 
economic crisis in 2008 was quite devastating for many families. Investments were devalued, 
people lost jobs, and budget cuts were made in the government as well as the private sector and 
this could strongly and negatively impact overall spending on basic needs including healthcare-
related utilization. A recent study by Piette et al.61 found that among chronically ill patients in 
2008, rates of medication-cost problems associated with recent economic recession impacted all 
 
 
107 
 
age groups including those >65 years of age and eligible for Medicare Part D. Rates were 
especially high among adults aged 40-64 years. 
 
3.5.3 Relationship between concomitant SSRIs with BPs and age 
The relationship between concomitant SSRIs with BP use and age was not consistent 
across the five year-period. Overall, concomitant use decreased with age from 2004 to 2005 but 
increased from 2006 to 2008. This can, in part, be explained by the confusion in age-related 
treatment options driven by the age-dependent bone density change62 and safety of hormonal 
treatments of menopause-related health outcomes.63 In younger postmenopausal women (after 50 
years old), increase in bone loss (osteoporosis) is related to a sharp drop in estrogens and thus 
hormonal therapy might be beneficial.62,63 Although HRT is associated with heart disease in 
postmenopausal women, complications of therapy occur in women many years after the start of 
menopause.64 In 2004, Anderson et al. released an updated interpretation of the WHI study (in 
comparison to the previous 2002 WHI study) that was supportive of estrogen use in the younger 
postmenopausal women below the age of 60 years.65 SERMs are considered first-line therapy in 
younger postmenopausal women at lower risk for hip fracture.5 Use of SERMs results in a 55% 
reduction in vertebral fractures but lacks advantage when looking at nonvertebral fractures.66 In 
older postmenopausal years (65 years and older), there is accelerated bone loss beginning at 70 
years old62 and bisphosphonates are the first-line therapy for osteoporosis.5 In reference to 
SSRIs, the downward trend from 2004 to 2005 was probably due to a fall in utilization. For 
example, Chen et al. in a study using Medicaid data found that the total number of antidepressant 
prescriptions increased from 1991 to 2004 (from 6.8 million to 35 million scripts), but then fell 
 
 
108 
 
in 2005 to 32.7 million prescriptions. SSRI prescriptions were 20.8 million in 2004 but fell to 
19.5 million in 2005.67 
The National Osteoporotic Foundation suggests age as one of the factors to consider 
when choosing a treatment. The foundation states that “some medicines may be more appropriate 
for younger postmenopausal women while others are more appropriate for older women.”68 This 
statement is likely to have an overall influence on physician prescribing habits, patient 
preferences, or healthcare systems. Under this confusion, some physicians might switch their 
patients to a safer alternative, or some might use their clinical judgment and experiences to wait 
and switch their patients later, patients’ preference might influence physician prescribing, or 
healthcare systems might tailor their formularies. In summary, the factors discussed above might 
be responsible to explain a downward (2004-2005) and upward (2006-2008) trend of 
concomitant SSRIs with BPs use with age in our present study. 
3.5.4 Strengths and limitations  
There are strengths and limitations in this study. Strengths: First, MEPS consists of 
patient-level data and is nationally representative of the U.S. civilian, non-institutionalized 
population. It was therefore suitable to use this dataset to describe national estimates of 
medication use. Secondly, self-reporting bias is minimal. This is because MEPS does seek 
permission from the respondents to verify medications use from their respective pharmacies. 
Limitations: Following age categorizations and medications use, all cell sizes for BPs+SSRIs use 
were small (less than 30). According to the National Center for Health Statistics, estimates 
determined to be statistically reliable are generally based on sample size (cell size greater than or 
equal to 30) and relative standard error (less than 30%).25 Therefore, interpretations of data under 
age categories is not representative of national estimates and caution is advised.  
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3.6 Conclusions 
We conclude that concomitant SSRIs with BPs use in adult women ≥45 years is not 
uncommon and might be higher in older postmenopausal women. The trend of concomitant use 
may be time-dependent and the utilization pattern over time may be influenced by patient-, 
provider/physicians-, and health-care system-level factors that determine prescribing of 
medications to particular patients. Unfortunately this study did not attempt to assess these factors 
but only suggested possible explanations from literature. As such there is still need to further 
investigate the impact of these factors on the utilization patterns of SSRIs with BPs using a large 
sample size and longitudinal data. Moreover, the observed concomitant use presents drug safety 
challenges surrounding the bone health of postmenopausal women. Studies are needed to 
investigate the potential interactive effects of SSRIs on BP therapy. 
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Chapter 4 
4.0 METHODS 
4.1 Study design 
A nested case-control study was performed to examine 1) the association between concomitant 
use of SSRIs or SNRIs with bisphosphonates and increased risk of osteoporotic-related fractures, 
and 2) whether the risk of osteoporotic-related fractures is related to the role of serotonin in bone 
rather than the disease (depression).  
4.1.1 Rationale  
One of the prime purposes of a pharmacoepidemiologic study is to determine whether 
drug exposure causes an adverse drug event (health outcome). Typically, the sequence of 
discovery of causal association between exposure and outcome using epidemiologic approaches 
involves five steps which include the analytic methods such as nested-case control study design 
(or the case-control in a cohort study).1 Nonetheless, many population-based case-control studies 
can be thought of as nested within an enumerated source population.2 This design is based on a 
sampling approach known as incidence density sampling or risk set sampling. In the nested-case 
control study, cases of the outcome of interest that occur in a defined cohort are identified, a risk 
set (i.e., that could become a case) corresponding to the cases is formed and, for each, a specified 
number of matched controls is randomly selected for each risk set from among those in the 
cohort who have not developed the outcome by the time of the outcome occurrence in the case.3 
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By using this strategy, cases occurring later in the follow-up are eligible to be controls for earlier 
cases.4  
Strengths exist in support of this study design strategy. First, the design combines some 
of the features and advantages of both cohort (i.e., limiting selection bias) and the efficiency of 
case-control designs approach. The likelihood of selection bias tends to be diminished in 
comparison with the traditional case-based case-control study. This is because cases and controls 
are selected from the same (defined) source cohort and because (as in any traditional cohort 
study) exposures are assessed before the disease occurs.4 In addition, this study approach can be 
relatively quicker and less expensive than cohort or experimental studies, primarily because the 
control group is a sample of the source population. Also, the design strategy involves potentially 
less complex analysis. Second, when the outcome being studied occurs rarely and/or is suspected 
to be a latent effect of the exposure, cohort studies become impractical and case-control studies 
become a useful and efficient alternative. This is because fewer subjects are needed than for 
cohort studies.2,5 Third, the likelihood of survival bias tends to be diminished in comparison with 
the traditional case-based case control study. Survival bias is a potential problem in a case-based 
case-control study carried out “cross-sectionally” because only cases with long survival after 
diagnosis (best prognosis) are included in the case group.4 Fourth, the study design is better in 
quantification of exposure with respect to time.3 Sampling is the equivalent of matching cases 
and controls on duration of follow-up (or respect to time), thus if time is related to exposure, the 
resulting data should be analyzed as matched data.2,4 
4.2 Data sources 
We used the random 5% sample data from the entire Medicare administrative claims data 
(see Table 4.1 for a description of the data obtained) from 2008 to 2010. (Part A Medicare claims 
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were of persons enrolled in fee-for-service because claims from these sources provide 
information needed for research purposes.) These data are available back to January 2006, when 
the program was implemented. The Centers for Medicare and Medicaid Services (CMS) 
administer Medicare. All requests for CMS research-identifiable Medicare Part D data was 
developed and reviewed with the assistance of the Research Data Assistance Center (ResDAC), a 
CMS contractor that provides free assistance to academic, government and nonprofit 
researchers.6  
4.2.1 Rationale  
Pharmacoepidemiologic research on the beneficial and adverse events of medications 
among older adults has used databases such as Medicare Current Beneficiary Survey (MCBS) or 
Medicare Expenditure Panel Survey (MEPS). However, these databases are limited by smaller 
sample sizes, which can limit statistical power.7 MCBS is a continuous, multipurpose survey 
(collected since 1991) of a representative sample of the Medicare population designed to aid the 
CMS administration, monitoring and evaluation of the Medicare program.8 Unlike the databases 
mentioned above, Medicaid database has a relatively large sample size of older adults and has 
been used for drug safety related studies.9  The specific limitation of this database is its 
generalizability. Those older adults who are not classified as of low income are not covered 
under the Medicaid program and so are not represented in findings based on this database.  
  The use of Medicare Part D data, like other administrative databases such as Medicaid 
data10 is faced with methodological challenges such as verifying data validity, confounding, and 
logistic problems. A central limitation with many implications is that such databases are 
collected for administrative rather than research purposes. These limitations are an important 
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source of bias in the results of most studies. Based on this understanding, new methods relating 
to data analysis approaches applicable to administrative claims data, such as Medicare Part D 
data, have been suggested. These efforts are geared towards improving the usefulness of these 
important data sources to evaluate drug safety and effectiveness.11 For example, recently, 
Graham et al.12 determined the increased risk of cardiovascular events by rosiglitazone compared 
with pioglitazone among 227,571 Medicare beneficiaries aged 65 years or older through a 
Medicare Part D prescription drug plan from July 2006-June 2009. The results showed that the 
prescription of rosiglitazone was associated with increased risk of cardiovascular events.12 
This underscores the statement noted by Strom13 that “Medicare Part D is one potential 
data source, which, when linked to other Medicare claims data, will be a unique resource on a 
massive and stable population”.13 Thus the main advantage of using this source of data is its 
large, nationally representative population of older adults. Also due the fact that out-of-pocket 
spending was reduced with this plan among older adults, prescription drug use increased 
significantly14 suggesting that Medicare Part D data potentially captures large numbers of users 
of prescription drugs. Medicare Part D provided an opportunity for those beneficiaries who had 
no drug coverage that were not poor and frail. Also, in a similar perspective, Platt and Ommaya15 
noted that linked Medicare Part D data presents a valuable resource to assess drugs under real-
life conditions, particularly in this vulnerable population, which is often excluded or 
underrepresented in clinical trials. Therefore, use of information from Medicare administrative 
claims data will be important because our preliminary studies using MEPS (see Chapter 3) have 
been limited by smaller sample sizes and have not provided statistically reliable findings. 
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Table 4.1. Description of CMS data files and key variables needed for analysis. 
Study objective Data variable (s) CMS data file (s) needed 
To examine the association of 
concomitant use of SSRIs/SNRIs, 
glucocorticoids, or PPIs and 
bisphosphonates and increased 
risk of osteoporosis-related 
fracture in adult women aged ≥65 
years  
Individual claims (e.g., fracture) 
submitted for each inpatient stay at a 
Medicare-approved facility (e.g., 
hospital) 
Medicare Part A (inpatient) 
 CCW Encrypted Part D Event 
Number, CCW Encrypted 
Beneficiary ID Number, Patient 
Date of Birth, Gender, RX Service 
Date (DOS), Encrypted Plan 
Contract ID, Compound Code, 
Quantity Dispensed, Days Supply, 
Dispensing Status Code, Patient Pay 
Amount, Medicare Part D formulary 
tier identifier 
Medicare Part D (prescription drug 
event) 
 CCW Encrypted Part D Event 
Number, CCW Encrypted 
Beneficiary ID Number, Brand 
Name, Generic Name, Drug 
Strength Description, Dosage Form 
Code, and Dosage Form Code 
Description 
Medicare Part D (drug 
characteristics file) 
 Provides a summary of the 
beneficiary’s use of various 
Medicare categories and prior 
history of various chronic conditions 
(e.g., myocardial infarction, 
depression, etc.) 
Beneficiary annual summary file 
 Provides basic beneficiary 
demographic and geographic data, as 
well as enrollment and eligibility 
information 
Beneficiary summary file 
 
4.2.2 Data elements 
The data elements from this database included a coded patient identifier (Medicare 
patients have a unique personal identification number (PIN) through which all health system 
encounters are tracked); patient demographics (age, race, and socioeconomic status); 
procedure/diagnostic codes (or medical diagnoses); claim admission codes and dates, and 
pharmacy claims details (National Drug Codes, drug names, date of drug dispensing, quantity 
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dispensed, number of days supplied, and refill status).96 See Table 4.1 for a description of the 
data variables obtained. 
4.3 Study population 
4.3.1 Inclusion criteria 
Cases and controls were eligible for inclusion in the study if they were females and aged 
65 years or older. Cases were defined as women with a first osteoporotic-related fracture 
matching with the fracture index date. The fracture index date (date of experiencing a fracture) 
was defined as the first documentation of an osteoporotic-related fracture during the study period 
(January 2008 to December 2010) associated with hospitalization. Fracture identification was 
based on the International Classification of Diseases, 9th revision; Clinical Modification (ICD-9-
CM) codes for fracture at six of the most common fracture sites from inpatient encounters: hip, 
spine, distal radius/ulna, tibia/fibula or ankle, and humerus from inpatient encounters (Table 
4.2). Only patients using bisphosphonates were included in the study.  
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Table 4.2. Description of osteoporotic fracture sites included in the study. 
Fracture site Fracture type                         ICD-9-CM 
Hip or pelvis 
fracture 
Closed Pathologic 
Transcervical 
Pertrochanteric 
Unspecified hip 
Acetabulum 
Pubis 
Other specified 
Unspecified 
733.14 
820.0x 
820.2x 
820.8x 
808.0x 
808.2x 
808.4x 
808.8x 
Femur Closed Pathologic 
Shaft/unspecified 
Lower end 
733.15 
821.0x 
821.2x 
Vertebral (without 
spinal cord injury) 
Closed Pathologic 
Cervical 
Thoracic/Dorsal 
Lumbar 
Sacrum & coccyx 
Unspecified 
733.13 
805.0x, 806.0x 
805.2x, 806.2x 
805.4x, 806.4x 
805.6x, 806.6x 
805.8x, 806.8x 
Radius / ulna or 
wrist 
Closed Pathologic 
Upper end 
Shaft 
Lower end 
Unspecified  
733.12 
813.0x   
813.2x 
813.4x 
813.8x 
Humerus Closed Pathologic 
Upper end 
Shaft/unspecified 
Lower end 
733.11 
812.0x 
812.2x 
812.4x 
Tibia/fibula or ankle Closed  823.0x, 823.2x, 823.4x 
823.8x, 824.0x, 824.2x 
824.4x, 824.6x, 733.16 
 
 
4.3.2 Exclusion criteria  
Cases and controls were excluded if they had a history of prior fracture.  History of prior 
fracture was defined by any fracture in the first 6 months of observation if multiple fracture 
events are noted during the study period, only the first event was included in the study. Women 
with any fracture that was listed as “open” (e.g., 813.1x: fracture of radius/ulna, upper end, open) 
was excluded since open fractures are more likely the result of a major trauma rather than 
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osteoporosis. The complete list of open fractures is as follows: those with open fractures of the 
hip, ICD-9-CM codes: 820.1x (transcervical), 820.3x (pertrochanteric), and 820.9x (unspecified 
part of neck of femur); open wrist or radius/ulna fracture, ICD-9-CM codes: 813.1x (upper end), 
813.3x (shaft), 813.5x (lower end), and 813.9x (unspecified part of radius/ulna), and open 
vertebrae fracture with or without spinal code injury, ICD-9-CM codes: 805.1x, 806.1x 
(cervical), 805.3x, 806.3x (thoracic), 805.5x, 806.5x (lumbar), 805.7x, 806.7x (sacrum & 
coccyx), and 805.9x, 806.9x (unspecified part). Other exclusions were those women taking 
calcitonin (Miacalcin), parathyroid hormone teriparatide (Forteo), selective estrogen-receptor 
modulators (Evista), and also those women with diagnosis of Paget’s disease, or disabled people 
under 65 years of age. These patients are at a much higher risk for adverse bone health. 
4.4 Exposure to concomitant use 
  Assessments of the drug exposure as identified by their brand or generic names were as 
follows. The primary exposure variable was the concomitant use of SSRIs or SNRIs with 
bisphosphonates and was defined as having received at least one prescription for a 
bisphosphonate and a SSRI or SNRI (with no dispensing medication gap for a SSRI or SNRI of 
more than 90 days whereas users of bisphosphonates were those patients who were exposed for 
at least 180 days in the 360 day period). SSRI users were defined as women reporting SSRI use 
but no other antidepressants at a given visit. Likewise, SNRI users were defined as women 
reporting SNRI use but no other antidepressants at a given visit.16 Information on SSRI or SNRI 
use was classified as either ‘current’, ‘recent’, or ‘past’ users. A schematic representation is 
shown in Figure 4.1. Current users were defined as those individuals with a total of 90 day 
supply for a SSRI or SNRI and within 90 days (1 to 90) prior to the index date of sustained 
fracture. Recent users were defined as those individuals with a total of 90 day supply for a SSRI 
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or SNRI and within 91 days and 180 days prior to the index date of sustained fracture. Past 
users-those individuals who were not current users or recent users and had a supply for a SSRI or 
SNRI dispensed more than 180 days in the 360 day period prior to the index date of sustained 
fracture. These definitions have been used in a previous study to assess the association between 
antidepressants and risk of fracture of the hip or femur. In this study, compared with individuals 
who had never used an SSRI, the risk of hip/femur fracture increased with current use of SSRIs 
(adjusted OR=2.35, 95% CI 1.94-2.84), recent use (adjusted OR=1.48; 95% CI 1.14-1.93), and 
past use (adjusted OR=1.23; 95% CI 1.07-1.42).17   
 
Figure 4.1. Timing of SSRI or SNRI use. 
 
4.5 Regulatory approval 
This study was reviewed and approved by the Institutional Review Board (IRB) at Virginia 
Commonwealth University. 
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4.6 Statistical plan 
4.6.1 Selection of subjects: 
Flow charts for the selection of subjects eligible for analysis are shown in Figure 4.2 
(Specific Aim 1) and Figure 4.3 (Specific Aim 2). 
4.6.2 Dependent and independent variables: 
Dependent (or response) variable: increased risk of osteoporotic-related fractures 
Independent (treatment or explanatory) variables:  Concomitant use of SSRIs or SNRIs and 
bisphosphonates.  
4.7 Strategic framework to control for confounding 
A multivariable logistic regression model was developed to calculate the propensity score of 
individual patients. (Refer to more information on propensity score method in Chapter 2 Section 
IX). Propensity score is defined as the probability of receiving treatment rather than the control 
for a patient conditional on observed baseline covariates.18  In this study, the propensity score is 
the probability of receiving concomitant SSRIs or SNRIs with bisphosphonates versus 
bisphosphonate alone users as a function of all the potential confounders listed in Table 4.4. 
Medicare beneficiaries who were identified as “White” or “Black”, or “Hispanic” were 
categorized as “White”, or “Black”, or “Hispanic” respectively. However, beneficiaries who 
were identified as either “North American Native” or “Asian” or “Other” or “Unknown” were re-
classified as “Other”. To quantify patients’ comorbidities included in the logistic regression 
model, two potential comorbidity indices: Functional or Deyo-adapted Charlson Comorbidity 
Index can be used for this pharmacoepidemiologic study. Both of these indeces are described 
next, but we calculated the comorbidity scores using the Deyo-adapted Charlson Comorbidity 
index. The rationale for the comorbidity index choice is provided in the following description. 
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Table 4.3. Baseline patient characteristics of all antidepressant initiators. 
Characteristic 
Demographic 
Age (within 5 year bands): Aging is characterized by changes in pharmacokinetic and pharmacodynamic 
processes. These processes when altered increase the risk of adverse drug events, and increased sensitivity 
to medications.1 
Race (White, Black, Hispanic, or Other) 
SES (based on low income subsidy of the beneficiary, as a proxy for socioeconomic status) 
Health service-use intensity or Health care utilization factors 
Comorbidity score  
Number of unique prescribed medications 
Medical conditions 
Rheumatoid arthritis/ Osteoarthritis 
Osteoporosis 
Kidney disease 
Anxiety or sleep disorder 
Epilepsy 
Movement disorders (e.g., Parkinson’s disease) 
Cognitive dysfunction (e.g., Alzheimer’s disease or other diagnosis of dementia) 
Hypertension 
Congestive heart failure 
Diabetes mellitus 
Chronic obstructive pulmonary disease (COPD) 
Hyperparathyroidism 
Depression 
Orthostatic hypotention 
Use of other medications that may modify fracture risk 
Oral glucocorticoid use/oral corticosteroid use 
Proton pump inhibitor use 
Aromatase Inhibitors 
Thiazolidinediones use 
Estrogen use (or hormone replacement therapy) 
Warfarin use 
Anticonvulsant use 
Thyroid medication use 
Opioid use 
Antihypertensive use (thiazide diuretics, angiotensin II converting enzymes inhibitors, angiotensin II 
receptor blockers, beta-adrenergic blockers, or calcium channel blockers) 
Loop diuretic use (e.g. furosemide) 
Antipsychotics use, Methotrexate, and Lithium 
1Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and 
related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571-584. 
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4.7.1 Comorbidity score 
4.7.1.1 Functional comorbidity index 
 A functional comorbidity index is an index of comorbid diseases with physical function.  
The functional comorbidity index contains 18 diagnoses scored by adding the number of “yes” 
answers, with a score of 0, indicating no comorbid illnesses.19 The reason to use this index is 
because SSRIs are one of the examples of medications associated with drug-related falls.20 
SSRIs-related falls can be injurious and result in fractures. For example, in an observational 
study of 368 subjects (SSRI users, n=129; non-SSRIs, n=40; non-antidepressants, n=199) 
conducted in a nursing home setting showed high rate of falling in SSRIs users (24%, OR of 1.9 
or greater) and high rate of injurious falls (OR, 1.73) that resulted in fractures and/or 
hospitalization from a series of adjusted models compared with other two groups of subjects.21 
Also, French et al.22 in a national veterans study using outpatient medication data to assess fall-
related hip fracture hospitalization showed that usage of SSRIs was 2-fold higher in hip-fracture 
patients compared to the control groups.22 However, risk factors for falls and/or a fracture in 
older adults are multifactorial such as comorbid diseases and physical function. The diseases 
include but are not limited to diabetes mellitus, dementia, high blood pressure, chronic 
obstructive pulmonary disease, and arthritis.23 In fact, the diseases are all included in the 
functional comorbidity index.  
Overall physical functioning is one of the intrinsic factors associate with falls 
recommended to be assessed in an older patient reporting a fall.24 Therefore, the suggested index 
might be appropriate in quantifying comorbidities and physical function on fracture  outcomes. 
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4.7.1.2 Charlson comorbidity index 
There are thirteen different methods to assess comorbidity: one disease count and 12 
indices. Of these, the Charlson index is the most extensively studied comorbidity index.25 The 
Charlson comorbidity index is a summary score based on 19 major medical conditions including 
myocardial infarction, pulmonary disease, cancer, diabetes, renal disease, hepatic disease, HIV 
infection, etc. A score of 0 represents absence of comorbidity, and a higher score indicates a 
greater number of comorbid conditions. The index was originally developed and validated in 
1987 to classify prognostic comorbidity for patients enrolled in longitudinal studies; developed 
based on the inception cohort study of 604 patients admitted to the medical service at New York 
Hospital during 1 month in 1984 and then was tested for its ability to predict risk of death from 
comorbid disease in a cohort of 685 patients who were treated for primary breast cancer at Yale 
New Haven between 1962 and 1969. Its performance was compared to the method of classifying 
comorbid disease developed by Kaplan and Feinstein.26 In later studies, it was validated for a 
proposed age-comorbidity index in a different cohort of patients who had essential hypertension 
or diabetes and who were undergoing elective general surgery for diagnoses such as peripheral 
vascular disease and aortic aneurysm.27 
Deyo et al. adapted Charlson comorbidity index, designed for use with clinical records, 
for research relying on International Classification of Diseases (ICD-9-CM) diagnosis and 
procedure codes to examine the association of the adapted index with health outcomes and 
resource utilization. Data of all Medicare claims for beneficiaries who underwent lumbar spine 
surgery in 1985 (n = 27,111) was used. This was based on Part A Medicare claims. The study 
findings concluded that the Charlson index can be valuable in studies of disease outcome and 
resource utilization when used with ICD-9-CM administrative databases.28 In further support, 
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other studies have also validated use of Charlson index with administrative databases. D’Hoore 
et al. adapted Charlson comorbidity index to ICD-9 codes to perform analysis on 1990-1991 
MED-ECHO database (Québec) with 36,012 patient admissions with ischemic heart disease and 
associated in-hospital death. The study concluded that the Charlson comorbidity index may be an 
efficient approach to risk adjustment from administrative databases.29  
Following validation of Charlson comorbidity index with administrative databases, the 
index has gained popular use in epidemiologic research. For example, the Deyo-adapted 
Charlson Comorbidity index has been used to quantify patients’ comorbidities and scores used in 
a propensity score method to estimate the incidence rates and hazard ratios of subtrochanteric 
and femoral fractures in elderly patients treated with oral biphosphonates compared with those 
treated with either raloxifene or calcitonin.30 Since this dissertation project uses Medicare claims 
data (administrative database), which was used to validate Charlson comorbidity index, then the 
rationale for using the index is strongly justified and therefore Charlson comorbidity index was 
adapted instead of the functional comorbidity index. Another reason is that obesity and/or body 
mass index is one of the 18 diagnoses scored in the functional comorbidity index. Medicare 
claims data does not provide information for these variables. 
 4.7.2 Propensity score matching 
The primary analysis used a greedy algorithm for 1:1 propensity score matching to 
control for confounding. Users of SSRIs were matched to potential users of SSRIs based on the 
estimated propensity scores. All potential confounders included in the propensity-score model 
are provided in Table 4. To assess achieving balance in baseline covariates between treatment 
groups, standardized difference was used.31 
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4.8 Statistical analysis 
 4.8.1 Descriptive analysis 
After the propensity score matching, subjects were then analyzed. Descriptive statistics 
comparing the baseline characteristics of the cases and the controls was performed. Continuous 
variables were expressed as mean ± SD, 95% CI and categorical data was reported as 
proportions. The characteristics of patients in each group were compared before and after the 
propensity score matching. Baseline characteristics included sociodemographic characteristics 
(age, race/ethnicity, and socioeconomic status), distinct prescription drugs (excluding SSRIs) and 
co-morbidities (including depression), and prior and current use of exposures of interest (Table 
4).  
4.8.2 Multivariable analysis 
Using bisphosphonate-alone users as our comparison group (controls), Cox proportional 
hazard models were constructed to assess the risk of osteoporotic-related fractures among 
bisphosphonates, SSRIs, and SNRIs users separately and among concomitant users of 
bisphosphonates with SSRIs or SNRIs. Hazard ratios (HRs) and 95% CI were estimated. Since 
we matched the groups on propensity scores containing potential confounders, the Cox 
regression models contained only a variable for exposure of interest, with bisphosphonate-alone 
users as the reference/comparison exposure.  
The software SAS 9.3 version (SAS Institute, Cary, NC) was used and the level of 
significance of α=0.05 was considered for all statistical tests.  
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Figure 4.2. Flow chart showing selection of subjects from the Medicare part D, under stand-
alone prescription drug plan eligible for analysis (Specific Aim 1): 2008-2010. 
 
 
 
 
 
 
 
1,518,401 subjects enrolled 
in Medicare Part D claims 
data, under stand-alone PDP 
plans: 2008-2010 
52,258 subjects with 
bisphosphonate prescription: 
2008-2010 
15,281 subjects with 
concomitant use of 
bisphosphonates and SSRIs: 
2008-2010 
3,646 subjects with 
concomitant use of 
bisphosphonates and SNRIs: 
2008-2010 
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Figure 4.3. Flow chart showing selection of subjects from the Medicare Part A, fee-for-service 
and Medicare part D, under stand-alone prescription drug plan (Specific Aim 2): 2008-2010. 
 
 
 
 
68,861 subjects in the 
inpatient file, fee-for-service 
claims data: 2009 
105,894 subjects in the 
inpatient file, fee-for-service 
claims data: 2008 
75,484 subjects in the 
inpatient file, fee-for-service 
claims data: 2010 
17,805 subjects with BPs 
prescription in the Medicare 
Part D claims, under stand-
alone PDP: 2008 
18,981 subjects with BPs 
prescription in the Medicare 
Part D claims, under stand-
alone PDP: 2009 
15,472 subjects with BPs 
prescription in the Medicare 
Part D claims, under stand-
alone PDP: 2010 
5,894 subjects 
(bisphosphonate users) 
eligible for analysis: 2008 
7,558 subjects 
(bisphosphonate users) 
eligible for analysis: 2009 
9,197 subjects 
(bisphosphonate users) 
eligible for analysis: 2010 
1:1 Greedy matched pairs 
(N=1,171): concomitant 
users of BPs and SSRIs 
matched to bisphosphonate 
alone users: 2008 
1:1 Greedy matched pairs 
(N=1,318): concomitant 
users of BPs and SSRIs 
matched to bisphosphonate 
alone users: 2009 
1:1 Greedy matched pairs 
(N=1,725): concomitant 
users of BPs and SSRIs 
matched to bisphosphonate 
alone users: 2010 
Combined matched pairs for 
final analysis: N=4,214 
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Chapter 5 
 
5.0 Specific Aim 1: Results and Discussion 
5.1 Descriptive statistics 
5.1.1 Overall summary 
Descriptive statistics for the study population across the 3 year period are shown in Table 
5.1 and Table 5.2. During the time period examined (2008-2010), there were 17,805 (3.5%) 
patients aged 65 years or older who were bisphosphonate users in 2008, 18,981 (3.8%) patients 
in 2009, and 15,472 (3.1%) in 2010. Of these bisphosphonate users 28.4% also used SSRIs in 
2008, 28.8% in 2009, and 30.7% in 2010 (Table 5.1), whereas 6.7% used SNRIs in 2008, 6.9% 
in 2009, and 7.5% in 2010 (Table 5.2).  
Table 5.1: Descriptive statistics of Medicare PDP concomitant users of BPs and SSRIs. 
Characteristic 2008 2009 2010 
Composite PDP Enrollees, n 510,861 504,574 502,966 
Bisphosphonate users, n (%) 17,805 (3.5) 18,981 (3.8) 15,472 (3.1) 
Concomitant users, n (%) 5061 (28.4) 5474 (28.8) 4746 (30.7) 
Age, n (%)    
     65-69 557 (11.0) 692 (12.6) 634 (13.4) 
     70-74 828 (16.4) 852 (15.6) 713 (15.0) 
     75-79 959 (18.9) 997 (18.2) 865 (18.2) 
     80-84 1109 (21.9) 1214 (22.2) 1012 (21.3) 
     85+ 1608 (31.8) 1719 (31.4) 1522 (32.1) 
Race, n (%)    
     White 4366 (86.2) 4730 (86.4) 4013 (84.6) 
     Black 165 (3.3) 181 (3.3) 175 (3.7) 
     Hispanic 389 (7.7) 429 (7.8) 409 (8.6) 
     Other 141 (2.8) 134 (2.5) 149 (3.1) 
Socioeconomic status, n (%)    
     Low 2443 (48.3) 2706 (49.4) 2462 (51.9) 
     High 2618 (51.7) 2768 (50.6) 2284 (48.1) 
Abbreviations: PDPs, Medicare stand-alone prescription drug plans 
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Table 5.2. Concomitant use of bisphophonates and SNRIs. 
Characteristic 2008 2009 2010 
Composite PDP Enrollees, n 510,861 504,574 502,966 
Bisphosphonate users, n (%) 17,805 (3.5) 18,981 (3.8) 15,472 (3.1) 
Concomitant users, n (%) 1191 (6.7) 1300 (6.9) 1155 (7.5) 
Age, n (%)    
     65-69 189 (15.8) 214 (16.5) 237 (20.5) 
     70-74 220 (18.5) 238 (18.3) 213 (18.4) 
     75-79 225 (18.9) 260 (20.0) 210 (18.2) 
     80-84 265 (22.3) 264 (20.3) 225 (19.5) 
     85+ 292 (24.5) 324 (24.9) 270 (23.4) 
Race, n (%)    
     White 1049 (88.1) 1125 (86.5) 1013 (87.7) 
     Black 33 (2.8) 34 (2.6) 34 (2.9) 
     Hispanic 73 (6.1) 100 (7.7) 82 (7.1) 
     Other 36 (3.0) 41 (3.2) 26 (2.3) 
Socioeconomic status, n (%)    
     Low 577 (48.5) 679 (52.2) 618 (53.5) 
     High 614 (51.5) 621 (47.8) 537 (46.5) 
 
It appears that concomitant use of bisphosphonates and SSRIs/SNRIs among Medicare 
beneficiaries increased from 2008 through 2010, but utilization was observed to be more 
prevalent among SSRI than SNRI users (Figure 5.1). Among those patients who were 
bisphosphonate users, the proportions of SSRI use in the year 2010 was 2.3% points higher than 
in the year 2008 (30.7% vs. 28.4%)  and  1.9% points higher than in the year 2009 (30.7% vs. 
28.8%). On the other hand, the proportions of SNRI use in the year 2010 was 0.8% points higher 
than in the year 2008 (7.5% vs. 6.7%) and 0.6% points higher than in the year 2009 (7.5% vs. 
6.9%). However, linear trends in the standardized rates (Table 5.3 and Table 5.4) were not 
statistically significant and thus no evidence for change in concomitant use of bisphosphonates 
and SSRIs (slope: +112.5, p-value: 0.2227) or SNRIs (slope: +38.8, p-value: 0.2082) from 2008 
to 2010. This may not be surprising since a 3-year period is relatively short. 
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Abbreviations: Antidep, antidepressant 
 
Figure 5.1. Overall concomitant use of bisphosphonates and SSRIs or SNRIs. 
 
 
Table 5.3: Concomitant use of bisphosphonates (BPs) and SSRIs rates. 
 BPs + SSRIs 
users 
All BPs users Rate/10,000 95% CI 
2008 5061 17,805 2842.5 2764.2-2920.8 
2009 5474 18,981 2883.9 2807.5-2960.3 
2010 4746 15,472 3067.5 2980.2-3154.8 
Rate=2706.3 + 112.5year; p-value=0.2227 
Table 5.4: Concomitant use of bisphosphonates and SNRIs rates. 
 BPs + SSRIs 
users 
All BPs users Rate/10,000 95% CI 
2008 1191 17,805 668.9 630.9-706.9 
2009 1300 18,981 684.9 647.7-722.1 
2010 1155 15,472 746.5 703.1-789.6 
Rate=622.5 + 38.8year; p-value=0.2082 
Summary of concomitant use by demographic subgroups showed variations in 
concomitant use across the 3 years by age, socioeconomic status (SES), race, and geographic 
location (by states). Notably, concomitant use showed an increasing trend with increasing age, 
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concomitant use increased among those of low SES but showed decreasing trend among those of 
higher SES over time, and overall concomitant use was highest among white women compared 
to other races. However, these differences were more pronounced for concomitant use of 
bisphosphonates and SSRIs than with SNRIs. Small proportions of concomitant use (especially 
with SNRIs) as well as usage by race which were highly skewed were not described further in 
detail. Therefore, following is a further description of concomitant use of bisphosphonates and 
SSRIs by selected demographic characteristics (age, SES, and geographic location). 
 
5.1.2 Concomitant use by age 
Overall, we observed a steady and increasing trend of concomitant use across the 5 age 
groups and across the 3 years (Figure 5.2). Older adults over 85 years or older were about 2.5 
times as likely to have used bisphosphonates and SSRIs as those who were 65-69 years old 
(31.8% vs. 11.0% in 2008, 31.4% vs. 12.6% in 2009, and 32.1% vs. 13.4% in 2010). Findings 
from the year to year trend within age groups showed that concomitant use increased from 2008 
to 2010 for the 65-69 age groups, but we observed unstructured pattern of concomitant use for 
other age groups across the 3 years.  
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Figure 5.2. Proportions of concomitant use by age. 
 
5.1.3 Concomitant use by socioeconomic status and age 
We observed that concomitant use varied by SES and also by age within the two groups 
of SES (Figure 5.3). For all ages, concomitant use was slightly higher among women of higher 
SES (50.2%) than those of lower SES (49.8%). In terms of trend, we observed increasing pattern 
of concomitant use across age groups for those of higher SES, but decreasing pattern for those of 
lower SES.  The proportions ranged between 56.6% (age group: 65-69) to 46.5% (age group: 
85+) among women of lower SES and between 43.4% (age group: 65-69) to 53.5% (age group: 
85+) among those women of higher SES. When we observed concomitant use by SES across the 
3 year period (Figure 5.4), we found that concomitant use among women of lower SES 
increased (from 48.3% in 2008 to 51.9% in 2010), whereas that of higher SES decreased (from 
51.7% in 2008 to 48.1% in 2010) over time.  
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Figure 5.3. Proportions of concomitant use by socioeconomic status and age. 
 
 
Figure 5.4. Proportions of concomitant use by SES and year of enrollment. 
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5.1.4 Utilization by state 
Overall, we observed that concomitant use of bisphosphonates and SSRIs varied by state 
(Figure 5.5). The frequency of use appears to be higher in the South and North East regions of 
the U.S. compared to Western regions of the U.S. 
 
Figure 5.5. Overall variation in concomitant use of bisphosphonates and SSRIs: 2008-2010. 
 
Figures 5.6-5.8 shows the proportion of concomitant and bisphosphonate alone users by 
state across the 3 year period. The plots are placed side by side for each year. Overall, we 
observed that the number of Medicare beneficiaries who were bisphosphonate users or were 
concomitant users varied by states and across the years. Quartile ranking in bisphosphonate use 
by state for most of the states did not follow a similar pattern as the ranking in concomitant use. 
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The concomitant use proportions ranged between 10.0%-36.0% in 2008, 14.9%-36.2% in 
2009, and 8.7%-49.9% in 2010. The bottom 3 states with the lowest proportion of concomitant 
users in 2008 were Washington, D.C. (10.0%), Puerto Rico (12.5%), and Hawaii (16.4%) and the 
top 3 states with the highest proportion of concomitant use were Washington (34.3%), Tennessee 
(34.5%), and Delaware (36.0%). In 2009, the bottom 3 states were Hawaii (14.9%), Alaska 
(17.4%), and Washington, D.C. (19.0%) and the top 3 states were West Virginia (34.4%), 
Missouri (34.9%), and Tennessee (36.2%). In 2010 the bottom 3 states were Puerto Rico (8.7%), 
New Mexico (20.6%), and Hawaii (20.6%) and the top 3 states were Tennessee (38.5%), Alaska 
(46.7%), and Idaho (49.0%). Overall, we noted that Hawaii had consistently lower concomitant 
users in the 3 years, whereas the state of Tennessee had higher and slightly increased over time. 
These data suggested that concomitant use is influenced by multiple factors that vary from state 
to state. 
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(a)    
(b)   
Figure 5.6. Quartiles of concomitant and bisphosphonate alone use by state in 2008. Figure 5.6a 
shows variation in concomitant use, whereas figure 5.6b shows variation of bisphosphonate use.  
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(a)    
(b)  
Figure 5.7. Quartiles of concomitant and bisphosphonate alone use by state in 2009. Figure 5.7a 
shows variation in concomitant use, whereas figure 5.7b shows variation of bisphosphonate use.  
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(a)    
(b)   
Figure 5.8. Quartiles of concomitant and bisphosphonate alone use by state in 2010. Figure 5.8a 
shows variation in concomitant use, whereas figure 5.8b shows variation of bisphosphonate use.  
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5.2 Discussion 
This study examined utilization patterns of concomitant use of bisphosphonates and 
SSRIs among older postmenopausal women from 2008 to 2010. Our findings confirm that 
concomitant use of bisphosphonates and SSRIs is prevalent. Since this study was limited to 
Medicare Part D data, indications for these concomitant medications can only be inferred. As 
indicated earlier bisphosphonates are the most widely FDA-approved pharmacologic agents for 
treatment of postmenopausal osteoporosis.1 On the other hand, SSRIs are the most popular 
medications in treating depression.2 Therefore our findings suggest that exposure to concomitant 
use is most likely due to the prevalent comorbid osteoporosis and depression among older 
postmenopausal women. There is a strong positive relationship between osteoporosis and 
depression, and both diseases are more prevalent among women than men.3 Although it is still 
unclear the association between these two chronic conditions,3 existing research shows that 
depression is associated with increased risk for both low bone mineral density and fractures.4 On 
the other hand, fractures which can be clinical consequences of osteoporosis can also cause 
psychological symptoms, most notably depression.5 
Given the high prevalence of osteoporosis and depression among older women, the use 
and pattern of concomitant use of bisphosphonates and SSRIs was not surprising. Our findings 
further showed that concomitant use varied with demographic characteristics, notably age, race, 
socioeconomic status, and geographic locations in the United States. Medicare beneficiaries 
under study were more likely to be concomitant users as they aged, if they were of Caucasian 
race or of higher socioeconomic status. It has been shown that relative to women aged 50-54, the 
odds of having osteoporosis is 5.9-fold higher in women aged 65-69 and 14.3-fold higher in 
women aged 75-79.6 On the other hand, although the prevalence of depression is lower among 
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older adults than younger people, aging people experience changes in their health and their 
lifestyles (considered risk factors) that make an older adult more vulnerable to becoming 
depressed. These risk factors for depression can include changes in physical health or 
fumctioning, mental health, or circumstances or social support.7 The increasing trend of 
osteoporosis with age and the susceptibility of depression with aging are therefore reflective of 
our findings that concomitant use increases with age. 
The higher proportions of concomitant use among the white women could be attributed to 
the high prevalence of osteoporosis and the propensity to receiving antidepressant treatment 
compared to minority groups. Osteoporosis is more frequent in white women than other races. In 
the U.S, the rates of osteoporosis and/or osteoporotic fractures are higher among white women 
compared to Asian or African American women.8 Similarly, white race has been found to be a 
strong predictor of antidepressant use over time. White patients with major depression were 
found to be more likely than African Americans to receive antidepressant medications.9 A 
previous study had also showed that persons from racial or ethnic minority groups were more 
likely than whites to report major depression and less likely to receive treatment.10  
The observed concomitant use that varied with socioeconomic status over time was 
probably influenced by the economic downturn beginning in 2008 and might have impacted 
cost-related non-adherence among those considered to be of higher SES.  This is consistent with 
a study by Piette et al. that found substantial increase in medication-cost problems was 
associated with the economic crisis in 2008 especially among chronically ill older adults. Those 
aged 65 or older reported delayed filling a prescription because of financial reasons despite the 
availability of Medicare Part D benefits.11 On the other hand, existing research suggests that 
socioeconomic status is associated with negative impact on the psychological health of aging 
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individuals. Those at the lower levels of socioeconomic status are often most likely to be 
afflicted with disorders such as depression.12 The financial crisis probably worsened the situation 
and thus increasing the incidence of depression. Therefore, our findings were consistent with the 
existing research that patients of low SES were more likely to be prescribed SSRIs for depressive 
symptoms beginning 2008 and thus having an overall influence on concomitant usage over time. 
Another explanation that could explain the reversed trend over time is that, the financial crisis 
beginning in 2008 qualified more beneficiaries to be considered of low SES over time shifting 
them from higher SES to lower SES. 
With regards to the findings for concomitant use by state, the usage pattern primarily 
indicates that the prevalence of use is a nationwide problem. For some states, however, the 
prevalence and pattern of use varied across the 3 years. In addition, ranking on quartiles showed 
that for most of the states the proportions of concomitant use did not parallel the proportions of 
bisphosphonate alone use suggesting that comorbid osteoporosis and depression varies by state. 
Because of the haphazard pattern of concomitant and bisphosphonates alone use, it is unclear 
what factors might have influenced the pattern that we observed. Using secondary analysis 
results, we did not observe a clear pattern with SES status of the patients across the states. 
Although it might be obvious that the care that Medicare beneficiaries receive will vary 
depending on where they live and their physicians and hospitals, more research is needed to 
investigate predictors of use across states. 
Overall, the steady rates (2842.5 per 10,000 populations in 2008, 2883.9/10,000 in 2009, 
and 3067.5/10,000 in 2010) and non-significant trend of concomitant use did not mirror the 
count of those females enrolled with Part D coverage provided under PDPs during the same 
period. Using the CMS reported statistics for the actual proportions of female beneficiaries who 
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were Part D enrolled for 100% of Medicare beneficiaries during the same period, the female 
counts dropped in 2009 and then increased sharply in 2010 compared to 2008. The proportions 
enrolled were 59.5% females in 2008, 59.1% in 2009, and 58.8% in 2010 (Table 5.5). 13 Their 
corresponding estimated counts were 11,192,051 females with Part D coverage under PDPs in 
2008, 11,172,347 females in 2009, and 11,304,283 females in 2010. This lack of parallel trend 
suggests that not only did the prevalence rates of concomitant use of bisphosphonates and SSRIs 
(a proxy of comorbid osteoporosis and depression prevalence) not change over time, but also 
was less impacted by changes in population of older postmenopausal women. 
Despite the non-significant trend of concomitant use across the 3 years, our findings 
suggest that large numbers of older postmenopausal women prescribed bisphosphonates are also 
on SSRIs. These findings were consistent with our preliminary study using MEPS data (see 
Chapter 3). Following extrapolation of our estimates to all Medicare beneficiaries with Part D 
coverage under PDPs, our findings suggest that there were 391,721 (3.5%) females who were 
bisphosphonate users in 2008, 424,549 (3.8%) females in 2009, and 350,432 (3.1%) females in 
2010. Of these bisphosphonate users, there were 111,248 (28.4%) females who were also on 
SSRIs in 2008, 122,270 (28.8%) females in 2009, and 107,582 (30.7%) in 2010. The positive 
side of this is that patients with potential comorbid osteoporosis and depression are receiving 
respective therapies for treatment. The National Institute of Mental Health (NIMH) recommends 
that treatment of depression (commonly using SSRIs or SNRIs) can help patients manage their 
osteoporosis and improve overall health.14 The NMIH also adds that while currently available 
common treatments for depression are generally well tolerated and safe, some medications, 
including some antidepressants (such as SSRIs or SNRIs), can increase a patient’s risk for 
osteoporosis.14 
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Table 5.5. CMS Chronic Condition Data Warehouse: Medicare Part D Beneficiary Counts for 
2008 through 2010. 
Beneficiary 
Demographics 
2008 2009 2010 
Part D Enrolled    
   Total 27,529,528 28,722,645 29,740,680 
Part D Plan Type    
   PDP 18,810,171 18,904,141 19,224,972 
Gender    
Female, n (%) 16,377,483 (59.5) 16,976,321 (59.1) 17,493,688 (58.8) 
Age    
     65-74 10,966,227 11,591,840 12,069,321 
     75-84 7,674,907 7,855,991 7,995,935 
     85+ 3,575,116 3,704,040 3,813,281 
 
Selective serotonin reuptake inhibitors or SNRIs have been documented to be associated 
with increasing a patient’s risk for osteoporosis. Two meta-analysis studies have summarized 
these findings. Wu et al. results showed that overall, SSRIs use was associated with a 
significantly increased risk of fracture (RR=1.72;95% CI, 1.51-1.95).15 Eom et al. in a meta-
analysis based on 12-observational studies showed that the overall risk of fracture was higher 
among people using SSRIs (adjusted OR=1.69, 95% CI 1.51-1.90).16 This evidence is troubling 
especially considering that the patients in reference are those already on bisphosphonates or will 
be prescribed bisphosphonates at some point in their lifetime. This situation presents a prime 
example of potentially risky bisphosphonate-drug combinations with potential interaction 
resulting in increased risk of fracture. 
Although there is a paucity of documented reports on these particular interactions, 
research has suggested that medications associated with increased risk of fracture might attenuate 
the beneficial effects of bisphosphonates when used concomitantly. Concerns about this 
phenomenon has focused on medications such as proton pump inhibitors17,18, glucocorticoids19,20, 
and levothyroxine21, but the interaction of bisphosphonates and SSRIs or SNRIs has not been 
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investigated yet. The common aspect about proton pump inhibitors, glucocorticoids, 
levothyroxine, and SSRIs is that all of these medications are associated with increased risk of 
fracture.1 So, SSRIs or SNRIs also have the potential of demonstrating similar attenuating 
effects, but this phenomenon in currently unknown. Animal studies have shown that increased 
levels of nuclear factor kappa ligand (RANKL) due to high blood levels of serotonin 
significantly attenuated (or antagonized) the ability of clodronate and alendronate to induce 
osteoclast apoptosis and inhibit bone resorption.22 In normal bone remodeling in healthy 
physiologic systems, bone stromal cells, including cells of the osteoblast lineage, provide a 
limited amount of RANKL, which leads to osteoclast differentiation, survival, and activation and 
subsequent bone resorption. Resorption is balanced by osteoblast-dependent new bone 
formation.23 Clearly we can see that there is need for randomized clinical trials or observational 
studies to investigate further the interaction between bisphosphonates and SSRIs. The evidence 
following this research will be important to the clinicians and the older adult patients with 
comorbid osteoporosis and depression to aid in developing optimal care strategies. When 
presented with patients with osteoporosis and other comorbidies (such as depression), the 
clinician should consider the common disease-disease and drug-disease interactions, and screen 
for or treat these as appropriate to the patient’s goals and preferences.24 
Similarly, The American Geriatrics Society expert panel has documented an approach by 
which clinicians can care optimally for older adults with multimorbidity (multiple chronic 
conditions). In this document the society acknowledges that clinicians need a better management 
approach to clinical decision- making. One example of such an approach would require an 
assessment of patient preferences for all clinical decisions. The first step in the process of 
eliciting patient preference is to recognize when the older adult with multimorbidity is facing a 
 
 
153 
 
“preference sensitive” decision. In this step the clinician tries to understand what is most 
important to the patient to determine the best option.25 An example would be medications that 
may improve one condition but make coexisting condition worse for example inhaled 
corticosteroids to treat chronic obstructive pulmonary disease may worsen osteoporosis.26 
Clearly, the tradeoff between managing depressive symptoms and worsening osteoporosis varies 
from patient to patient. Given supportive evidence from research about whether SSRIs may 
worsen osteoporosis when given concomitantly with bisphosphonates, clinicians will have new 
information that will aid optimal care for these patients. More emphasis for optimal care will be 
among postmenopausal women as they advance in age, those who are of white race, and/or of 
low socioeconomic status.  
 
5.2.1 Strengths and limitations of the study 
   5.2.1.1 Strengths 
 The strengths of our study are that to the best of our knowledge, this study is the first to 
describe concomitant use of bisphosphonates and SSRIs or SNRIs among older postmenopausal 
women. Also this study used Medicare Part D data, which is a large national database with 
prescription drug data primarily for older adults 65 years or older. Therefore this dataset was 
suitable to describe national estimates of medications use for older postmenopausal women 65 
years or older and are more generalizable.  
   5.2.1.2 Limitations  
The use of Medicare Part D data, like other administrative databases is faced with 
methodological challenges such as verifying data validity. A central limitation with many 
implications is that such databases are collected for administrative rather than research purposes. 
These limitations are an important source of bias. For example the complexity of preparing 
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claims data (prescribing, dispensing, and the third party payer adjudication and entering into the 
computer system for billing purposes) can result in misclassification bias. Misclassification of 
bisphosphonate or SSRIs or SNRIs could bias estimates of proportions of concomitant use in this 
study.  
Another bias introduced into the Medicare Part D data that is a limitation to our findings 
is the bias of limited generalizability and information bias. This bias is a limitation because of 
the assumption that the dataset is accurate and also that the data includes every encounter with 
health professionals. Generalizability or external validity is defined as the validity of the 
inferences as they pertain to people outside the source population.27 In this study the referred 
people outside the source population are those women aged ≥ 65 years old but are not Medicare 
part D beneficiaries. By using Medicare Part D data, we have made the assumption that the 
database captures every encounter of women aged ≥ 65 years. Although Medicare Part D offers 
prescription coverage to all those eligible for Medicare, not all beneficiaries are enrolled in a part 
D plan. Of those who were Medicare eligible between 2008 and 2010, 57.5% were enrolled in a 
part D plan in 2008, 58.7% in 2009, and 59.4% in 2010.  The rest were not covered by part D 
and with no credible coverage or with other credible coverage, or were enrolled in retirement 
drug subsidy.13 Credible coverage sources are required to have approval from Medicare as being 
equivalent or better than part D plans. Examples include the U.S. Department of Veterans 
Affairs, the military health plan (TRICARE), the Federal Employees’ Health Benefits (FEHB) or 
are active workers under employer sponsored programs.  
Furthermore, our findings may not be generalizable to all women ≥ 65 years old 
including the more affluent and employed and also those who might be healthier. The healthier 
lifestyle could be promoted by insurance under the wellness programs- a feature of the consumer 
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driven healthcare which is typical for the employed.28 Finally, exclusion of men in our study can 
also be considered a limitation of generazability to the entire older adult population. Although 
comorbid osteoporosis and depression is more prevalent among women than men,3 the safety of 
concomitant use of bisphosphonates and SSRIs or SNRIs is as important to men as it is to 
women. 
 
5.3 Conclusions 
In summary, this study determined that concomitant use of bisphosphonates and SSRIs is 
prevalent and varies with demographic characteristics and geographic location in the U.S. 
Concomitant use seems to increase with aging, among the white race and those who are of low 
socioeconomic status. The prevalence and variation of concomitant use is troubling because of 
the potential interaction between SSRIs and bisphosphonates with potential antifracture efficacy 
of bisphosphonates. With this growing concern, understanding the number of patients exposed to 
the concurrent medication use will be used to initiate further studies to assess the potential 
consequence of the problem, if any. Given that the population of older adults is high and is 
projected to increase in the future, the prevalence of use is expected to grow exponentially and 
the associated economic impact of antifracture efficacy of bisphosphonates on the U.S. 
healthcare system will be enormous. Potential antifracture efficacy will result in worsened 
osteoporosis and greater risk of fractures suggesting more hospitalizations for expensive bone 
related procedures, and wasted resources on prescriptions that are suboptimal. This underscores 
the need for research to investigate the effect of SSRIs on the beneficial effects of 
bisphosphonates which may be useful for physicians to integrate in clinical decision-making for 
optimal care of older postmenopausal women with multimorbidity.  
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Chapter 6 
 
 
6.0 Specific Aim 2: Results and Discussion 
 
6.1 Bisphosphonates and fracture reduction 
6.1.1 Matching process and patient characteristics 
 
A total of 178,167 postmenopausal female Medicare beneficiaries between 2008 and 
2010 were eligible for analysis after application of the inclusion and exclusion criteria. Of these 
Medicare beneficiaries, 18,074 were bisphosphonate (BP) users. Figure 6.1a shows the 
distributions of propensity scores for the 160,093 BP non-users and the 18,074 BP users before 
matching. We can see that the distribution before matching shows a good discrimination between 
the two groups of patients. The distributions of propensity scores between the two groups after 
1:1 matching are shown in Figure 6.1b. The distributions of the propensity scores for the 
matched groups were similar suggesting that treated subjects (BP users) are similar to the control 
subjects (BP non-users) with respect to background variables (or covariates) measured on all 
subjects, as would be expected in a randomized experiment. Thus, two matched subjects (one in 
treated and one in control group), with the same propensity score, are imagined to be ‘randomly’ 
assigned to each group in the sense of being equally likely to be treated or control.1 Previous 
research has demonstrated that matching on propensity score can result in a greater reduction in 
treatment selection bias than stratification on propensity score.2 
Table 6.1 shows the baseline characteristics of the two groups after matching and the 
standardized differences (<0.1) between them. The average age of those who were BP users was 
80.6 ± 7.7 (SD) years and that of BP non-users was 80.8 ± 8.4 (SD) years. For both treatment 
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groups, there were more white women than other minority races and also within the age groups, 
the proportions of older adults 85 years or older was the highest compared to other age groups. 
The proportions of both BP users and non-users were higher for women of higher socioeconomic 
status and lower for those of lower socioeconomic status. 
(6.1a)  
(6.1b)  
Figure 6.1. Distribution of propensity scores: (6.1a) shows the distribution for 178,167 
patients before matching and (6.1b) shows the distribution for 17,953 patients after matching. 
The curved lines are normal distribution curves. 
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Table 6.1. Baseline patient characteristics of propensity score matched cohort. 
Characteristic Bisphosphonate 
users (N=17,953) 
Bisphosphonate non- 
users (N=17,953) 
Standardized 
differences 
Demographic    
Age , mean ± SD 80.6 (7.7) 80.8 (8.4) 0.021 
     65-69 1706 (9.5) 2079 (11.6)  
     70-74 2638 (14.7) 2548 (14.2)  
     75-79 3476 (19.4) 3228 (18.0)  
     80-84 4193 (23.4) 3779 (21.1)  
     85+ 5940 (33.1) 6319 (35.2)  
Race, n (%)     
     White 14928 (83.2) 15187 (84.6)  
     Black 905 (5.0) 809 (4.5)  
     Hispanic 1170 (6.5) 1114 (6.2)  
     Other 950 (5.3) 843 (4.7)  
Socioeconomic status, n (%)    
     Low income 6794 (37.8) 6605 (36.8)  
     Higher income 11159 (62.2) 11348 (63.2)  
 Health care utilization factors, mean 
(SD) 
   
Comorbidity score  2.2 (2.0) 2.2 (2.0) 0.001 
Number of unique prescribed medications 12.2 (6.7) 12.3 (7.5) 0.002 
Medical conditions, n (%)    
     Osteoporosis 10494 (58.5) 10453 (58.2) 0.005 
     Rheumatoid arthritis/ Osteoarthritis 10206 (56.9) 10279 (57.3) 0.008 
     Depression 3095 (17.2) 3059 (17.0) 0.005 
     Hyperparathyroidism 4838 (27.0) 4775 (26.6) 0.008 
     Kidney disease 4680 (26.1) 4661 (26.0) 0.002 
     Diabetes mellitus 5499 (30.6) 5366 (29.9) 0.016 
     Chronic obstructive pulmonary disease 4651 (25.9) 4693 (26.1) 0.005 
     Congestive heart failure 6435 (35.8) 6493 (36.2) 0.007 
     Hypertension 15701 (87.5) 15645 (87.1) 0.009 
     Anxiety  474 (2.6) 467 (2.6) 0.002 
     Parkinson’s disease 260 (1.5) 233 (1.3) 0.013 
     Alzheimer’s disease  1994 (11.1) 1883 (10.5) 0.02 
     Epilepsy 260 (1.5) 252 (1.4) 0.004 
     Orthostatic hypotension 726 (4.0) 737 (4.1) 0.003 
Medications, n (%)    
     Oral glucocorticoid use 4217 (23.5) 4257 (23.7) 0.005 
     Proton pump inhibitor use 6124 (34.1) 6161 (34.3) 0.004 
     Aromatase inhibitors 413 (2.3) 408 (2.3) 0.002 
     Thiazolidinediones use 674 (3.8) 692 (3.9) 0.005 
     Hormone replacement therapy 1284 (7.2) 1292 (7.2) 0.002 
     Antihypertensive use 11306 (63.0) 11415 (63.6) 0.013 
     Anticonvulsant use 2795 (15.6) 2831 (15.8) 0.006 
     Thyroid medication use 4862 (27.1) 4864 (27.1) 0.0 
     Warfarin use 2531 (14.1) 2514 (14.0) 0.003 
     Loop diuretic use 4781 (26.6) 4846 (27.0) 0.008 
     Opioid use 7382 (41.1) 7535 (42.0) 0.017 
     Antipsychotics use 824 (4.6) 814 (4.5) 0.003 
     Lithium 41 (0.2) 37 (0.2) 0.005 
     Methotrexate 467 (2.6) 429 (2.4) 0.014 
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6.1.2 Bisphosphonates use and risk of fracture: Minor findings 
Table 6.2. Cox proportional hazard model for risk of fractures among BP users and non-users. 
 Non-Bisphosphonate users Bisphosphonate users 
Total number of patients 17,953 17,953 
Any fracture   
   Total events 1031 922 
   Hazard Ratio (95% CI) 1.00 (Reference) 0.89 (0.81, 0.97) 
Hip/Pelvis/Femur fracture   
   Total events 678 592 
   Hazard Ratio (95% CI) 1.00 (Reference) 0.87 (0.77, 0.97) 
Vertebral fracture   
   Total events 164 153 
   Hazard Ratio (95% CI) 1.00 (Reference) 0.93 (0.75, 1.16) 
 Humerus   
   Total events 80 75 
   Hazard Ratio (95% CI) 1.00 (Reference) - 
Radius/Ulna   
   Total events 39 41 
   Hazard Ratio (95% CI) 1.00 (Reference) - 
Tibia/Fibula   
   Total events 70 61 
   Hazard Ratio (95% CI) 1.00 (Reference) - 
 
Table 6.2 presents results from the Cox proportional hazards model. Among the 
propensity score matched patients, 922 bisphosphonate users experienced at least one first 
fracture of the hip, vertebral, humerus, radius/ulna, or tibia/fibula, whereas 1,031 BP non-users 
experienced at least one first fracture during the 3 year period (2008 – 2010).  Of these patients, 
592 BP users and 678 BP non-users experienced a hip fracture.  
With regards to the hazard ratios, we observed that BP use was associated with 
statistically significant reduction of any fracture (HR=0.89, 95% CI, 0.81-0.97) and hip fracture 
(HR=0.87, 95% CI, 0.77-0.97), and statistically non-significant reduction for vertebral fracture 
(HR=0.93, 95% CI, 0.75-1.16). There were no results obtained for the humerus, radius/ulna, or 
tibia/fibula fractures because of very small sample size.  
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6.2 SSRIs and increased risk of fracture 
6.2.1 Matching process and patient characteristics 
 
A total of 206,883 postmenopausal female Medicare beneficiaries between 2008 and 
2010 were eligible for analysis after application of the inclusion and exclusion criteria. Of these 
Medicare beneficiaries, 46,777 were SSRI users. Figure 6.2a shows the distributions of 
propensity scores for the 160,106 SSRI non-users and the 46,777 SSRI users before matching. 
We can see that the distribution before matching shows a good discrimination between the two 
groups of patients. The mean age was 79.0 ± 8.4 (SD) years for SSRI users and 79.3 ± 8.5 (SD) 
years for SSRI non-users. The distributions of propensity scores between the two groups after 
1:1 matching are shown in Figure 6.2b. The mean age was 79.1 ± 8.5 (SD) years for SSRI users 
and 79.1 ± 8.4 (SD) years for SSRI non-users. Table 6.3 shows the baseline characteristics of the 
two groups after matching and the standardized differences between them. All the standardized 
differences were < 0.10 suggesting a balance between the two groups on observed covariates. 
 
(6.2a)  
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(6.2b)  
Figure 6.2. Distribution of propensity scores: (6.2a) shows the distribution for 206,883 patients 
before matching and (6.2b) shows the distribution for 39,660 patients after matching.  
 
6.2.2 SSRI use and increased risk of fracture: Minor findings 
Our findings showed that SSRI use was associated with statistically significant increased risk for 
any fracture (HR=1.17, 95% CI, 1.09-1.26), hip fracture (HR=1.16, 95% CI, 1.06-1.26), and for 
Tibia/fibula fracture (HR=1.33, 95% CI, 1.05-1.68). We also observed increased risk for 
vertebral fracture (HR=1.10, 95% CI, 0.89-1.36), but statistical significance was not achieved. 
(see Table 6.4) 
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Table 6.3. Baseline patient characteristics of propensity score matched cohort.  
Characteristic SSRI users 
(N=39,660) 
SSRI Non-users 
(N=39,660) 
Standardized 
differences 
Demographic    
Age , mean ± SD 79.1 (8.5) 79.1 (8.4) 0.002 
     65-69 6609 (16.7) 6392 (16.1)  
     70-74 6677 (16.8) 6708 (16.9)  
     75-79 7148 (18.0) 7354 (18.5)  
     80-84 7651 (19.3) 7756 (19.6)  
     85+ 11575 (29.2) 11450 (28.9)  
Race, n (%)     
     White 33859 (85.4) 34067 (85.9)  
     Black 2838 (7.2) 2784 (7.0)  
     Hispanic 2286 (5.8) 2204 (5.6)  
     Other 677 (1.7) 605 (1.5)  
Socioeconomic status, n (%)    
     Low income 19691 (49.6) 19550 (49.3)  
     Higher income 19969 (51.4) 20110 (50.7)  
 Health care utilization factors, 
mean(SD) 
   
Comorbidity score  2.6 (2.1) 2.6 (2.1) 0.001 
Number of unique prescribed medications 13.4 (6.8) 13.3 (7.6) 0.023 
Medical conditions, n (%)    
     Osteoporosis 6286 (15.9) 6219 (15.7) 0.005 
     Rheumatoid arthritis/ Osteoarthritis 21660 (54.6) 21626 (54.3) 0.002 
     Depression 23483 (59.2) 23660 (59.7) 0.009 
     Hyperparathyroidism 10711 (27.0) 10760 (27.1) 0.003 
     Kidney disease 12456 (31.4) 12481 (31.5) 0.001 
     Diabetes mellitus 16621 (41.9) 16671 (42.0) 0.003 
     Chronic obstructive pulmonary disease 12770 (32.2) 12898 (32.5) 0.007 
     Congestive heart failure 17418 (43.9) 17406 (43.9) 0.001 
     Hypertension 35614 (89.8) 35668 (89.9) 0.005 
     Anxiety  2114 (5.3) 2239 (5.7) 0.014 
     Parkinson’s disease 780 (2.0) 738 (1.9) 0.008 
     Alzheimer’s disease  7829 (19.4) 7736 (19.5) 0.006 
     Epilepsy 651 (1.6) 642 (1.6) 0.002 
     Orthostatic hypotension 1542 (3.9) 1539 (3.9) 0.0 
Medications, n (%)    
     Oral glucocorticoid use 9118 (22.9) 9093 (22.9) 0.001 
     Proton pump inhibitor use 16800 (42.4) 16849 (42.5) 0.002 
     Aromatase inhibitors 538 (1.4) 537 (1.4) 0.0 
     Thiazolidinediones use 1866 (4.7) 1856 (4.7) 0.001 
     Hormone replacement therapy 2878 (7.2) 2957 (7.5) 0.008 
     Antihypertensive use 25204 (63.6) 25470 (64.2) 0.014 
     Anticonvulsant use 8138 (20.5) 8301 (20.9) 0.01 
     Thyroid medication use 11247 (28.4) 11304 (28.5) 0.003 
     Warfarin use 5691 (14.4) 5736 (14.5) 0.003 
     Loop diuretic use 13455 (33.9) 13437 (33.9) 0.001 
     Opioid use 18991 (47.9) 19120 (48.2) 0.007 
     Antipsychotic use 4942 (12.4) 4643 (11.7) 0.023 
     Lithium 155 (0.4) 177 (0.5) 0.009 
     Methotrexate 432 (1.1) 443 (1.1) 0.003 
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Table 6.4. Cox proportional hazard model for risk of fractures among SSRI users and non-users. 
 SSRI non-users SSRI users 
Total number of patients 39,660 39,660 
Any Fracture   
   Total events 1,443 1,675 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.17 (1.09, 1.26) 
Hip/Pelvis/Femur fracture   
   Total events 994 1,141 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.16 (1.06, 1.26) 
Vertebral fracture   
   Total events 163 179 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.10 (0.89, 1.36) 
 Humerus   
   Total events 116 143 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.23 (0.97, 1.58) 
Radius/Ulna   
   Total events 51 54 
   Hazard Ratio (95% CI) 1.00 (Reference) - 
Tibia/Fibula   
   Total events 119 158 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.33 (1.05, 1.68) 
 
 
6.3 Concomitant use of bisphosphonates and SSRIs and increased risk of fracture 
6.3.1 Matching process and patient characteristics 
A total of 22,702 postmenopausal female Medicare beneficiaries who were BP users 
between 2008 and 2010 were identified after application of the inclusion and exclusion criteria. 
Alendronate (overall: 61.9%), 70 mg (58.2%) was the most frequently prescribed BP followed 
by risedronate (overall: 24.4%), 35 mg (20.6%) and ibandronate 150 mg (13.7%). Of these BP 
users, 4,662 were also on SSRIs and 18,040 were BP alone users. Table 6.5 shows baseline 
characteristics of all BP users who were eligible for analysis.  The average age of those who 
were concomitant users of BPs and SSRIs was 80.2 ± 8.0 (SD) years and that of BP alone users 
was 80.6 ± 7.7 (SD) years. For both treatment groups, there were more white women than other 
minority races and also within the age groups, the proportions of older adults 85 years or older 
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was the highest compared to other age groups. Concomitant users were equally distributed 
among women of lower and higher socioeconomic status, but BP alone users of higher 
socioeconomic status (62.0%) were almost twice that of low socioeconomic status (38.0%). 
Figure 6.3a shows the distributions of propensity scores for the 18,040 BP alone users 
and the 4,662 concomitant users of BPs and SSRIs before matching. We can see that the 
distribution before matching shows a good discrimination between the two groups of patients. 
The distributions of propensity scores between the two groups after 1:1 matching are shown in 
Figure 6.3b. The distributions of the propensity scores for the matched groups were similar 
suggesting that treated subjects (concomitant users) are similar to the control subjects 
(concomitant non-users) with respect to background variables measured on all subjects, just like 
in a randomized experiment.  
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Table 6.5. Baseline patient characteristics of all bisphosphonate users eligible for analysis. 
Characteristic Concomitant users 
(n=4,662) 
Non concomitant 
users (n=18,040) 
Demographic   
Age , mean ± SD 80.2 (8.0) 80.6 (7.7) 
     65-69 552 (11.8) 1718 (9.5) 
     70-74 705 (15.1) 2657 (14.7) 
     75-79 847 (18.2) 3493 (19.4) 
     80-84 1040 (22.3) 4218 (23.4) 
     85+ 1518 (32.6) 5954 (33.0) 
Race, n (%)    
     White 4,041 (86.7) 14,953 (82.9) 
     Black 139 (3.0) 906 (5.0) 
     Hispanic 366 (7.9) 1179 (6.5) 
     Other 116 (2.5) 1002 (5.6) 
Socioeconomic status, n (%)   
     Low income 2350 (50.4) 6860 (38.0) 
     Higher income 2312 (49.6) 11,180 (62.0) 
 Health care utilization factors, mean (SD)   
     Comorbidity score  2.4 (2.0) 2.2 (2.0) 
     Number of unique prescribed medications 16.0 (7.6) 12.3 (6.8) 
Medical conditions, n (%)   
     Osteoporosis 2727 (58.5) 10588 (58.7) 
     Rheumatoid arthritis/ Osteoarthritis 2854 (61.2) 10271 (57.0) 
     Depression 3214 (68.9) 3111 (17.3) 
     Hyperparathyroidism 1365 (29.3) 4872 (27.0) 
     Kidney disease 1394 (29.9) 4716 (26.1) 
     Diabetes mellitus 1564 (33.6) 5540 (30.7) 
     Chronic obstructive pulmonary disease 1603 (34.4) 4686 (26.0) 
     Congestive heart failure 1965 (42.2) 6473 (35.9) 
     Hypertension 4123 (88.4) 15783 (87.5) 
     Anxiety  242 (5.2) 475 (2.6) 
     Parkinson’s disease 134 (2.9) 266 (1.5) 
     Alzheimer’s disease  1096 (23.5) 2000 (11.1) 
     Epilepsy 103 (2.2) 265 (1.5) 
     Orthostatic hypotension 196 (4.2) 729 (4.1) 
Medications, n (%)   
     Oral glucocorticoid use 1296 (27.8) 4265 (23.6) 
     Proton pump inhibitor use 2236 (48.0) 6186 (34.3) 
     Aromatase inhibitors 101 (2.2) 421 (2.3) 
     Thiazolidinediones use 208 (4.5) 678 (3.8) 
     Hormone replacement therapy 362 (7.8) 1291 (7.2) 
     Antihypertensive use 2869 (61.5) 11,385 (63.1) 
     Anticonvulsant use 1051 (22.5) 2831 (15.7) 
     Thyroid medication use 1405 (30.1) 4897 (27.2) 
     Warfarin use 633 (13.6) 2537 (14.1) 
     Loop diuretic use 1529 (32.8) 4806 (26.6) 
     Opioid use 2326 (49.9) 7413 (41.1) 
     Antipsychotics use 671 (14.4) 827 (4.6) 
     Lithium 27 (0.6) 41 (0.2) 
     Methotrexate 125 (2.7) 488 (2.7) 
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(6.3a)  
(6.3b)  
Figure 6.3. Distribution of propensity scores: (6.3a) shows the distribution for 22,702 patients 
before matching and (6.3b) shows the distribution for 4,214 patients after matching.  
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Table 6.6. Baseline patient characteristics of propensity score matched cohort. 
Characteristic Concomitant users 
(N=4,214) 
Non concomitant 
users (N=4,214) 
Standardized 
differences 
Demographic    
Age , mean ± SD 80.2 (8.0) 80.4 (7.9) 0.025 
     65-69 500 (11.9) 476 (11.3)  
     70-74 628 (14.9) 594 (14.1)  
     75-79 765 (18.2) 774 (18.4)  
     80-84 926 (22.0) 958 (22.7)  
     85+ 1395 (33.1) 1412 (33.5)  
Race, n (%)     
     White 3653 (86.7) 3620 (85.9)  
     Black 133 (3.2) 151 (3.6)  
     Hispanic 313 (7.5) 322 (7.6)  
     Other 115 (2.7) 121 (2.9)  
Socioeconomic status, n (%)    
     Low income 2043 (48.5) 2083 (49.4)  
     Higher income 2171 (51.5) 2131 (50.6)  
 Health care utilization factors, 
mean(SD) 
   
Comorbidity score  2.4 (2.0) 2.4 (2.0) 0.01 
Number of unique prescribed medications 15.5 (7.2) 15.5 (7.9) 0.005 
Medical conditions, n (%)    
     Osteoporosis 2476 (58.8) 2420 (57.4) 0.027 
     Rheumatoid arthritis/ Osteoarthritis 2574 (61.1) 2592 (61.5) 0.009 
     Depression 2767 (65.7) 2767 (65.7) 0.0 
     Hyperparathyroidism 1224 (29.1) 1238 (29.4) 0.007 
     Kidney disease 1245 (29.5) 1245 (29.5) 0.0 
     Diabetes mellitus 1405 (33.3) 1395 (33.1) 0.005 
     Chronic obstructive pulmonary disease 1397 (33.2) 1398 (33.2) 0.001 
     Congestive heart failure 1725 (40.9) 1781 (42.3) 0.027 
     Hypertension 3725 (88.4) 3743 (88.8) 0.013 
     Anxiety  208 (4.9) 213 (5.1) 0.005 
     Parkinson’s disease 113 (2.7) 109 (2.6) 0.006 
     Alzheimer’s disease  920 (21.8) 912 (21.6) 0.005 
     Epilepsy 84 (2.0) 88 (2.1) 0.007 
     Orthostatic hypotension 170 (4.0) 173 (4.1) 0.004 
Medications, n (%)    
     Oral glucocorticoid use 1153 (27.4) 1168 (27.7) 0.008 
     Proton pump inhibitor use 1934 (45.9) 1976 (46.9) 0.02 
     Aromatase inhibitors 96 (2.3) 90 (2.1) 0.01 
     Thiazolidinediones use 172 (4.1) 182 (4.3) 0.012 
     Hormone replacement therapy 316 (7.5) 331 (7.9) 0.013 
     Antihypertensive use 2593 (61.5) 2623 (62.1) 0.015 
     Anticonvulsant use 927 (22.0) 953 (22.6) 0.015 
     Thyroid medication use 1254 (29.8) 1243 (29.5) 0.006 
     Warfarin use 589 (14.0) 589 (14.0) 0.0 
     Loop diuretic use 1349 (32.0) 1392 (33.0) 0.022 
     Opioid use 2046 (48.6) 2101 (49.9) 0.026 
     Antipsychotics use 553 (13.1) 520 (12.3) 0.023 
     Lithium 21 (0.5) 28 (0.7) 0.022 
     Methotrexate 109 (2.6) 114 (2.7) 0.007 
 
 
171 
 
Table 6.6 shows the baseline characteristics of the two groups after matching and the 
standardized differences (difference in means of continuous variables or proportions of binary 
variables divided by standard error) between them. The standardized difference effect size can be 
treated as equivalent to a Z-score of a standard normal distribution which can suggest non-
overlap in distributions between two study groups (treatment and control groups).3 Standardized 
difference of ≥ 0.10 are commonly used to indicate important imbalance between treatment 
groups.4 Overall, good balance was achieved on observed variables that entered the propensity 
score, with the largest standard difference being equal to 0.027 which is well below the 
suggested threshold (< 0.10). 
 
6.3.2 Concomitant use and risk of fractures: Major findings 
Among the patients who were eligible for analysis before matching, there were a total of 
1,213 patients with the fracture outcome of interest. Specific fractures were hip/pelvis/femur 
(762), vertebral (194), humerus (92), radius/ulna or wrist (50), and tibia/fibula fracture (85). 
Table 6.7 presents results from the Cox proportional hazards model. Among the propensity score 
matched patients, 256 concomitant users and 201 BP alone users experienced at least one first 
fracture of the hip, vertebral, humerus, radius/ulna, or tibia/fibula during the 3 year period (2008 
– 2010).  Of these patients, 161 concomitant users and 140 BP alone users experienced a hip 
fracture. Overall, concomitant users of BPs and SSRIs had slightly higher number of fracture 
outcomes for individual fracture subtypes of the hip, vertebral, humerus, radius/ulna, and 
tibia/fibula. 
With regards to the hazard ratios, we observed that concomitant use was associated with 
statistically significant increased risk for any fracture (HR=1.29, 95% CI, 1.07-1.57), but not 
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with statistically significant increased risk for hip fracture (HR=1.16, 95% CI, 0.92-1.47) and 
vertebral fracture (HR=1.55, 95% CI, 0.97-2.48). No results were obtained for the humerus, 
radius/ulna, or tibia/fibula fractures because of very small sample size. The estimated results 
were graphically presented using a forest plot shown in Figure 6.4. The plot also includes 
treatment effects of BPs and risk reduction of any, hip, and vertebral fractures, SSRIs and 
increased risk of fracture. These treatment effects serve as references and were obtained from 
pooled results of meta-analysis studies5-7 as well as BP use and fracture reduction results and 
SSRI use and increased risk of fracture from this study. 
 
Table 6.7. Cox proportional hazard model for risk of fractures among concomitant users of BPs 
and SSRIs. 
 Non concomitant users Concomitant users 
Total number of patients 4,214 4,214 
Any Fracture   
   Total events 201 256 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.29 (1.07, 1.57) 
Hip/Pelvis/Femur fracture   
   Total events 140 161 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.16 (0.92, 1.47) 
Vertebral fracture   
   Total events 29 45 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.55 (0.97, 2.48) 
 Humerus   
   Total events 15 17 
   Hazard Ratio (95% CI) 1.00 (Reference) - 
Radius/Ulna   
   Total events 7 11 
   Hazard Ratio (95% CI) 1.00 (Reference) - 
Tibia/Fibula   
   Total events 10 22 
   Hazard Ratio (95% CI) 1.00 (Reference) - 
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Abbreviations: RR, Relative risk; HR, Hazard ratio; SSRI&Fract, SSRI use and increased risk of fracture 
(reference)5; SSRIAnyFs, SSRI use and increased risk of any fracture (this study); AnyFractc, Any fracture (this 
study); SSRI&HIPs, SSRI use and increased risk of hip fracture (this study);  HipFractc, concomitant use of BPs and 
SSRIs and risk of hip fracture (this study);  VrtFractc, concomitant use of BPs and SSRIs and risk of vertebral 
fracture (this study);  BISPH&AF, BPs use and the reduction of any fracture (this study); Bisp&Hip, BPs use and 
the reduction of hip fracture (this study); BISPH&Hip, BPs use and the risk reduction of hip fracture (reference)6;  
ALN&vertF, Alendronate and the risk reduction of vertebral fracture (reference);  RSN&vertF, Risedronate and the 
risk reduction of vertebral fracture (reference); IBN&vertF, Ibandronate and the risk reduction of vertebral fracture 
(reference)7. Note: Details and references are provided under the discussion section.  
Figure 6.4. Forest plot of treatment effects and risk of fracture 
 
Our findings indicate that concomitant users of BPs and SSRIs have a 1.29 times chance 
of experiencing any fracture compared to BP alone users at any given time. These findings 
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suggest that SSRIs might be associated with attenuation of antifracture efficacy of 
bisphosphonates. Based on the non-significance of our results for hip and vertebral fracture, we 
cannot determine the attenuation of the risk reduction associated with concomitant use of BPs 
and SSRIs, but we cannot rule out subtle attenuating effects.   
 
6.3.3 Sensitivity analysis 
Two sensitivity analyses were performed to assess the robustness of our findings. First, 
we conducted a separate analysis among the same patients for the primary analysis, except that 
we redefined the exposure of concomitant use. Concomitant use of SSRIs with BPs was defined 
as having received at least one prescription for a BP and a SSRI (with no dispensing medication 
gap for a SSRI of more than 30 days whereas users of BPs were still defined as those patients 
who were exposed for at least 180 days in the 360 day period). The distributions of propensity 
scores between the two groups after 1:1 matching are shown in Figure 6.5b.   Table 6.8 shows 
the fracture outcomes from this analysis. The results were similar to the primary analysis, except 
that we observed slightly stronger associations and we also observed statistically significant risk 
for vertebral fracture. However, the wide confidence interval suggests that these results might 
have not had enough events for statistically reliable estimates. 
In the second sensitivity analysis test, we used the matched data from the primary 
analysis but instead assessed the effect of short or long term exposure to SSRIs prior to a fracture 
event. The durations were exposure to SSRIs up to 90 days versus greater than 90 days. The 
fracture outcome results are shown in Table 6.9a and Table 6.9b. The results were similar to the 
primary analysis. Both of the durations of concomitant use showed no statistically significant 
association between concomitant use and increased risk of any fracture and were still non-
significant for the hip fracture. However, the results for vertebral fracture were unstable. The 
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association was statistically significant when the duration of exposure was less than 90 days (but 
with wide confidence interval), but statistically non-significant when the exposure was greater 
than 90 days. This instability may be due to small sample size. 
 
(6.5a)  
(6.5b)  
Figure 6.5. Distribution of propensity scores: (6.5a) shows the distribution for 21,437 
patients before matching and (6.5b) shows the distribution for 3,292 patients after 
matching.  
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Table 6.8. Cox proportional hazard model for risk of fractures among concomitant users of 
bisphosphonates and SSRIs: Sensitivity analysis 1. 
 Non concomitant users Concomitant users 
Total number of patients 3,292 3,292 
Any fracture   
   Total events 160 211 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.35 (1.09, 1.68) 
Hip/Pelvis fracture   
   Total events 116 139 
   Hazard Ratio (95% CI) 1.00 (Reference) 1.21 (0.94, 1.55) 
Vertebral fracture   
   Total events 17 35 
   Hazard Ratio (95% CI) 1.00 (Reference) 2.13 (1.17, 3.85) 
 
Table 6.9a.  Cox proportional hazard model for risk of fractures among concomitant users of 
bisphosphonates and SSRIs (concomitant use ≤90 days before fracture): Sensitivity analysis 2. 
 Non concomitant users Concomitant users 
Any Fracture   
   Hazard Ratio (95% CI) 1.00 (Reference) 1.38 (1.08, 1.75) 
Hip/femur/pelvis fracture   
   Hazard Ratio (95% CI) 1.00 (Reference) 1.25 (0.93, 1.68) 
Vertebral fracture   
   Hazard Ratio (95% CI) 1.00 (Reference) 1.88 (1.02, 3.44) 
 
Table 6.9b. Cox proportional hazard model for risk of fractures among concomitant users of 
bisphosphonates and SSRIs (concomitant use >90 days before fracture): Sensitivity analysis 2. 
 Non concomitant users Concomitant users 
Any fracture   
 Hazard Ratio (95% CI) 1.00 (Reference) 1.39 (1.04, 1.86) 
Hip//pelvis fracture   
   Hazard Ratio (95% CI) 1.00 (Reference) 1.27 (0.89, 1.81) 
Vertebral fracture   
   Hazard Ratio (95% CI) 1.00 (Reference) 1.23 (0.59, 2.56) 
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6.4 Discussion 
This study assessed potential attenuation of the beneficial effects of BPs by SSRIs and 
increased risk of fracture. Given the popularity of BPs as the first-line therapy for the treatment 
of postmenopausal osteoporosis and reduction of fracture risk,8 the potential antifracture efficacy 
of BPs is a major concern. Due to the high prevalence of comorbid osteoporosis and depression 
among women,9 concomitant use in these patients is not uncommon. Indeed, our study found that 
of the BP users eligible for analysis in the study, the overall proportion of those patients who 
were reported with both depression and osteoporosis was 17.5% (i.e., 19.3% in 2008, 15.6% in 
2009, and 17.9% in 2010). Furthermore, of the BP users, 20.5% were also on SSRIs.  
Overall, our estimates showed an increased risk of fracture for any, hip, and vertebral 
fractures which suggested attenuation of BP, but the associations were not statistically significant 
for the hip and vertebral fracture. In other words, among all those already prescribed BPs, the 
risk of hip and vertebral fractures was not significantly different between those who added on 
SSRIs in their medication regimen compared to those who were only users of BPs, but the risk of 
any fracture was significantly different between these groups. These findings suggested that 
overall there is a potential antifracture efficacy of BPs but the effect was not significantly 
different between users and non users of concomitant use for individual fracture subtypes. 
Furthermore, sensitivity analysis results were similar: non-significant for hip and vertebral 
fracture and were still significant for the any fracture. These results suggested that the period of 
SSRIs exposure prior to a fracture event and a wider gap (up to 90 days between dispensing 
dates of BPs and SSRIs) did not affect the fracture outcome. 
Bisphosphonates have been shown in randomized clinical trials to be beneficial in the 
reduction of fracture. A recent meta-analysis study found that oral BPs (i.e., alendronate, 
etidronate, risedronate, and clodronate) are effective in reducing the risk of hip fracture by 42%. 
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The pooled estimate of relative risk based on the Bayesian random-effects model was 0.58 (95% 
CI, 0.42-0.80).6 Also pooled results as obtained with the network meta-analysis to evaluate the 
efficacy of BPs in the prevention of vertebral, hip, and nonvertebral-non hip fractures in 
postmenopausal women with osteoporosis found that vertebral fracture reduction with 
alendronate was RR=0.53, 95% CI, 0.44-0.65, risedronate: RR=0.59, 95% CI, 0.47-0.75, and 
ibandronate: RR=0.51, 95% CI, 0.34-0.74. The risk reduction for nonvertebral-non hip fractures 
for alendronate was RR=0.88, 95% CI, 0.77-1.00, risedronate: RR=0.62, 95% CI, 0.43-0.88, and 
ibandronate: RR=1.11, 95% CI, 0.80-1.52.7 In this study, we also established antifracture 
efficacy of BPs for any and hip fracture. 
A possible explanation for the variability observed in antifracture efficacy is that the 
antiresorptive relative potencies for osteoclast inhibition leading to increased bone mineral 
density and fracture risk reduction is related to their molecular structures.10 Both BPs affinities’ 
for crystalline hydroxyapatite and inhibitory effects on osteoclasts are important pharmacological 
features. The high affinity for bone mineral allows BPs to achieve a high local concentration 
throughout the entire skeleton. Suppressed bone resorption after BP initiation suggests BP 
efficacy and potency in promoting the apoptosis of osteoclasts actively engaged in degradation 
of mineral on the bone surface.11 Antiresorptive therapies that produce larger increases in bone 
mineral density tend to have greater antifracture efficacy.12 It is also important to note that 
improved BP treatment persistence and compliance are factors that have an overall influence on 
fracture risk reduction.13 
We hypothesized that the established antifracture efficacy of BPs would be attenuated 
through an interaction with SSRIs. We observed this potential phenomenon and increased risk of 
any fracture. Although we were not able to determine with statistical certainty that SSRIs may 
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attenuate the antifracture efficacy of BPs and increased risk of fracture for hip and vertebral 
fracture (may be because of sample size issues), we cannot completely rule out subtle 
counteractive effects due to the well-established association of SSRIs and decreased BMD 
leading to increased risk of fracture. Using data for this study, we found strong association 
between SSRI use and increased risk of any and hip fracture. Both findings were consistent with 
reports from two prospective studies on the associations of SSRIs and increased risk of fracture. 
Spangler et al. in a prospective cohort study of 93,676 postmenopausal women, found that 
compared to women using other types of antidepressants, women using SSRIs had increased 
adjusted risk of any fracture (HR=1.30, 95% CI, 1.20-1.41) and hip fracture (HR=1.33, 95% CI, 
0.95-1.86), but statistical significance was not achieved at the hip.14 Diem et al. in a recent study 
based on a 10-year follow-up medication-use data involving 9,704 women aged 65 years and 
older recruited in the prospective Study of Osteoporotic Fractures, showed that of these women, 
2,809 experienced an incident nonspine fracture over the follow-up period, including 936 with a 
hip fracture. Women taking SSRIs experienced a higher adjusted risk of nonspine fracture 
compared with nonusers (HR=1.38, 95% CI, 1.10-1.72) in a multivariable model. The risk of hip 
fracture was close to 1.0 (HR=1.01, 95% CI, 0.71-1.44) for SSRI users compared with nonusers 
due to potential confounding factors.15 Overall, in a meta-analysis study, a summary of pooled 
estimates of risk associated with SSRI use in cohort and case-control studies has demonstrated 
that SSRI use is associated with a significantly increased risk of fracture (RR=1.72, 95% CI, 
1.51-1.95).5  
The link between SSRIs and bone health is based on the adverse effects of serotonin on 
the bone remodeling process. Bone cells (i.e., osteocytes, osteoblasts, and osteoclasts) possess a 
functional serotonin (5-HT) signal transduction mechanism (5-HT receptors and the serotonin 
 
 
180 
 
transporters [5-HTT]) for both responding to and regulating the uptake of serotonin.16-20 These 
reports further suggested that serotonin may be involved in bone metabolism and the potential 
consequences on bone health. For example the study by Gustafsson et al. examined the in vitro 
effects of 5-HT and 5-HTT inhibitor fluoxetine (Prozac®) and found that serotonin as well as 
fluoxetine increased the total number of differentiated human osteoclasts as well as osteoclast 
activity. Fluoxetine was also found to increase receptor activator of nuclear factor kappa B 
ligand (RANKL) release.20 
Possible bone metabolism pathways have also been proposed. In gut-derived 5-HT on 
osteoblasts, binding of 5-HT to 5-HT1B, which is linked to the Gαi protein, inhibits adenylyl 
cyclase which in turn inhibits second-messenger cAMP production and protein kinase A (PKA)-
mediated cAMP response element-binding (CREB) phosphoslylation. This process leads to 
decreased expression of Cyclin (Cyc D1) genes and decreased osteoblast proliferation. As a 
result, bone formation is slowed.  On the other hand, in brain-derived 5-HT on osteoblasts, 
binding of 5-HT negatively controls osteoblast proliferation via the molecular clock gene (Cyc 
D1) cascade and positively regulates bone resorption via activation of a PKA/ATF4-dependent 
pathway (ATF-4: a transcription factor protein), leading to increased synthesis of RANKL, an 
activator of osteoclast differentiation and function.21,22 In other words, 5-HT activation can also 
directly produce RANKL in addition to the RANKL produced during normal bone remodeling 
process.  
During normal bone remodeling in healthy physiologic systems, bone stromal cells, 
including cells of the osteoblast lineage, provide a limited amount of RANKL, which leads to 
osteoclast differentiation, survival, and activation and subsequent bone resorption. Bone 
resorption is balanced by osteoblast-dependent new bone formation.23 RANKL is a member of 
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the tumor necrosis factor (TNF) superfamily, produced and secreted by osteoblasts.24 RANKL 
stimulates osteoclasts through its own receptor RANK, which is a membrane-bound protein 
present on osteoclast precursors, inducing the formation of osteoclasts and subsequent bone 
resorption.25 Increased RANKL expression has been shown to be present in bone marrow cells 
from postmenopausal women.26 
How does this role of 5-HT-RANKL in bone metabolism relate to its potential 
attenuating effects of BPs? The elevation of RANKL because of 5-HT probably reflects a 
mechanism counter-regulating excessive bone resorption and increased risk of fracture. 
Treatment of homozygous oim/oim mice (the oim/oim mouse is an established model of 
moderate to severe osteoporosis) with either a BP (alendronate) or RANKL inhibitor (Rank-Fc) 
has been reported to cause decreases in fracture incidence.27 Although research findings have 
suggested that treatment with BPs does not change RANKL serum levels,28 Sutherland et al. has 
demonstrated that RANKL can attenuate the beneficial effects of bisphosphonates. In an in vitro 
study using rabbit osteoclasts treated with the bisphosphonates clodronate or alendronate for up 
to 48 hours in the absence or presence of RANKL found that RANKL significantly attenuated 
(or antagonized) the ability of both clodronate  and alendronate to induce osteoclast apoptosis 
and inhibit bone resorption. The authors conclude that RANKL protects osteoclasts from the 
apoptosis-inducing and anti-resorptive effects of BPs in vitro.29 This is an example of a 
pharmacodynamic drug interaction. 
 In pharmacodynamic interactions, the two drugs act at the same or interrelated receptor 
sites and may behave in an additive, synergistic, or antagonistic fashion.30 Suppression of 
osteoclast bone resorption is the pharmacodynamic effect of BPs and so are the elevated levels of 
RANKL which in turn leads to osteoclast differentiation, survival, and activation and subsequent 
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bone resorption the pharmacodynamic effect of SSRIs.  Concomitant BP and SSRI use may 
increase the risk of osteoporosis/bone loss and fracture through the antagonizing or attenuating 
effects of SSRIs on the beneficial effects of BPs. The pharmacodynamic interaction of these 
combinations would result in attenuation of BP effects, hence increasing the risk of fracture for 
the patient. However, our study provided evidence which only suggests the possibility of this 
phenomenon for any fracture, but was not well powered to determine the treatment effects for 
individual skeletal sites. So, further investigations are needed to provide more understanding. 
An alternative explanation to our findings is that what we have demonstrated could be 
potential good news to patients on SSRIs and also prescribed BPs. It is possible that BPs are 
actually protective against SSRI-induced osteoporosis and increased risk of fracture and 
treatments effect estimates would have shifted toward less than 1.0.  However, due to the 
potential for residual confounding bias for fracture not measured in Medicare claims data but are 
measured in Medicare Current Beneficiary Survey (MCBS) data (e.g., current tobacco smoking, 
alcohol intake, body mass index, or activities of daily living score, cognitive impairment, and 
Rosow-Breslau physical impairment scale)31 which we did not control for in this study, both 
concomitant users of BPs and SSRIs and those on BPs alone probably had an equal probability 
of increased risk of fracture. Hence, the lack of substantial difference in increased risk of hip and 
vertebral fractures.  
To ascertain this alternative hypothesis, further sensitivity analysis can be performed with 
an aim to correct effect estimates for unmeasured confounding using external information such 
as MCBS that contains additional survey information for some of the patients that were included 
in our study.32  The MCBS is a continuous, multipurpose survey (collected since 1991) of a 
representative sample of the Medicare population designed to aid the CMS administration, 
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monitoring and evaluation of the Medicare program.33 This sensitivity analysis technique has 
been used to investigate the association between selective COX-2 inhibitor use and the incidence 
of myocardial infarction.34 With regards to concomitant use of BPs and SSRIs, findings favoring 
antifracture efficacy of BPs than antifracture attenuating effects of SSRIs could be welcome 
research findings as far as caring for older postmenopausal women that would need long term 
use of SSRIs. 
6.4.1 Strengths and limitations of the study 
   6.4.1.1 Strengths 
There are two key aspects that contributed to the strengths of findings from this study. 
These include the use of Medicare data and the study design strategy. The use of a large, 
nationally representative database for older adults 65 years or older is a source of strength 
because the findings are more generalizable to the population of older postmenopausal women. 
As for the design strategy, we believe that potential confounding of observed variables was well 
accounted for through propensity score matching. Confounding bias is of particular concern in 
observational epidemiologic studies of drug effects.35 Using propensity score method it is 
possible to duplicate one crucial feature of randomized experiment of designing an observational 
study without access to the outcome data.36 Propensity score method  allows researchers to 
reconstruct counterfactuals using observational data, a situation similar to random assignment, 
albeit only with respect to observed variables.37 Another strength in our design strategy is that 
the study design is better in quantification of exposure with respect to time.38 Sampling is the 
equivalent of matching cases and controls on duration of follow-up (or respect to time). 
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   6.4.2.2 Limitations 
  On the other hand, our study findings were also faced with some limitations. One key 
limitation in this study was the small number of fractures by anatomical site and so the study had 
insufficient power to detect treatment effect as statistically significant.39 This can be explained in 
part by the existing imbalance in enrollment in Medicare Part A and Part D.  Although Medicare 
Part D offers prescription coverage to all those eligible for Medicare, not all beneficiaries are 
enrolled in a Part D plan. Of those who were Medicare eligible between 2008 and 2010, 57.5% 
were enrolled in a Part D plan in 2008, 58.7% in 2009, and 59.4% in 2010.  The rest were not 
covered by Part D and with no credible coverage or with other credible coverage, or were 
enrolled in a retirement drug subsidy.40 This limitation significantly resulted in the exclusion of 
many Medicare Part A patients who had no medication history available from the study cohorts. 
For example, of the 7,757 patients with hip/pelvis/femur fractures enrolled in Medicare Part A 
and were eligible for this study, only 762 (9.8%) patients with hip fracture were enrolled in both 
plans (before matching).  Also, vertebral fractures are frequently undetected by physicians41 and 
so this can lead to the pronounced problem of too small number of events in the 5% random 
sample. Both of these issues could be dealt with by obtaining a 10% or greater sample from CMS 
rather than a 5% sample. 
Second, we lacked precise information about when patients first initiated BPs. The period 
after initiating therapy of BPs (≥ 3 months) plays a role in the antifracture efficacy of these 
medications and this was the basis for our inclusion and exclusion criteria.42 However, due to the 
limitations of the data, patients on BPs for at least 6 months were assumed to be continuous 
users. It is likely that BPs would be significantly attenuated among those who are new users than 
those who have been on BPs for longer periods of time. 
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Third, our study is faced with the increased possibility of bias because of the 
retrospective nature of the data collection. Bias may entirely account for any weak associations 
that we may have observed. Potential misclassification bias, also called measurement error, is 
probably the most common form of bias in epidemiologic research.43 Misclassification can occur 
for both drug exposure and the outcome of interest. With respect to drug exposure with 
outpatient prescription claims, a greater number of opportunities for misclassification in the 
direction of not exposed exist given the multiple channels by which members can receive their 
medications outside of the reimbursement arrangements of Medicare program, for example 
physician samples. In addition, one of the tips for Medicare Part D patients to avoid the coverage 
gap is the recommendation that patients pay cash for selected medications and request that the 
pharmacy not bill the Part D plan if cash prices are less than the co-payment. Discount generic 
programs (e.g., $4 generic prescription programs) are one of the recommended strategies.44 SSRI 
medications in the generic programs include citalopram, fluoxetine, and paroxetine and BPs 
include alendronate.45 Another potential misclassification bias of exposure is the assumption we 
made in our study that patients in Medicare data with records of dispensed BPs or SSRIs actually 
took them even though they may not have. In this case, patients who were non persistent and/or 
adherent were misclassified as exposed, thereby biasing our estimates. With respect to outcomes, 
misclassification of diagnostic codes can result due to ambiguity in diagnoses for example a self-
reported fracture that is not adjudicated with radiographic reports.46  
Fourth, coding of claims and filing of complete claims is done by the coding staff. During 
this aspect of data generation potential sources of bias introduced are miscoding of primary and 
secondary diagnoses and procedures and also failure to file claims properly and hence possible 
under-reporting of diagnoses. Finally, the temporal relationship between exposure and disease 
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may be difficult to establish given the fact that the study is retrospective.43 This is especially so if 
important information may be missing on intermediate clinical outcomes such BMD and 
RANKL measurements.  
6.5 Conclusions 
In summary, we did not observe a significant association of antifracture efficacy of BPs 
with SSRIs for hip and vertebral fracture but significance was achieved for any fracture. Because 
this is the first study to investigate this phenomenon, further studies are needed to provide more 
understanding on the clinical impact of concomitant use of BPs and SSRIs among older 
postmenopausal women. Especially further studies that could prospectively assess changes in 
biochemical markers of bone turnover (e.g., RANKL) and BMD would provide better 
understanding of the potential attenuation of antifracture efficacy of BPs by SSRIs. Currently 
there are no clinical guidelines for the treatment of SSRI–related bone loss and such information 
would be important to be integrated in its development. It is probable to suggest that future 
concomitant use of BPs and SSRIs will continue to rise in this population due to the projected 
future increase in population of older adults. Therefore, results from studies such as this could 
add to the current body of literature and be useful for physicians treating osteoporosis and/or 
osteoporotic fractures by highlighting possible safety concerns that may be important to consider 
when optimizing patient care. Also these results might be relevant to policymakers concerned 
with meeting the needs of aging Americans, especially the health of older women. 
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Chapter 7 
 
Specific Aim 3: To assess the increased risk of osteoporotic-related fractures associated with 
the concomitant SNRIs with BPs use and whether the risk of osteoporotic-related fractures is 
related to the role of serotonin in bone rather than the disease (depression). 
 
7.0 Results 
We did not report findings for this specific aim. This is because we failed to determine 
the effects of concomitant use of bisphosphonates and SNRIs and increased risk of fracture. 
Although there were enough number of events to investigate the composite effect of SNRIs on 
the antifracture effects of bisphosphonates, the events were not sufficient enough to investigate a 
dose response effect which was our primary goal (see Table 7.1). SNRIs are less popularly used 
for the treatment of depression compared to SSRIs. Indeed, findings from Chapter 5 found that 
the prevalence of concomitant bisphosphonates and SSRIs use was higher than SNRIs. This 
limitation suggests that for future studies involving SNRIs and increased risk of fracture in older 
adults should use a larger sample of the Medicare claims data. If possible we recommend >5% to 
100% samples of the Medicare claims data to be able to capture all the associated events with 
use of SNRIs.  
 
Table 7.1. Descriptive statistics of matched concomitant users of bisphosphonates and SNRIs, 
dosage, and fracture events. 
 Dosage 
Description ≤ 37 mg > 37 - ≤ 60 mg >60 - ≤ 75 mg >75 mg 
Concomitant users 590 511 377 205 
Hip fracture 36 42 34 21 
Vertebral Fracture 10 3 5 1 
Humerus 5 2 3 4 
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